Beyond Nature's Blueprint: Harnessing Diversity-Oriented Synthesis to Unlock Novel Chemical Space from Natural Product Scaffolds

Julian Foster Jan 09, 2026 57

This article provides a comprehensive exploration of Diversity-Oriented Synthesis (DOS) as a transformative strategy for generating structurally diverse and complex chemical libraries inspired by natural product scaffolds.

Beyond Nature's Blueprint: Harnessing Diversity-Oriented Synthesis to Unlock Novel Chemical Space from Natural Product Scaffolds

Abstract

This article provides a comprehensive exploration of Diversity-Oriented Synthesis (DOS) as a transformative strategy for generating structurally diverse and complex chemical libraries inspired by natural product scaffolds. Targeting researchers and drug development professionals, it systematically details the foundational principles that justify natural products as privileged starting points, modern synthetic methodologies like C-H functionalization and ring distortion, key optimization strategies to overcome synthetic bottlenecks, and rigorous approaches for biological validation and chemical space analysis. The content synthesizes the latest research to demonstrate how DOS bridges the gap between natural product complexity and synthetic accessibility, aiming to populate biologically relevant but underexplored chemical space for the discovery of novel bioactive probes and therapeutic leads.

The Privileged Foundation: Why Natural Products are Ideal Springboards for Diversity-Oriented Synthesis

The persistent decline in drug discovery productivity, despite advances in genomics and high-throughput screening, points to a fundamental deficiency in the chemical matter being explored [1]. The prevailing reliance on "flat," two-dimensional aromatic compounds has created a chemical library landscape lacking the three-dimensional structural complexity required to interact with sophisticated biological targets [2]. This is particularly problematic for the ~85% of the human proteome deemed "undruggable," which includes targets involved in protein-protein interactions, transcription factors, and other regulatory complexes that present broad, shallow binding surfaces [3].

This article, framed within a broader thesis on diversity-oriented synthesis (DOS) from natural product scaffolds, argues that bridging this dimensionality gap is the critical path forward. Natural products, evolutionarily optimized for biological interaction, serve as the ideal inspiration. They are "libraries of pre-validated, functionally diverse structures" that inherently possess high skeletal diversity and 3D complexity [4]. By leveraging DOS strategies to create synthetic libraries that mimic the architectural and spatial features of natural products, we can generate chemical probes and leads capable of modulating previously inaccessible disease pathways [2].

The Structural Deficiency of Traditional Screening Libraries

2.1 The "Flatland" Problem Commercial and legacy pharmaceutical screening collections are overwhelmingly populated by compounds adhering to simplified medicinal chemistry rules (e.g., Lipinski's Rule of Five). These molecules are often characterized by high aromatic ring count, low sp3-carbon fraction (Fsp3), and limited stereochemical complexity. This results in planar structures that are proficient at fitting into deep, hydrophobic pockets of enzymes like kinases but are ill-suited for engaging the more complex, topologically varied surfaces of many disease-relevant targets [2] [3].

2.2 Quantitative Analysis of the Diversity Gap The following table contrasts the structural characteristics of traditional compound libraries with those of natural products and the desired profile for libraries targeting undruggable space.

Table 1: Structural Characteristics of Different Compound Classes

Structural Characteristic Traditional Screening Libraries Natural Products Target Profile for Undruggable Targets
Predominant Scaffolds Simple, planar heteroaromatics (e.g., pyridines, pyrimidines) Complex, polycyclic, bridged, and spiro systems High skeletal diversity; bridged and spirocyclic frameworks [4] [2]
Stereogenic Centers Low count (often 0-1) High count (often 3+) Multiple, well-defined stereocenters [4]
Fraction of sp3 Carbons (Fsp3) Low (<0.3) High (>0.5) High (>0.5) for 3D shape [2]
Molecular Rigidity/Conformational Lock Variable, often flexible High (from rings and unsaturated bonds) High, to pre-organize for binding [4]
Representative Targets Kinases, GPCRs, Enzymes Diverse, including PPI interfaces, ribosomes Protein-protein interactions, transcription factors, RNA [3]

2.3 Consequences in Phenotypic Screening This structural bias directly impacts early discovery. Phenotypic screens, which identify compounds based on a biological effect without a predefined target, are powerful for novel biology but hit a bottleneck when the active compounds are flat molecules. These hits often lack novelty, target multiple promiscuous proteins, or fail to be optimized into selective leads due to their inherent chemical simplicity [1]. The "limitations of small molecule...screening in phenotypic drug discovery" are, in part, a direct consequence of the limited chemical space sampled [1].

Foundational Solution: Diversity-Oriented Synthesis from Natural Product Scaffolds

Diversity-Oriented Synthesis (DOS) is a strategic approach to efficiently populate broad regions of chemical space by generating libraries of small molecules with high scaffold diversity [2]. When inspired by natural product architectures, DOS provides a principled method to escape flatland.

3.1 Core DOS Strategies for 3D Complexity DOS employs several key strategies to build complexity, mirroring biosynthesis:

  • Folding Pathways: Using reagents that can form different products based on reaction conditions, akin to biomolecular folding.
  • Functional Group Pairing: Pairing mutually reactive functional groups on a common substrate to create diverse ring systems.
  • Build/Couple/Pair: A highly successful algorithm where simple building blocks are coupled to form linear precursors, which then pair through intramolecular reactions to form diverse polycyclic scaffolds [4] [2].

3.2 Classification of Natural Product-Inspired Scaffolds for Library Design Natural product scaffolds can be categorized to guide DOS library design towards 3D complexity.

Table 2: Classification of Natural Product Scaffolds for DOS Library Design

Scaffold Class Key 3D Features Biological Relevance DOS Synthesis Challenge
Polycyclic Alkaloids Multiple fused rings, bridgehead atoms, nitrogen heterocycles. Ion channel modulation, receptor antagonism. Controlling regiochemistry and stereochemistry in ring fusion.
Macrocycles & Cyclic Peptides Conformationally restrained large rings, peptide backbone. Disrupting large protein interfaces (PPIs). Achieving efficient macrocyclization without oligomerization.
Spirocyclic & Propellane Systems Orthogonal ring systems, high steric congestion, distinct vectorial display. Unique binding modes to challenging pockets. Constructing the quaternary spiro center with control over stereochemistry.
Glycosylated Molecules Sugar appendages, high density of stereocenters and H-bond donors/acceptors. Cell surface recognition, trafficking. Stereoselective glycosylation reactions on complex aglycons.

Application Notes & Protocols: Implementing 3D Complexity in Discovery

Application Note 1: Generating a Phenotypically Relevant 3D Screening Environment Using Human Organoids Context: Transitioning from 2D cell monolayers to 3D organoid models is essential for evaluating 3D complex molecules in a physiologically relevant context that includes cell-cell interactions, gradients, and microenvironmental signals [5]. Protocol: Generation of Patient-Derived Intestinal Organoids for Compound Screening

  • Tissue Dissociation: Obtain crypt cells from intestinal biopsy or surgical resection. Dissociate tissue in Gentle Cell Dissociation Reagent for 20-30 minutes at 4°C.
  • Crypt Isolation: Filter suspension through a 70-μm strainer. Centrifuge and resuspend crypts in Basement Membrane Extract (BME) matrix (e.g., Matrigel).
  • 3D Culture: Plate BME-cell suspension droplets in a pre-warmed culture plate. Polymerize for 20-30 minutes at 37°C. Overlay with Intestinal Organoid Growth Medium containing EGF, Noggin, R-spondin-1, and Wnt-3a.
  • Maintenance & Passage: Culture at 37°C, 5% CO2. Change medium every 2-3 days. Passage every 7-10 days by mechanically breaking organoids and re-embedding in fresh BME.
  • Screening Assay: At day 5-7 post-passage, treat organoids with DOS library compounds (typically 1-10 µM) for 72-120 hours. Fix, stain (e.g., for viability, apoptosis, organoid size), and image using confocal or high-content microscopy. Quantify organoid number, area, and staining intensity relative to controls [5].

start Patient Biopsy dissoc Crypt Isolation & Dissociation start->dissoc embed Embed in BME Matrix dissoc->embed culture 3D Culture (Growth Factors) embed->culture mature Mature Organoid culture->mature screen Dosage with 3D Compound Library mature->screen image High-Content 3D Imaging screen->image analyze Phenotypic Analysis image->analyze output Validated 3D-Active Compound analyze->output

Application Note 2: Screening 3D-Shaped Libraries Against Undruggable Targets Using DNA-Encoded Libraries (DEL) Context: DNA-Encoded Library technology allows for the ultra-high-throughput screening (billions of compounds) of complex, natural product-inspired libraries against purified protein targets, ideal for identifying binders to shallow surfaces [3]. Protocol: Selection of Binders from a DEL Built from Spirocyclic Scaffolds

  • DEL Synthesis: Construct the library via a split-and-pool approach. In each cycle, couple a building block (e.g., a spirocyclic amine derivative) to the growing compound and ligate a corresponding DNA barcode.
  • Target Immobilization: Biotinylate the purified target protein (e.g., a transcription factor) and immobilize it on streptavidin-coated magnetic beads. Include a non-target protein control bead preparation.
  • Selection: Incubate the DEL (at ~100 nM library concentration) with target beads in selection buffer (PBS with 0.05% Tween, BSA) for 1-2 hours at 4°C with rotation.
  • Washing: Perform multiple stringent washes with buffer to remove non-binders.
  • Elution & PCR: Elute bound compounds by denaturing the protein (e.g., with heat or SDS). Recover the associated DNA barcodes and amplify via PCR.
  • Sequencing & Hit Triage: Perform next-generation sequencing on the PCR product. Identify enriched barcode sequences. Decode sequences to reveal the corresponding chemical structures of binders. Prioritize hits containing 3D scaffolds (spirocycles, bridged systems) for off-DNA synthesis and validation [3].

lib Spirocyclic-Focused DNA-Encoded Library incubate Incubation & Binding Selection lib->incubate target Immobilized Protein Target target->incubate wash Stringent Washes incubate->wash elute Elute & PCR Amplify DNA Barcodes wash->elute seq Next-Generation Sequencing elute->seq decode Decode to Chemical Structures seq->decode output Validated 3D Binder decode->output

Application Note 3: Validating Mechanism in a 3D Integrated Brain Model (miBrain) Context: For neuroscience targets, advanced 3D models like MIT's "miBrains"—which integrate all major brain cell types—are necessary to validate compound mechanism in a system that recapitulates human cellular interactions and pathology [6]. Protocol: Evaluating a Tau Pathology Modulator in an APOE4 miBrain Model

  • miBrain Generation: Differentiate induced pluripotent stem cells (iPSCs) harboring the APOE4 genotype into neural progenitor cells (NPCs), astrocytes, microglia, etc. Combine cell types in a defined "neuromatrix" hydrogel at optimized ratios to form self-assembling 3D miBrain units [6].
  • Disease Phenotyping: Culture APOE4 and isogenic APOE3 miBrains for 60+ days. Confirm disease phenotype via immunostaining for phosphorylated Tau (pTau) and amyloid-beta accumulation.
  • Compound Treatment: Treat mature (day 60) APOE4 miBrains with the candidate compound (identified from a DOS library screen) at multiple doses. Include vehicle and APOE3 miBrain controls.
  • Readout: After 14-21 days of treatment, fix miBrains and perform multiplexed 3D immunofluorescence imaging (e.g., light-sheet microscopy) for pTau, amyloid-beta, and cell-type markers.
  • Analysis: Use volumetric image analysis to quantify a reduction in pTau signal intensity and plaque number in treated vs. untreated APOE4 miBrains. Assess cell-type-specific effects by co-localization analysis [6].

The Scientist's Toolkit: Essential Reagent Solutions

Table 3: Key Research Reagents for 3D Complexity & DOS Research

Reagent/Material Function/Description Application in 3D/DOS Research
Basement Membrane Extract (BME, e.g., Matrigel) A gelatinous protein mixture providing a 3D scaffold for cell growth. Essential substrate for cultivating organoids from various tissues [5].
Defined Neuromatrix Hydrogel A synthetic, tunable hydrogel mimicking brain extracellular matrix. Critical for assembling advanced 3D models like miBrains with multiple cell types [6].
Spirocyclic & Bridged Building Blocks Chemically synthesized cores with inherent 3D geometry. Key starting materials in DOS for constructing shape-diverse libraries targeting undruggable surfaces [4] [3].
DNA Encoding Reagents Sets of oligonucleotide tags for covalent attachment to small molecules. Enables the construction and screening of ultra-large DNA-Encoded Libraries (DELs) [3].
Selective Growth Factor Cocktails Combinations of recombinant proteins (e.g., Wnt, R-spondin, Noggin). Directs stem cell differentiation and maintains specific cell fates in 3D organoid cultures [5].
3D Imaging-Compatible Antibodies Antibodies validated for immunostaining in thick tissue sections/whole organoids. Enables volumetric phenotyping and target engagement analysis in 3D models [7].

The path to drugging the undruggable proteome requires a concerted shift in the chemical and biological dimensions of discovery research. As demonstrated, the strategic union of Diversity-Oriented Synthesis—inspired by the rich 3D architectures of natural products—with sophisticated 3D biological models like organoids and integrated tissue platforms creates a powerful pipeline. This approach moves beyond flat molecules to generate "Goldilocks" compounds with the just-right size and complexity, and evaluates them in physiological systems that reveal true mechanistic efficacy and toxicity [6] [3] [5].

The future of discovery lies in this integrated paradigm: synthesizing chemical matter that matches the complexity of biology and evaluating it in systems that respect the multidimensionality of human disease.

Within the broader thesis of diversity-oriented synthesis (DOS), natural products (NPs) represent a foundational and pre-validated entry point into biologically relevant chemical space. Through evolutionary pressure, NPs have evolved to interact specifically with biological macromolecules, meaning their complex scaffolds are inherently biologically pre-validated [4]. However, traditional NP discovery faces limitations in availability and synthetic tractability [8]. The core thesis posits that by employing DOS principles—which aim to generate structural diversity efficiently—to these NP blueprints, researchers can create synthetic libraries that retain biological relevance while vastly expanding accessible scaffold diversity [2] [8]. This approach, encompassing strategies like pseudo-natural product (PNP) design, navigates beyond the constraints of natural biosynthesis to explore novel regions of chemical space, thereby accelerating the discovery of probes and leads for underexplored biological targets [8] [9].

Application Notes: Strategic Frameworks and Analyses

Strategic Frameworks for Exploiting NP Scaffold Diversity

The transition from natural product inspiration to diverse synthetic libraries is governed by several strategic frameworks, each offering a unique path to scaffold diversification.

  • Biology-Oriented Synthesis (BIOS): This strategy uses the core scaffold of a biologically relevant NP as the starting point. Synthesis is directed towards generating analogs and derivatives that explore the structure-activity relationships around that specific, privileged scaffold [9].
  • Pseudo-Natural Product (PNP) Design: This innovative framework involves the de novo computational fragmentation of unrelated NPs and the recombination of their characteristic fragments into novel molecular architectures not found in nature [8] [9]. The resulting PNPs inherit biological relevance from their NP-derived fragments but occupy unexplored chemical space. A key advancement is the Divergent Intermediate Strategy, where a single synthetic intermediate is transformed via different pathways into multiple distinct PNP scaffolds [8].
  • Complexity-to-Diversity (CtD): This approach subjects a single, synthetically accessible complex NP-like molecule to a series of ring-distorting reactions (e.g., cycloadditions, rearrangements). These transformations dramatically alter the core scaffold, rapidly generating a collection of architecturally diverse and complex molecules from a common precursor [8].

Cheminformatic Analysis of Scaffold Diversity

Quantitative analysis confirms the superior and distinct chemical space occupied by NP-inspired libraries compared to typical synthetic collections.

Table 1: Comparative Molecular Descriptor Analysis of Compound Collections

Molecular Descriptor Typical Commercial/Combinatorial Library [2] Natural Product-Inspired/DOS Library [8] [9] Biological Relevance Implication
Fraction of sp3 Carbons (Fsp3) Lower (more "flat", aromatic) Higher (more 3D shape, saturated) Increased 3D complexity improves selectivity for binding complex protein surfaces [8].
Number of Stereogenic Centers Fewer Greater Enhances specificity for chiral biological targets and reduces the likelihood of off-target effects [2].
Scaffold Diversity Low (few core skeletons with varied appendages) [2] High (many distinct molecular frameworks) [10] [8] Broad coverage of "shape space" increases the probability of modulating diverse and "undruggable" targets [2].
Structural Complexity Generally lower Higher (more rings, bridged systems) Correlates with improved binding affinity and specificity for challenging targets like protein-protein interfaces [9].

Analysis of a specific 154-member PNP library synthesized via a divergent intermediate strategy [8] reveals the success of this approach:

  • The collection comprised eight distinct molecular classes with unique fusion patterns (e.g., spirocyclic, bridged).
  • Cheminformatic principal component analysis (PCA) demonstrated clear separation between the different PNP classes in chemical space, confirming high inter-class scaffold diversity.
  • Importantly, the library members exhibited a range of calculated properties (e.g., polar surface area, molecular weight) that align with those of successful bioactive molecules.

Table 2: Bioactive Hits Identified from a 154-Member PNP Library [8]

PNP Class Identified Bioactivity Molecular Target/Pathway Significance
Class B (Spiro-indoline–indanone) Potent Inhibitor Hedgehog (Hh) Signaling Represents a novel chemotype for targeting this critical developmental and oncogenic pathway.
Class D (Exocyclic-olefinic α-halo-amide) Inhibitor Tubulin Polymerization A new structural scaffold with antimitotic potential, distinct from known colchicine or taxane sites.
Class E (Indoline–indanone–isoquinolinone) Inhibitor De novo Pyrimidine Biosynthesis Validates the strategy for discovering probes against metabolic pathways.
Class G (Not detailed in source) Inhibitor DNA Synthesis Confirms the library's functional diversity and ability to perturb fundamental cellular processes.

Experimental Protocols

Protocol 1: Divergent Synthesis of PNP Scaffolds via Indole Dearomatization

This protocol outlines the core methodology for generating multiple PNP classes from a common indole-based divergent intermediate, as detailed in the seminal 2024 study [8].

Objective: To synthesize a library of structurally diverse pseudo-natural products starting from a planar indole derivative through a palladium-catalyzed dearomatization cascade and subsequent diversification.

Materials:

  • Starting Material: C3-tethered indole substrate (e.g., 1a, R1 = Me, R2–6 = H) [8].
  • Catalyst System: Palladium acetate (Pd(OAc)2), Xantphos (4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene).
  • CO Surrogate: N-Formylsaccharin (safer, in-situ CO source).
  • Base: Sodium carbonate (Na2CO3).
  • Solvent: Anhydrous N,N-Dimethylformamide (DMF).
  • Diversification Reagents: Hantzsch ester, pyridinium p-toluenesulfonate (PPTS), α-halo-acetyl chlorides, methyl 2-bromobenzoate.

Procedure: Part A: Synthesis of Core Scaffold (Class A - Spiroindolylindanones)

  • Reaction Setup: In a flame-dried Schlenk tube under an inert atmosphere (N2 or Ar), combine the indole substrate 1a (1.0 equiv), Pd(OAc)2 (5 mol%), Xantphos (10 mol%), and Na2CO3 (2.0 equiv).
  • Addition: Add anhydrous DMF (0.1 M concentration relative to substrate) followed by N-formylsaccharin (1.5 equiv).
  • Dearomatization: Seal the tube and heat the reaction mixture to 100°C with stirring for 16-24 hours. Monitor reaction progress by TLC or LC-MS.
  • Work-up: After cooling to room temperature, dilute the mixture with ethyl acetate and wash with water and brine. Dry the organic layer over anhydrous MgSO4, filter, and concentrate under reduced pressure.
  • Purification: Purify the crude residue by flash column chromatography (silica gel, hexanes/ethyl acetate gradient) to obtain the dearomatized product A1 (spiroindolylindanone) as a single diastereomer in high yield (>85%) [8].

Part B: Diversification to Generate Additional PNP Classes

  • To Class B (Spiro-indoline–indanones): Dissolve compound A1 (1.0 equiv) in dichloroethane (DCE). Add Hantzsch ester (1.2 equiv) and a catalytic amount of PPTS (0.1 equiv). Stir at room temperature until complete reduction of the indolenine is confirmed by TLC. Purify via flash chromatography to obtain B1 with high diastereoselectivity (d.r. > 20:1) [8].
  • To Class D (Exocyclic-olefinic α-halo-amides): Treat A1 (1.0 equiv) with an α-halo-acetyl chloride (e.g., 2-bromoacetyl chloride, 1.5 equiv) and a non-nucleophilic base (e.g., DIPEA, 2.0 equiv) in dichloromethane at 0°C to room temperature. Work up and purify to yield the α-halo-amide product.
  • To Class E (Indoline–indanone–isoquinolinone): Subject A1 (1.0 equiv) to a palladium-catalyzed coupling with methyl 2-bromobenzoate (1.2 equiv) using Pd(OAc)2/Xantphos as the catalyst system and K3PO4 as base in toluene at 110°C. This domino coupling/dearomatization installs the fused isoquinolinone fragment.

Key Notes: The use of N-formylsaccharin as a solid, safe CO surrogate is critical for operational safety and efficiency compared to using toxic CO gas [8]. The substrate scope for Part A is broad, tolerating electron-rich and electron-deficient aryl bromides, enabling rapid library expansion.

Protocol 2: Phenotypic Screening and Target Identification for PNP Hits

Objective: To identify and characterize bioactive molecules from a PNP library using cell-based phenotypic screening and subsequent target deconvolution.

Materials:

  • Cell Line: Relevant reporter cell line (e.g., NIH/3T3 Shh-Light2 cells for Hedgehog pathway screening) [8].
  • Assay Reagents: Luciferase assay kit, cytotoxicity assay kit (e.g., MTT or CellTiter-Glo), fluorescent probes for phenotypic profiling (e.g., Cell Painting dyes).
  • Affinity Matrix: Activated sepharose beads for immobilizing the bioactive PNP (as a derivative with a synthetically added linker).

Procedure:

  • Primary Phenotypic Screening: Plate reporter cells in 384-well plates. Treat with PNP library compounds (typically at 10 µM) in duplicate or triplicate. Incubate for 24-48 hours. Measure reporter activity (e.g., luminescence) and cell viability. Identify hits causing significant pathway modulation without cytotoxicity.
  • Morphological Profiling (Cell Painting): Treat a wild-type cell line (e.g., U2OS) with hit compounds at multiple concentrations. After fixation, stain cells with a panel of fluorescent dyes targeting multiple organelles (RNA, nucleoli, ER, mitochondria, actin, plasma membrane). Acquire high-content images and extract quantitative morphological features. Use unsupervised clustering (e.g., principal component analysis) to generate a "phenotypic fingerprint" for each compound. Compare fingerprints to reference compounds with known mechanisms to generate hypotheses on the mode of action [8].
  • Chemical Proteomics for Target Identification: a. Probe Synthesis: Synthesize a functionalized derivative of the hit PNP containing a terminal alkyne or amine for "click chemistry" conjugation. b. Cell Lysate Treatment: Incubate the functionalized probe with lysate from relevant cells. Simultaneously, run a control with an excess of unmodified hit compound for competition. c. "Click" Conjugation and Pull-down: Use copper-catalyzed azide-alkyne cycloaddition (CuAAC) to conjugate the probe to azide-tagged agarose beads. Wash the beads extensively. d. Mass Spectrometry (MS) Analysis: Elute bound proteins, digest with trypsin, and analyze by liquid chromatography-tandem MS (LC-MS/MS). Identify proteins enriched in the probe sample versus the competition control sample. e. Validation: Validate candidate target interactions using techniques like cellular thermal shift assay (CETSA), surface plasmon resonance (SPR), or enzymatic assays.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagent Solutions for NP-Inspired DOS

Reagent / Material Function / Role in DOS Key Consideration
N-Formylsaccharin [8] Safe, solid CO surrogate for palladium-catalyzed carbonylative dearomatization and cyclization reactions. Eliminates need for handling toxic CO gas; provides controlled CO release.
Hantzsch Ester [8] Biomimetic hydride donor for selective reduction of iminium ions (e.g., in indolenine reduction). Enables diastereoselective synthesis of complex indolines under mild conditions.
Xantphos Ligand [8] Bulky, bidentate phosphine ligand for stabilizing Pd(0) and Pd(II) intermediates in cross-coupling and carbonylation. Crucial for successful dearomatization cascade; broad substrate tolerance.
Diversity-Oriented Building Blocks (e.g., amino acids, diverse aryl halides, cyclic ketones) [4] Provide appendage and functional group diversity in build/couple/pair (BCP) synthesis. Should contain orthogonal, differentially protected functional groups for sequential coupling.
Solid Support (e.g., Polystyrene beads) [4] Enables split-pool combinatorial synthesis for generating ultra-large, one-bead-one-compound (OBOC) libraries. Facilitates rapid screening and deconvolution via microsequencing or tagging.
Phenotypic Profiling Dye Set (Cell Painting) [8] A panel of 6 fluorescent dyes for high-content imaging and morphological profiling. Generates unbiased, high-dimensional data for mechanism-of-action hypothesis generation.

Strategic and Synthetic Pathway Visualizations

G NP Natural Product (NP) Libraries BIOS Biology-Oriented Synthesis (BIOS) NP->BIOS  Uses Core Scaffold PNP Pseudo-NP (PNP) Design NP->PNP  Fragment & Recombine CtD Complexity-to-Diversity (CtD) NP->CtD  Start from Complex NP-like Molecule Lib1 Focused NP Analog Library BIOS->Lib1 DivInt Divergent Intermediate Strategy PNP->DivInt Enables Lib2 Novel Scaffold PNP Library PNP->Lib2 Lib3 Ring-Distorted Complex Library CtD->Lib3 Lib4 Multi-Scaffold dPNP Library DivInt->Lib4 Generates Screen Phenotypic & Target-Based Screening Lib1->Screen Lib2->Screen Lib3->Screen Lib4->Screen Hits Bioactive Probe / Lead Candidates Screen->Hits

Strategic Workflow from NP Blueprints to Bioactive Compounds

G Start Common Indole-Based Divergent Intermediate PathA Pd/Xantphos, N-Formylsaccharin Na₂CO₃, DMF, 100°C Start->PathA ClassA Class A Spiroindolylindanone PathA->ClassA PathB Hantzsch Ester, PPTS DCE, rt ClassA->PathB Diversification PathC α-Halo-acetyl Chloride Base, DCM ClassA->PathC Diversification PathE Pd/Xantphos Methyl 2-bromobenzoate ClassA->PathE Diversification ClassB Class B Spiro-indoline–indanone PathB->ClassB ClassD Class D Exocyclic-olefinic α-halo-amide PathC->ClassD ClassE Class E Indoline–Indanone– Isoquinolinone PathE->ClassE

Divergent Synthetic Pathways to PNP Classes A-E

Diversity-Oriented Synthesis (DOS) is a deliberate synthetic strategy designed to populate broad regions of biologically relevant chemical space with structurally complex and diverse small molecules [2]. This approach stands in contrast to target-oriented synthesis (focused on a single compound) and traditional combinatorial chemistry (focused on appendage variations around a common core) [4] [11]. The core philosophy of DOS is to generate small-molecule libraries that emulate the profound structural diversity and three-dimensional complexity found in natural products, thereby increasing the probability of discovering novel bioactive compounds, especially against challenging or "undruggable" targets [2] [12].

Within the broader thesis of natural product scaffold research, DOS serves as a critical methodological bridge. Natural products are "pre-validated" by evolution to interact with biomacromolecules and occupy privileged regions of chemical space [4]. By using natural product scaffolds as inspiration, DOS aims not merely to replicate known natural products, but to diversify their core architectures intentionally. This generates libraries of novel, natural product-like compounds that can probe biological function and identify new therapeutic leads in ways the original natural products could not [4] [13]. The ultimate goal is to drive the discovery of small molecules with previously unknown biological functions, advancing both chemical biology and early drug discovery [4] [2].

Foundational Principles: The Three Dimensions of DOS Diversity

The structural diversity pursued in DOS is systematically decomposed into three interdependent dimensions: skeletal, stereochemical, and appendage diversity. Together, these dimensions dictate the overall molecular shape and functional group display, which are primary determinants of biological activity [2].

Table 1: The Three Core Dimensions of Diversity in DOS

Diversity Dimension Definition Key Role in Bioactivity Representative Synthetic Strategy
Skeletal (Scaffold) Diversity Variation in the core connectivity framework (the molecular skeleton) [2]. Most fundamental for defining 3D molecular shape and covering broad shape space; scaffolds present chemical information in unique spatial orientations [2]. Branching pathways; build/couple/pair (B/C/P) algorithm; late-stage skeletal reorganization [14] [15].
Stereochemical Diversity Variation in the configuration of stereogenic centers, axial chirality, or overall topography [16]. Directly impacts complementarity with chiral biological targets; different stereoisomers can engage targets with vastly different affinities and selectivities [16] [11]. Use of chiral building blocks; stereoselective or stereodivergent reactions [4] [11].
Appendage (Building-Block) Diversity Variation in the functional groups and substituents attached to a common skeleton or intermediate [2]. Modulates physicochemical properties, target affinity, and selectivity; provides vectors for fragment growth in drug discovery [2] [14]. Combinatorial attachment of different building blocks at diversification sites [4].

Core Methodologies and Experimental Protocols

The Build/Couple/Pair (B/C/P) Algorithm

The B/C/P algorithm is a foundational, systematic framework for planning DOS pathways to generate skeletal and stereochemical diversity [15]. It mimics biosynthetic logic by progressing from simple building blocks to complex, diverse products.

Table 2: The Build/Couple/Pair Algorithm Protocol

Phase Objective Protocol Details & Techniques Outcome
Build Prepare chiral, polyfunctional building blocks. Synthesize or procure enantiopure building blocks with orthogonal reactive groups (e.g., amines, aldehydes, alkenes). Asymmetric synthesis or use of commercially available chiral pools (e.g., amino acids, sugars) is common [15]. A collection of structurally varied precursors primed for coupling.
Couple Intermolecular union of building blocks. Employ robust, high-yielding coupling reactions (e.g., amide formation, Suzuki-Miyaura, aldol, Ugi) to combine build phase products in multiple combinations. This step generates stereochemical and appendage diversity [15]. Linear or branched precursors containing paired functional groups.
Pair Intramolecular cyclization or coupling. Subject couple-phase products to different cyclization modes (e.g., Ring-Closing Metathesis (RCM), Michael addition, Diels-Alder, Huisgen cycloaddition). The choice of "pair" reaction dictates the final skeletal framework [14] [15]. A collection of distinct molecular scaffolds (skeletal diversity) from common intermediates.

BCP_Algorithm DOS Build/Couple/Pair Algorithm Workflow Build Build Phase Synthesize chiral building blocks (A, B) Couple Couple Phase Intermolecular reaction (A + B → A-B) Build->Couple Combinatorial coupling Pair1 Pair Phase Intramolecular cyclization (via Path X) Couple->Pair1 e.g., RCM Pair2 Pair Phase Intramolecular cyclization (via Path Y) Couple->Pair2 e.g., Michael Scaffold1 Scaffold 1 Pair1->Scaffold1 Skeletal diversity Scaffold2 Scaffold 2 Pair2->Scaffold2 Skeletal diversity

Protocol for Chemoenzymatic DOS (CeDOS) via Late-Stage Functionalization

Recent advances integrate biocatalysis with DOS. This protocol outlines a chemoenzymatic DOS (CeDOS) strategy using engineered cytochrome P450 enzymes to achieve skeletal diversification [13].

Application Note: This protocol is ideal for diversifying natural product-like cores, such as sesquiterpene lactones (e.g., parthenolide), by performing late-stage, site-selective C–H oxidations that unlock subsequent rearrangement pathways [13].

Materials:

  • Parent natural product-like core (e.g., parthenolide).
  • Library of engineered P450 enzymes (e.g., variants of CYP102A1/P450BM3) or expressed natural P450s.
  • Cofactor regeneration system (e.g., glucose/glucose dehydrogenase for NADPH).
  • Solvents (e.g., potassium phosphate buffer, methanol, acetonitrile).
  • Analytical standards and reagents for downstream chemical rearrangements (e.g., acids, bases, catalysts).

Procedure:

  • Enzyme Screening: Set up parallel reactions containing the parent compound (0.1-1 mM) with individual P450 enzyme variants in appropriate buffer with a cofactor regeneration system. Incubate at 25-30°C with shaking for 2-16 hours [13].
  • Analytical Monitoring: Monitor reaction progress by UPLC-MS/MS. Identify variants that produce distinct, monohydroxylated regioisomers with clean product profiles.
  • Scale-Up and Isolation: Scale up productive reactions. Extract products, purify by preparative HPLC, and characterize regioisomer structures by NMR.
  • Skeletal Diversification: Subject each isolated hydroxylated regioisomer to divergent chemical synthesis conditions. For example:
    • Acid-mediated rearrangements: Treat with mild Lewis or Brønsted acids to trigger epoxide openings, cyclizations, or Wagner-Meerwein shifts [17].
    • Oxidation/functionalization: Further oxidize alcohols to ketones for subsequent aldol or nucleophilic addition reactions.
    • Side-chain elaboration: Functionalize the new hydroxyl group as a leaving group or couple to additional appendages.
  • Library Purification and Analysis: Purify all final compounds. Analyze the library using principal moment of inertia (PMI) plots to confirm coverage of 3D shape space [14].

CeDOS_Protocol Chemoenzymatic DOS via P450 Diversification Parent Parent Scaffold (e.g., Parthenolide) P450 P450 Enzymes (Regiodivergent C-H Oxidation) Parent->P450 ISO1 Hydroxylated Regioisomer A P450->ISO1 Variant A ISO2 Hydroxylated Regioisomer B P450->ISO2 Variant B Chem1 Divergent Chemical Synthesis (e.g., Acid Rearrangement) ISO1->Chem1 Chem2 Divergent Chemical Synthesis (e.g., Oxidation) ISO1->Chem2 ISO2->Chem1 LibA Diversified Scaffold A1 Chem1->LibA LibC Diversified Scaffold B1 Chem1->LibC LibB Diversified Scaffold A2 Chem2->LibB

Protocol for Generating Stereochemical Diversity via Stereocomplementary Synthesis

This protocol details an approach to synthesize all possible stereoisomers of a key scaffold, enabling rigorous study of stereochemistry-activity relationships [16] [11].

Application Note: Essential for probing chiral target spaces, this method moves beyond single stereoisomer synthesis to populate libraries with defined stereochemical variations of the same skeleton [16].

Materials:

  • Achiral or prochiral substrate attached to solid support (e.g., Wang resin) for ease of purification.
  • Set of enantiopure chiral reagents or catalysts known to deliver complementary stereochemical outcomes (e.g., (R)- and (S)-catalysts for asymmetric allylation).
  • Standard reagents for solid-phase synthesis, cleavage, and purification.

Procedure:

  • Solid-Phase Functionalization: Load substrate onto solid support, introducing a functional group for subsequent stereodetermining transformation.
  • Parallel Stereodivergent Synthesis: Divide the resin-bound substrate into separate reaction vessels. To each, apply a different stereoselective condition:
    • Vessel 1: Use catalyst (R)-Cat to induce (R)-configuration.
    • Vessel 2: Use catalyst (S)-Cat to induce (S)-configuration.
    • Vessel 3 & 4: Employ substrate-controlled diastereoselective reactions or kinetic resolutions to access other diastereomers.
  • Monitoring and Iteration: Cleave small aliquots from each resin batch for LC-MS analysis to confirm stereochemical purity and identity. Repeat stereochemical diversification if multiple centers are targeted.
  • Cleavage and Elaboration: Cleave products from solid support. Subject each stereoisomeric core to parallel appendage diversification (e.g., acylation, alkylation) to generate the final library.
  • Validation: Characterize stereochemistry of final compounds by chiral HPLC and optical rotation comparison to known standards or calculated values.

The Scientist's Toolkit: Essential Research Reagent Solutions

Table 3: Key Reagents and Materials for DOS Library Construction

Reagent/Material Function in DOS Specific Application Example
Solid Supports (e.g., Polystyrene, Macrobeads) Enables split-pool synthesis, simplifies purification via filtration, and facilitates encoding strategies for large libraries [4]. Used in synthesis of 1,3-dioxane libraries and encoded dihydropyrancarboxamide libraries [4].
Engineered Cytochrome P450 Enzymes Biocatalysts for regio- and stereoselective C–H functionalization, providing uniquely functionalized intermediates for skeletal reorganization [13]. Key to the CeDOS strategy for diversifying parthenolide into over 50 novel scaffolds [13].
Chiral Pool Building Blocks (e.g., Amino Acids, Sugars) Readily available sources of stereochemical complexity and diverse functionality for the "Build" phase [15]. Used as starting points for DOS of fragment-like, polycyclic compounds [14].
Pluripotent Intermediates Reactive intermediates (e.g., α,β-unsaturated acyl-imidazolidinones) capable of undergoing multiple different cycloaddition or annulation reactions to yield distinct scaffolds [12]. Intermediate 5 was diversified via [3+2], [4+2] cycloadditions and dihydroxylation to generate multiple cores [12].
Orthogonal Coupling Reagents & Catalysts To reliably execute the "Couple" phase under mild conditions with high fidelity, enabling combinatorial assembly [15]. Palladium catalysts for cross-coupling, HATU for amide formation, and organocatalysts for asymmetric reactions.
Ring-Closing Metathesis (RCM) Catalysts (e.g., Grubbs II) Key "Pair" phase tool for forming medium and large rings, generating significant 3D shape diversity [14]. Used in B/C/P strategies to form spiro- and fused bicyclic systems from diene precursors [14].

Application in Drug Discovery: From Library Synthesis to Bioactive Hits

The primary application of DOS libraries is in unbiased phenotypic screening and target-based assays to identify novel chemical probes and lead compounds [2].

Case Study 1: Discovery of an Anti-MRSA Agent A DOS library of 242 compounds based on 18 distinct natural product-like scaffolds was synthesized using a pluripotent intermediate strategy [12]. Phenotypic screening against methicillin-resistant Staphylococcus aureus (MRSA) identified gemmacin, a novel broad-spectrum antibiotic with low cytotoxicity [12]. This validates the DOS principle: skeletal diversity accesses new chemical space, leading to novel bioactivity against a pressing drug-resistant pathogen.

Case Study 2: Modulating a Challenging Protein-Protein Interaction A DOS library of approximately 2,070 macrolactones, inspired by natural product frameworks, was screened for inhibitors of the Sonic Hedgehog (Shh) signaling pathway [12]. This led to the discovery of robotnikinin, a small molecule that inhibits Gli expression by targeting the Shh protein itself, a challenging extracellular protein-protein interaction target [12]. This demonstrates DOS's power in addressing "undruggable" target classes.

Case Study 3: Generating 3D Fragments for FBDD DOS strategies have been specifically adapted to create fragment libraries (<300 Da) with high fraction of sp3 carbons (Fsp3) and multiple vectors for growth [14]. For example, a B/C/P approach using proline derivatives yielded a library of 35 diverse, rule-of-three-compliant fragments with broad 3D shape coverage, as confirmed by PMI analysis [14]. Such libraries address a critical shortage of synthetically tractable, three-dimensional fragments in fragment-based drug discovery (FBDD).

The discovery of novel bioactive small molecules, particularly for historically "undruggable" targets such as protein-protein interactions or RNA, demands access to structurally and stereochemically diverse chemical libraries [18] [2]. Diversity-Oriented Synthesis (DOS) has emerged as a pivotal strategy to systematically populate unexplored regions of biologically relevant chemical space [19]. Unlike target-oriented synthesis, DOS employs forward-synthetic analysis, where the products of each transformation become branching points for divergent subsequent steps, enabling exponential increases in molecular diversity from common intermediates [18].

Natural products serve as a paramount inspiration for DOS due to their inherent "pre-validated" biological relevance, complex three-dimensional architectures, and high fraction of sp³-hybridized carbons [4] [2]. The strategic frameworks of Build/Couple/Pair (B/C/P) and computational Forward-Synthetic Analysis provide complementary, systematic blueprints for transforming natural product scaffolds and other privileged structures into diverse libraries. These frameworks aim to escape the limitations of "flat" medicinal chemistry space by generating compounds with the globularity and complexity characteristic of natural products, thereby increasing the probability of identifying probes for novel biological mechanisms [19] [20].

The Build/Couple/Pair (B/C/P) Strategy: Principles and Applications

The B/C/P strategy is a highly systematic and widely adopted DOS framework that deliberately engineers skeletal and stereochemical diversity through three distinct phases [18] [15].

  • Build Phase: This involves the synthesis or procurement of chiral, pluripotent building blocks embedded with orthogonal functional groups suitable for downstream coupling. Ideally, these building blocks are commercially available or accessible via robust asymmetric synthesis [15].
  • Couple Phase: This stage employs intermolecular reactions (e.g., cross-couplings, condensations) to combine the building blocks in various combinations and stereochemical permutations. This phase primarily establishes stereochemical and appendage diversity [18] [15].
  • Pair Phase: This final, complexity-generating stage involves intramolecular reactions (e.g., cyclizations, cycloadditions) between the functional groups installed during the couple phase. The pairing order and mode (e.g., A-B vs. C-D) dictate the core scaffold of the final product, leading to significant skeletal diversity from common intermediates [18].

The power of B/C/P lies in its biomimetic logic, mirroring how organisms assemble complex natural products from simple precursors, and its modularity, which allows for the application of different reaction sequences to shared intermediates [15].

Application Notes: B/C/P in Natural Product Diversification

A seminal application of B/C/P is the synthesis and diversification of Lycopodium alkaloid scaffolds. As illustrated in the workflow below, chiral intermediate 1 (from build/couple phases) underwent an early pairing to form intermediate 2. A subsequent, strategically chosen later pairing phase (e.g., B–C followed by E–F) enabled access to distinct core skeletons, leading to the total synthesis of (+)-serratezomine A and the creation of an unnatural analog of (–)-serratinine with a different ring system (6/5/6/5) [18]. This demonstrates how B/C/P can be used not just for library synthesis, but for planning the concise, divergent total synthesis of natural product families.

G Build Build Phase: Synthesis of chiral building blocks Couple Couple Phase: Intermolecular coupling for stereochemical diversity Build->Couple Functional Group Installation IPair Intermediate Pairing (e.g., Ring Formation) Couple->IPair Dense Array of Reactive Sites Divergent Divergent Intermediate IPair->Divergent NP1 Natural Product A (e.g., (+)-Serratezomine A) Divergent->NP1 Pairing Path 1 (B–C then E–F) NP2 Unnatural Analog B (6/5/6/5 System) Divergent->NP2 Pairing Path 2 NP3 Tricyclic Compound C Divergent->NP3 Pairing Path 3 (A–B then C–E)

B-C-P Workflow for Natural Product Analogs

Quantitative Outcomes of B/C/P Libraries

Table 1: Representative Library Outputs from B/C/P Strategy [18]

Library Focus Scaffold Diversity Total Compounds Key Synthetic Features
Macrocycles 59 distinct scaffolds 73 Fluorous-tagged azido building blocks, pluripotent aza-ylides, post-pairing modification.
Natural Product-like Compounds Multiple polycyclic systems (e.g., 6/6/6/5, 6/5/6/5, 5/6/5) 10+ (focused library) Stepwise double pairing processes on a common tricyclic intermediate.

Forward-Synthetic Analysis: Principles and Computational Implementation

Forward-synthetic analysis in DOS refers to the planning of synthesis pathways where each step generates intermediates capable of branching into multiple downstream products [18]. In its modern, computational incarnation, this involves predictive modeling of reaction outcomes to plan or analyze synthetic sequences toward diverse libraries [21] [22].

Computational tools perform forward prediction: given a set of reactants and conditions, the model predicts the major product(s) [21]. This capability is crucial for planning the branching steps in DOS. When combined with retrosynthetic analysis, it forms a powerful recursive design loop: a target scaffold is deconstructed to commercially available starting materials (retrosynthesis), and then forward prediction is used to map out the divergent pathways available from those materials back toward the target and its analogs [22].

This retro-forward synthesis design pipeline, as demonstrated in recent work, can rapidly propose thousands of synthesizable analogs of a "parent" drug molecule (e.g., Ketoprofen, Donepezil) by identifying viable substrates and guiding their combination through reaction networks focused on structural similarity to the parent [22]. This represents a formalized, algorithm-driven execution of the forward-synthetic analysis principle.

Application Notes: Computational Workflow for Analog Design

The following diagram outlines a contemporary computational pipeline for analog design using retro-forward synthesis, integrating both strategic frameworks [22].

G Parent Parent Molecule (e.g., Drug) Replicas Parent 'Replicas' (Substructure Replacements) Parent->Replicas Diversification Retro Retrosynthetic Analysis (Depth ~5 steps) Replicas->Retro G0 Substrate Set (G0) Commercial + Auxiliary Building Blocks Retro->G0 Substrate ID Fwd Guided Forward-Synthetic Network G0->Fwd Beam Search (Similarity-Guided) Candidates Candidate Analogs (Synthesizable & Similar) Fwd->Candidates Evaluation Experimental Validation (Synthesis & Affinity Assay) Candidates->Evaluation

Retro-Forward Computational Pipeline

Quantitative Performance of Forward-Synthetic Tools

Table 2: Capabilities and Accuracy of Computational Forward-Synthetic Analysis [21] [22]

Task Model Performance / Outcome Key Tools / Constraints
Product Prediction >80% top-1 accuracy on benchmark datasets. Neural network models (e.g., wln-5) trained on reaction databases (e.g., Pistachio).
Analog Synthesis Planning Proposed syntheses for 1000s of analogs in minutes; experimental validation success: 12/13 routes. Guided reaction networks with similarity "beam width"; ~25,000 reaction rules.
Binding Affinity Prediction Order-of-magnitude accuracy; can distinguish binders but not precisely rank high-affinity candidates. Used alongside docking programs (e.g., AutoDock Vina, Glide) in integrated pipeline.

Comparative Strategic Analysis and Integration

While B/C/P is a chemistry-driven blueprint for manual library construction, computational Forward-Synthetic Analysis provides a data-driven planning and prediction engine. Their integration represents the cutting edge of DOS library design.

Table 3: Strategic Comparison of B/C/P and Forward-Synthetic Analysis

Aspect Build/Couple/Pair (B/C/P) Computational Forward-Synthetic Analysis
Primary Objective Systematic generation of skeletal & stereochemical diversity via phased synthesis. Prediction of synthetic outcomes & planning of divergent pathways to accessible analogs.
Core Principle Biomimetic, phase-separated modularity (Build → Couple → Pair). Similarity-guided exploration of chemical reaction networks from a substrate set.
Driver Chemical intuition, known reactivity, and modular reaction design. Algorithms, reaction rule databases, and predictive ML models.
Optimal Application De novo library synthesis from simple blocks; inspired by natural product scaffolds. Rapid exploration of analog space around a lead; validation of synthetic accessibility.
Output Physical compound libraries with high 3D complexity. Virtual libraries with predicted synthetic routes and properties.

Synergistic Integration: Computational forward analysis can optimize the "Build" phase by selecting optimal building blocks from commercial catalogs. It can also predict outcomes of "Pair" phase reactions, helping chemists choose the most successful cyclization modes. Conversely, experimentally successful B/C/P pathways enrich the reaction databases that fuel computational models [22] [20].

Experimental Protocols

Protocol: DOS Library Synthesis via B/C/P Using Natural Product-Inspired Scaffolds

Objective: To synthesize a library of macrocyclic compounds featuring natural product-like complexity and skeletal diversity [18].

  • Build Phase (Preparation of Pluripotent Building Block):
    • Synthesize or obtain a chiral amino acid derivative (e.g., a fluorous-tagged azido amino acid).
    • Key Reaction: Asymmetric alkylation or enzymatic resolution to ensure enantiopurity. Protect functional groups as necessary, leaving an azide and a carboxylic acid active for coupling.
  • Couple Phase (Intermolecular Diversification):
    • Activate the carboxylic acid of the building block (e.g., as an acyl chloride or using HATU).
    • In parallel, prepare a set of diverse amine nucleophiles (e.g., 10-20 variations with differing chain length, rigidity, and sterics).
    • Couple each amine to the activated building block to generate a library of amide intermediates. This step establishes appendage diversity.
    • Purification: Use fluorous solid-phase extraction (F-SPE) if a fluorous tag is employed for efficient intermediate purification [18].
  • Pair Phase (Macrocyclization for Skeletal Diversity):
    • Reduce the azide on each intermediate to a primary amine in situ using a reagent like triphenylphosphine.
    • The resulting amine can react with the amide carbonyl in a base-mediated intramolecular cyclization to form a macrocyclic lactam. Alternatively, employ different pairing modes:
      • Use the amine for a reductive amination with a separate aldehyde moiety installed during the couple phase.
      • Utilize ring-closing metathesis (RCM) if olefin-containing appendages were coupled.
    • Purification & Analysis: Perform final purification via preparative HPLC. Confirm structures using LC-MS and NMR. Analyze skeletal diversity by clustering based on core ring size and topology.

Protocol: Computational Design & Validation of Analogs via Retro-Forward Analysis

Objective: To design and prioritize synthesizable structural analogs of a known drug for experimental testing [22].

  • Input & Diversification:
    • Input the SMILES string of the parent molecule (e.g., Ketoprofen) into the computational pipeline.
    • The algorithm automatically identifies key substructures (e.g., the benzophenone core) and generates "replicas" by replacing them with bioisosteric or similarly shaped fragments from a curated library.
  • Retrosynthetic Substrate Identification:
    • Initiate a retrosynthetic search (depth-limited to ~5 steps) for each replica using a knowledge base of robust medicinal chemistry reactions.
    • Aggregate all commercially available starting materials (from vendors like Mcule) identified in these retrosynthetic trees. Augment this set with simple, synthetically versatile "auxiliary" chemicals (e.g., formaldehyde, acetylene).
    • This combined set forms the substrate pool (Generation G0).
  • Guided Forward-Synthetic Network Expansion:
    • The algorithm applies forward reaction rules to all pairwise combinations within G0 to create Generation G1 (thousands of virtual molecules).
    • Only the top W molecules (e.g., 150) most structurally similar to the parent (using a molecular fingerprint metric) are retained.
    • Iterate: Allow retained molecules from Gi to react with all molecules from earlier generations (Gi-1, Gi-2...G0), again retaining only the top W most parent-like products. This "beam search" focuses the network toward synthesizable analogs.
  • Candidate Selection & Experimental Validation:
    • Select candidate analogs from the final guided network based on a combination of high predicted synthetic accessibility (short route from G0 substrates), structural novelty, and predicted binding affinity (from a fast docking score).
    • Synthesis: Execute the computer-proposed synthetic routes for the top 5-10 candidates.
    • Assay: Test purified analogs in the relevant biological assay (e.g., COX-2 inhibition for Ketoprofen analogs) to validate binding and compare to computational predictions.

Table 4: Key Reagents and Resources for Implementing B/C/P and Forward-Synthetic Analysis

Item Name / Category Function in DOS Specific Role / Example
Chiral Pool Building Blocks Foundation of the "Build" phase; source of stereochemical diversity. Commercially available enantiopure amino acids, hydroxy acids, terpene derivatives.
Fluorous-Tagged Reagents Enables rapid purification of intermediates in multi-step DOS sequences. Fluorous-tagged azides or amines used in B/C/P for facile F-SPE separation [18].
Broad-Scope Coupling Catalysts Facilitates "Couple" phase reactions between diverse building blocks. Pd catalysts for cross-coupling (Suzuki, Sonogashira); HATU/T3P for amide bond formation.
Complexity-Generating Reaction Reagents Drives the "Pair" phase to form diverse scaffolds. Gold(I) catalysts for cycloisomerizations; Grubbs catalysts for RCM; Di-/Tris-phosgene for macrocyclizations.
Reaction Database Fuel for computational forward and retrosynthetic models. Pistachio, Reaxys; provides millions of examples to train predictive algorithms [21].
Forward Prediction Software Predicts products and impurities for proposed reactions. ASKCOS Forward Prediction module; guides branching decisions in synthetic planning [21].
Retrosynthetic Planning Software Identifies viable synthetic routes from substrates to target. ASKCOS retrosynthesis, Allchemy; used to define starting substrate set (G0) [22].
Commercial Substrate Catalogs Source of tangible building blocks for G0 in computational pipelines. Curated lists from Mcule, Enamine REAL Space; >2.5M available compounds for virtual screening [22].

Abstract This application note details a synergistic methodology integrating Density of States (DOS)-based quantum chemical descriptors with Diversity-Oriented Synthesis (DOS) strategies, guided by natural product scaffolds. We posit that the "flatland" of conventional, lipophilic compound libraries can be escaped by using electronic structure descriptors to navigate towards rich, underexplored regions of chemical space. This approach, framed within a broader thesis on biologically relevant chemical space, enables the rational design of skeletally diverse, complex small molecules with enhanced potential to modulate challenging biological targets. We provide detailed experimental and computational protocols for DOS fingerprint generation, library design, and synthesis, supported by visualization tools and a curated research toolkit.

The central thesis of this work is that Diversity-Oriented Synthesis (DOS) inspired by natural product scaffolds provides a synthetic roadmap to biologically relevant chemical space, while electronic Density of States (DOS) descriptors offer a computational compass to navigate it. Traditional drug discovery libraries are often mired in "flatland"—characterized by low three-dimensionality, high aromaticity, and limited functional group diversity, which reduces their ability to interact with complex protein surfaces, particularly those involved in protein-protein interactions [2] [23].

Natural products, in contrast, are evolutionarily pre-validated to interact with biomacromolecules. They typically possess high sp³-character, multiple stereocenters, and structural complexity, making them ideal starting points for DOS to generate skeletally diverse libraries that probe broader swathes of bioactive space [4] [2]. The challenge lies in rationally prioritizing which novel, natural product-inspired scaffolds to synthesize.

Here, we introduce DOS-DOS theory: using quantum-chemical DOS as a primary descriptor to quantify and visualize the "electronic shape" of molecules. By mapping the DOS profiles of natural product archetypes and virtual libraries, we can identify clusters of compounds with similar electronic structures—a proxy for potential bioactivity—and flag electronically novel regions that remain underexplored [24]. This guides synthetic efforts towards creating compounds that escape flatland, both structurally and electronically.

Conceptual Foundations and Data Presentation

Key Definitions and Quantitative Landscape

  • Chemical Space: The vast, multidimensional universe of all possible molecules. Estimates suggest over 10⁶⁰ drug-like molecules exist, with only a minuscule fraction synthesized or tested [25].
  • "Flatland": A derogatory term for regions of chemical space occupied by simple, planar, lipophilic compounds common in commercial libraries. They exhibit low Scaffold Diversity, a key deficiency [2].
  • Diversity-Oriented Synthesis (DOS): A synthetic strategy aimed at efficiently generating libraries with high skeletal (scaffold), stereochemical, and appendage diversity from common precursors, as opposed to targeting a single compound [4] [2].
  • Density of States (DOS): In quantum chemistry, a function ρ(E) that describes the distribution of electronic energy levels in a material or molecule. It encodes critical information about reactivity, stability, and optical properties [24].

Table 1: Comparison of Key DFT Software for DOS Calculations in Drug Discovery [26] [23]

Software Basis Set Type Periodic Boundary Conditions? Key Strengths for DOS-DOS Typical Use Case in Protocol
Gaussian Gaussian-Type Orbitals (GTO) No (Molecular) High accuracy for molecular properties, excellent for single molecules & conformers. Calculating DOS of final proposed library members for validation.
VASP Plane Waves (PW) Yes Gold standard for solid-state, periodic systems. Essential for studying crystal forms & polymorphs. Analyzing DOS of solid-state API forms or co-crystals [26].
Quantum ESPRESSO Plane Waves (PW) Yes Open-source, robust functionality. Good balance of performance and accessibility. High-throughput DOS calculation for large virtual libraries.
CP2K Mixed GTO & PW Yes Efficient for large systems, excellent for molecular dynamics. Studying DOS changes during dynamic processes (e.g., binding).

Table 2: Components of Structural Diversity in Library Design [2]

Diversity Component Description Impact on Chemical Space Natural Product Trait
Skeletal (Scaffold) Variation in the core molecular framework. Most significant. Defines overall shape and 3D surface. High - diverse cyclic/ bridged systems.
Stereochemical Variation in chiral center configuration. Alters 3D presentation of functional groups. Very High - multiple stereocenters common.
Appendage (Building-Block) Variation in peripheral substituents. Modifies local interactions and properties (e.g., logP). Moderate to High.
Functional Group Variation in chemically reactive moieties. Directly influences binding interactions (H-bond, ionic). High - rich in heteroatoms.

Core Application Notes & Protocols

Application Note 1: DOS Fingerprint Generation for Molecular Clustering

Objective: To convert the continuous electronic DOS spectrum of a molecule into a discrete, comparable fingerprint for unsupervised machine learning and similarity analysis [24].

Protocol 1.1: Generation of Tunable DOS Fingerprint

  • Quantum Chemical Calculation: Optimize the geometry of the target molecule using DFT (e.g., B3LYP/6-31G*). Perform a single-point energy calculation to obtain the total DOS, ρ(E). Software: Gaussian or ORCA [23].
  • Energy Alignment: Shift the DOS spectrum so that a key reference energy (ε_ref) is at zero. For drug discovery, the Fermi level (highest occupied molecular orbital, HOMO) or the energy of a frontier orbital is typically used [24].
  • Non-Uniform Binning: Discretize the energy axis into a histogram {ρ_i} using a variable-width scheme.
    • Define parameters: N_ε (number of bins, e.g., 256), Δε_min (minimal bin width, e.g., 0.1 eV), W (feature region width, e.g., 2.0 eV), N (max width multiplier).
    • The bin width Δε_i increases from Δε_min near ε=0 to N*Δε_min for |ε| > W. This focuses resolution on electronically relevant frontier orbitals [24].
    • Integrate: ρ_i = ∫_{ε_i}^{ε_{i+1}} ρ(ε) dε.
  • Intensity Quantization: Discretize the DOS intensity (y-axis) for each bin i into N_ρ levels using a similar variable-height scheme (parameters: W_H, N_H, Δρ_min).
  • Fingerprint Encoding: Generate a binary 2D raster image (size N_ε × N_ρ). Pixel (i, j) is set to 1 if ρ_i exceeds the threshold for level j, else 0. Flatten this image to a binary vector f, the final DOS fingerprint [24].

Protocol 1.2: Similarity Analysis and Clustering

  • Similarity Metric: Calculate the similarity S(f_i, f_j) between two fingerprints using the Tanimoto coefficient (Tc) [24]: S(f_i, f_j) = (f_i · f_j) / (|f_i|² + |f_j|² - f_i · f_j)
  • Clustering: Apply an unsupervised clustering algorithm (e.g., hierarchical clustering, k-means) to the matrix of pairwise Tc similarities.
  • Analysis: Identify clusters of molecules with similar electronic structures. Correlate clusters with structural features (e.g., specific natural product scaffolds) or calculated properties (band gap, polarizability). Identify "outlier" molecules with unique DOS profiles as candidates for novel exploration [24].

G Start Molecule Structure DFT DFT Calculation (e.g., B3LYP/6-31G*) Start->DFT RawDOS Raw DOS Spectrum ρ(E) DFT->RawDOS Align Align Spectrum (Set ε_ref = 0) RawDOS->Align Bin Non-Uniform Energy Binning Align->Bin Hist Integrated Histogram {ρ_i} Bin->Hist Quantize Intensity Quantization Hist->Quantize Binary2D Binary 2D Raster Image Quantize->Binary2D Fingerprint Flatten to Binary Fingerprint f Binary2D->Fingerprint

Title: Workflow for Generating a DOS Fingerprint

Application Note 2: Natural Product-Inspired DOS Library Design

Objective: To design a synthetically accessible, skeletally diverse library where member scaffolds are inspired by natural products and selected based on DOS profile novelty.

Protocol 2.1: Scaffold Selection & Virtual Library Generation

  • Natural Product Archetype Identification: Choose 3-5 structurally distinct natural product scaffolds with known bioactivity but synthetic tractability (e.g., galanthamine-like alkaloids, macrolide cores, flavone variants) [4].
  • DOS Fingerprint Baseline: Calculate DOS fingerprints for the chosen archetypes (Protocol 1.1).
  • Virtual Library Enumeration: Use retrosynthetic analysis and forward-synthesis planning software to generate a virtual library of 500-2000 analogs for each scaffold. Diversify using:
    • Skeletal Diversification: Employ DOS strategies like build/couple/pair (B/C/P) with pluripotent functional groups [2].
    • Appendage Diversification: Incorporate diverse, commercially available building blocks.
  • DOS-Based Prioritization:
    • Calculate DOS fingerprints for all virtual library members.
    • Perform similarity mapping (Protocol 1.2) including the natural product archetypes and a set of representative "flat" molecules.
    • Prioritize for synthesis those virtual compounds that: a) Cluster with the parent natural product (validating inspiration). b) Form new clusters in regions of chemical space distant from both the "flatland" reference and other known bioactive clusters (indicating novelty).

Table 3: Example Parameters for DOS Fingerprint-Based Library Prioritization

Parameter Typical Value Role in Library Design
Tanimoto Similarity (Tc) Threshold 0.7 - 0.8 Compounds with Tc > threshold to a known bioactive are considered in the same "electronic cluster".
Novelty Radius (Min. Tc) < 0.4 to all references Compounds with Tc < threshold to all reference sets (flat, bioactive NPs) are flagged as high-priority novel candidates.
Cluster Size 5 - 50 members Identifies electronically coherent groups for representative synthesis.

Protocol 2.2: Synthesis of a Skeletally Diverse Library (Example) This protocol is inspired by solid-phase DOS approaches for generating scaffolds like 1,3-dioxanes and dihydropyrancarboxamides [4].

  • Solid-Phase Functionalization: Load a pluripotent building block (e.g., a tyrosine-derived epoxide) onto a solid support (e.g., polystyrene resin) [4].
  • Skeletal-Diversifying Step: Split the resin into multiple portions. Subject each to a different cyclization or coupling reaction (e.g., nucleophilic ring opening followed by acetal formation, hetero-Diels-Alder cyclization) to generate distinct core scaffolds [4].
  • Appendage-Diversifying Steps: Recombine and split resins iteratively, performing reliable reactions (e.g., amide coupling, reductive amination, Mitsunobu alkylation) to introduce varied substituents (R¹, R², etc.).
  • Cleavage and Purification: Cleave products from the solid support under mild conditions. Purify via automated reverse-phase HPLC to yield the final library members for biological testing and DOS validation.

G NP_Scaffolds Select Natural Product Scaffold Archetypes Calc_DOS_Base Calculate DOS Fingerprints (Baseline) NP_Scaffolds->Calc_DOS_Base Enum_Lib Enumerate Virtual Library via DOS Strategy Calc_DOS_Base->Enum_Lib Calc_DOS_Virtual Calculate DOS Fingerprints (Virtual Lib) Enum_Lib->Calc_DOS_Virtual Map_Space Map & Cluster in Chemical Space Calc_DOS_Virtual->Map_Space Analyze Cluster with NP AND Novel Region? Map_Space->Analyze Priority High-Priority Synthesis Targets Analyze->Priority Yes LowPri Lower Priority Virtual Compounds Analyze->LowPri No

Title: DOS-Guided Library Design and Prioritization Workflow

The Scientist's Toolkit: Essential Research Reagents & Materials

Table 4: Key Research Reagent Solutions for DOS-DOS Exploration

Item / Reagent Function / Purpose in Protocol Example / Specification
DFT Software License Performing quantum chemical calculations to obtain electronic DOS. Gaussian, VASP, Quantum ESPRESSO (open source) [26] [23].
Cheminformatics Toolkit Handling molecular structures, fingerprint calculation, similarity metrics, and clustering. RDKit (open source), KNIME, Pipeline Pilot.
Chemical Space Visualization Software Projecting high-dimensional descriptor/data into 2D/3D maps for analysis. ChemMaps, t-SNE, or PCA implementations in Python/R [27].
Solid-Phase Synthesis Resin Platform for executing DOS pathways and enabling combinatorial diversification. Polystyrene-based Wang resin, Rink amide resin [4].
Pluripotent Building Blocks Starting materials capable of undergoing multiple distinct reaction pathways to yield different scaffolds. Epoxy-alcohols, vinylogous carbonyls, amino acid derivatives [4] [2].
Diversification Reagent Sets Sets of structurally diverse, commercially available reagents for appendage modification. Sets of carboxylic acids, amines, alkyl halides, boronic acids for coupling reactions.
High-Throughput Purification System Purifying library members post-synthesis for biological testing. Reverse-phase HPLC with mass-directed fraction collection.

The full integrated workflow for escaping "Flatland" combines computational guidance with synthetic execution, creating a virtuous cycle for exploring underexplored chemical territories.

G Step1 1. Computational Navigation Step2 2. DOS-Inspired Synthesis Step1->Step2 Prioritized Targets Step3 3. Experimental Validation Step2->Step3 Physical Library Step4 4. Feedback & Model Refinement Step3->Step4 Bioactivity & DOS Data Step4->Step1 Refined Models

Title: Integrated DOS-DOS Discovery Cycle

Conclusion The fusion of electronic Density of States theory with Diversity-Oriented Synthesis, rooted in natural product inspiration, provides a powerful, principled framework for drug discovery. By using DOS fingerprints as a quantitative measure of electronic structure—a fundamental molecular property—researchers can move beyond simplistic "flat" molecular designs. The protocols outlined here enable the targeted exploration of complex, biologically relevant chemical space, increasing the likelihood of discovering novel probes and therapeutics for historically "undruggable" targets [2]. This DOS-DOS paradigm represents a critical step towards a more rational and comprehensive mapping of the chemical-biological galaxy [25].

Synthetic Toolbox: Key Methodologies for Diversifying Complex Natural Product Cores

C-H functionalization has emerged as a transformative strategy in synthetic organic chemistry, enabling the direct conversion of inert carbon-hydrogen bonds into versatile functional groups. This capability is particularly powerful within the paradigm of diversity-oriented synthesis (DOS), which aims to generate structurally and functionally diverse compound libraries from simple starting materials [2]. In the context of natural product research, late-stage C-H diversification offers an unparalleled opportunity to rapidly generate analogs from complex bioactive scaffolds, bypassing the need for de novo total synthesis and enabling systematic exploration of structure-activity relationships (SAR) [28]. Natural products inherently occupy biologically relevant chemical space, as they have evolved to interact with macromolecular targets; utilizing their scaffolds as platforms for DOS therefore provides a "privileged" starting point for drug discovery [4]. By treating inert C-H bonds as a universal handle for modification, chemists can directly diversify core structures, modulate physicochemical properties, and enhance biological activity, thereby accelerating the discovery of novel therapeutic agents and chemical probes [28] [29].

Methodological Advances in C-H Diversification for DOS

The successful integration of C-H functionalization into DOS campaigns hinges on the development of selective, robust, and sustainable methodologies. Recent innovations have focused on achieving site-selectivity on complex molecules and employing green chemistry principles to enhance practicality.

Table: Representative C-H Oxidation Methods for Natural Product Diversification

Method/Catalyst Natural Product Substrate Site Selectivity Yield/Selectivity Key Metric Primary Application
Fe(PDP) Catalyst [28] (+)-Sclareolide C2 vs C3 Oxidation 78% yield, C2:C3 = 1.4:1 sp³ C-H hydroxylation
Electrochemical Oxidation [28] (+)-Sclareolide C2-selective 47% yield, C2:C3 = 5.6:1 Scalable, oxidant-free oxidation
TFDO (dioxirane) [28] (+)-Sclareolide C3 preferential C3:C2 = 3.5:1 Electrophilic O-insertion
P450BM3 Enzymes [28] (+)-Sclareolide C3 β-hydroxylation High selectivity Biocatalytic hydroxylation
Electrochemical w/ Quinuclidine Mediator [29] Cedrol derivative Tertiary C-H 52% yield (single isomer) Remote C-H hydroxylation

Table: Green Strategies for Transition Metal-Catalyzed C-H Activation

Strategy Catalyst System Solvent/Reaction Medium Key Advantage Example Transformation
Biomass-Derived Solvents Ru, Pd, Co catalysts γ-Valerolactone (GVL), PEG-400 Renewable, low toxicity, biodegradable [30] C-H arylation, alkenylation [30]
Earth-Abundant 3d Metals Co(OAc)₂, CuBr PEG-400 [30] Cost-effective, sustainable catalyst [30] C-H/N-H annulation, alkynylation [30]
Electrochemical Synthesis Mediator-assisted Undivided cell (C/Ni electrodes) [29] External oxidant-free, tunable selectivity [29] C-H hydroxylation of alkanes [29]

Two key philosophies drive methodology development: the design of catalysts that recognize subtle steric and electronic differences in C-H bonds, and the use of directing groups or mediators to achieve remote functionalization [28] [29]. For instance, peptide-based catalysts have been engineered to differentiate between similar hydroxy groups in complex glycopeptides like vancomycin by mimicking substrate binding interactions [28]. In the realm of C-H activation, the choice of catalyst and oxidant system critically determines site-selectivity, as demonstrated by the divergent oxidation outcomes on the test substrate (+)-sclareolide [28]. Furthermore, sustainability is now a major focus, with advances in using earth-abundant 3d transition metals (e.g., Co, Cu), biomass-derived green solvents like γ-valerolactone (GVL), and electrochemistry to reduce environmental impact and improve atom economy [30].

Application Notes: Diversifying Natural Product Scaffolds

Case Study 1: Vancomycin Analogs via Site-Selective Modification The glycopeptide antibiotic vancomycin was diversified using peptide-based catalysts to perform site-selective acylations. Catalysts were designed based on the structure of vancomycin's native ligand (D-Ala-D-Ala) to selectively target specific alcohol groups (e.g., Z6-OH vs. G6-OH) [28]. Subsequent lipidation at the G4 position produced analogs with significantly enhanced potency (up to 64-fold) against vancomycin-resistant bacteria (e.g., VanB strain), directly linking a late-stage modification to a critical pharmacological improvement [28].

Case Study 2: Skeletal Diversification via C-H Oxidation The sesquiterpene (+)-sclareolide serves as a model scaffold for developing and applying diverse C-H oxidation methods. Each method offers a different selectivity profile, enabling access to distinct oxidation products from a single starting material [28]. This principle allows for the rapid generation of skeletally diverse analogs. For example, the C2-oxidized product from electrochemical oxidation was advanced in six steps to the meroterpenoid analog (+)-oxo-yahazunone, demonstrating how late-stage C-H functionalization can dramatically streamline synthetic routes to complex natural product-like structures [28].

Case Study 3: Spiroketal Libraries for Probe Discovery Spiroketals are privileged, three-dimensional substructures found in many natural products. Research has developed kinetically-controlled spiroketalization reactions to systematically generate libraries with stereochemical diversity, moving beyond traditional thermodynamic control [31]. This approach allows for the exploration of shape diversity—a key component of functional diversity—by presenting functional groups along well-defined vectors in space, making such libraries valuable for identifying probes for underexplored biological targets [2] [31].

Experimental Protocols

Protocol 1: Peptide-Catalyzed, Site-Selective Acylation of Vancomycin Aglycon [28]

  • Objective: Selective mono-acylation of a single hydroxy group on a complex polyol scaffold.
  • Materials:
    • Minimally protected vancomycin aglycon derivative.
    • Peptide catalyst (e.g., catalyst 21 for Z6-OH selectivity or 22 for G6-OH selectivity).
    • Acylating reagent (e.g., thiocarbonate or lipid anhydride).
    • Anhydrous dimethylformamide (DMF) or dichloromethane (DCM).
    • Inert atmosphere (Ar/N₂) glovebox or Schlenk line.
  • Procedure:
    • Charge a flame-dried vial with the vancomycin substrate (e.g., 500 mg scale) and the designated peptide catalyst (10-20 mol%).
    • Evacuate and backfill the vial with argon three times.
    • Add anhydrous solvent via syringe.
    • Cool the reaction mixture to 0°C.
    • Add the acylating reagent (1.1-1.5 equivalents) dropwise via syringe.
    • Allow the reaction to warm to room temperature and monitor by LC-MS/TLC.
    • Upon completion, dilute with ethyl acetate and wash sequentially with aqueous citric acid, saturated NaHCO₃, and brine.
    • Dry the organic layer over Na₂SO₄, filter, and concentrate.
    • Purify the product by flash chromatography.
  • Notes: Catalyst performance is highly dependent on precise hydrogen-bonding interactions. Screening a small library of peptide catalysts is recommended for new substrates. The selectivity is often predictable based on catalyst-substrate co-crystal structures.

Protocol 2: Electrochemical C-H Oxidation of (+)-Sclareolide [28] [29]

  • Objective: Regioselective electrochemical oxidation of an unactivated C-H bond on a gram scale.
  • Materials:
    • (+)-Sclareolide substrate.
    • Quinuclidine mediator (e.g., N-methylquinuclidinium salt).
    • Electrolyte (e.g., LiClO₄).
    • Solvent mixture: Acetonitrile (MeCN) / acetic acid (AcOH) / water.
    • Reticulated Vitreous Carbon (RVC) anode.
    • Nickel foil cathode.
    • Undivided electrochemical cell.
    • Constant current power supply.
  • Procedure:
    • In the electrochemical cell, combine (+)-sclareolide, the quinuclidine mediator (0.2 equiv), and electrolyte (0.1 M) in the solvent mixture (e.g., MeCN/AcOH/H₂O).
    • Assemble the cell with the RVC anode and Ni cathode. Ensure electrodes are properly spaced and immersed.
    • Connect to a DC power supply and apply a constant current (e.g., 10 mA/cm²).
    • Maintain the reaction at room temperature with stirring. Monitor reaction progress by TLC or LC-MS.
    • After consumption of starting material (typically 2-4 F/mol of charge passed), disconnect the power supply.
    • Dilute the reaction mixture with water and extract with ethyl acetate (3x).
    • Combine organic layers, wash with brine, dry over MgSO₄, and concentrate.
    • Purify the crude material by silica gel flash chromatography to isolate the C2-oxidized product.
  • Notes: The regioselectivity is mediated by the quinuclidine derivative. This protocol is highly scalable (demonstrated at 50 g) [28] and avoids the use of stoichiometric chemical oxidants.

Protocol 3: Ruthenium-Catalyzed C-H Alkenylation in Green Solvent [30]

  • Objective: Sustainable C-H functionalization using biomass-derived solvent.
  • Materials:
    • Aryl carboxylic acid substrate.
    • [RuCl₂(p-cymene)]₂ catalyst.
    • Cu(OAc)₂·H₂O oxidant.
    • γ-Valerolactone (GVL) solvent.
    • Alkene coupling partner.
    • Molecular oxygen (O₂) balloon.
  • Procedure:
    • In a Schlenk tube, combine the aryl carboxylic acid (1.0 equiv), [RuCl₂(p-cymene)]₂ (5 mol%), Cu(OAc)₂·H₂O (2.0 equiv), and the alkene (2.0 equiv).
    • Evacuate and backfill the tube with oxygen gas.
    • Add anhydrous GVL via syringe to make a 0.1-0.2 M solution.
    • Heat the reaction mixture to 120°C under an O₂ atmosphere (balloon) for 12-16 hours.
    • Cool to room temperature, dilute with water, and extract with methyl tert-butyl ether (MTBE).
    • Dry the combined organic extracts over Na₂SO₄, filter, and concentrate.
    • Purify the product via flash chromatography.
  • Notes: GVL is a high-boiling, renewable solvent that often improves reaction efficiency and facilitates product isolation. The catalyst system tolerates a wide range of functional groups, including halides [30].

The Scientist's Toolkit: Essential Reagents & Materials

Table: Key Research Reagent Solutions for C-H Functionalization

Item Function & Role in Experiment Key Characteristics
Fe(PDP) Catalyst [28] Non-heme iron catalyst for predictable, selective aliphatic C-H hydroxylation. Provides complementary selectivity to enzymatic and electrochemical methods.
TFDO (Trifluoromethyl dioxirane) [28] [29] Powerful electrophilic oxidant for O-insertion into strong, electron-rich C-H bonds. Useful for oxidizing specific methylene sites in complex terpenes.
Quinuclidine Mediators [29] Redox mediators in electrochemical C-H oxidation; govern site-selectivity. Tunable structure allows optimization of reactivity and selectivity for different substrates.
PEG-400 & γ-Valerolactone (GVL) [30] Green, sustainable solvents for transition metal-catalyzed C-H activation. Biodegradable, non-toxic, often improve catalyst stability/recycling.
Earth-Abundant Metal Salts (Co, Cu) [30] Catalysts for C-H activation as sustainable alternatives to precious metals. Cost-effective, low toxicity, suitable for diverse C-N, C-O, C-C bond formations.
RVC Anode / Ni Cathode [28] [29] Electrode pair for scalable electrochemical oxidations. Inexpensive, robust, enable constant-current electrolysis on multi-gram scale.

Diagrams

workflow Late Stage Diversification Workflow NP Natural Product Scaffold (e.g., Vancomycin, Sclareolide) ST Site-Selective Transformation NP->ST C1 C-H Oxidation (e.g., Fe(PDP), Electrochemical) ST->C1 C2 C-H Arylation/Alkenylation (e.g., Ru/Co in GVL) ST->C2 C3 Heteroatom Coupling (e.g., peptide-catalyzed acylation) ST->C3 Lib Diverse Analog Library C1->Lib C2->Lib C3->Lib App Application Lib->App SAR SAR Study App->SAR Probe Biological Probe App->Probe Lead Optimized Lead App->Lead

pathways C-H Oxidation Strategies for DOS Root Natural Product C-H Bond M1 Metal-Catalyzed (e.g., Fe, Mn, Co) Root->M1 M2 Electrochemical (Mediator-Assisted) Root->M2 M3 Organic Oxidant (e.g., dioxiranes) Root->M3 M4 Biocatalytic (e.g., P450 enzymes) Root->M4 P1 Hydroxyl (-OH) M1->P1 P2 Ketone (=O) M1->P2 M2->P1 M2->P2 M3->P2 M4->P1 DOS DOS Entry Point: Skeletal & Functional Group Diversity P1->DOS P2->DOS P3 Alkene (via dehydrogenation) P3->DOS P4 Halogen (e.g., -Cl, -Br) P4->DOS

Within the discipline of diversity-oriented synthesis (DOS), the ring distortion strategy has emerged as a powerful paradigm for the rapid generation of structurally complex and stereochemically rich small-molecule libraries [32]. This approach stands in contrast to traditional library synthesis by utilizing inherently complex natural products as strategic starting points. Through a series of deliberate ring system manipulations—including expansion, contraction, cleavage, fusion, and rearrangement—a single, readily available natural product scaffold can be divergently transformed into a collection of novel architectures that are distinct from each other and the parent compound [33] [34].

The strategic value of this "complexity-to-diversity" (CtD) approach is multifaceted [34]. First, it efficiently populates underexplored regions of chemical space, particularly with three-dimensional, sp³-rich compounds that are often required to modulate challenging biological targets like protein-protein interactions [33]. Second, it addresses the synthetic intractability of certain ring systems, such as medium-sized rings (8-11 members), by constructing them from more readily accessible smaller rings via expansion or from larger rings via contraction [35] [36]. This methodology aligns with the broader thesis of leveraging natural product scaffolds in DOS, moving beyond simple peripheral functionalization to achieve deep-seated skeletal diversity [32].

Foundational Reactions and Mechanisms

Ring distortion chemistry encompasses a suite of transformative reactions. The following table categorizes key reaction types, their general chemical transformations, and primary applications in scaffold remodeling.

Table 1: Classification of Core Ring Distortion Reactions

Reaction Type General Transformation Key Mechanism/Note Primary Application in Scaffold Remodeling
Ring Expansion Increases ring size by 1+ atoms. Often involves migration into an exocyclic electrophile or insertion via reactive intermediates [37]. Accessing medium (8-11) and large (>12) rings from more synthetically accessible smaller rings [35] [36].
Ring Contraction Decreases ring size by 1+ atoms. Typically proceeds via rearrangement of a cyclic cation or anion after cleavage of a bond [37]. Generating strained ring systems (e.g., cyclobutanes) from less strained precursors (e.g., cyclopentanones).
Fragmentation (Ring Cleavage) Breaks one or more bonds to open a ring, often forming new functional groups. Grob-type fragmentation requires anti-periplanar alignment of breaking bond and leaving group [36]. Disassembling polycyclic systems or converting a ring into an acyclic handle for subsequent recyclization.
Ring Fusion Forms a new ring shared with the original scaffold. Achieved via intramolecular cycloaddition or cyclization between a newly introduced handle and the core [33]. Increasing scaffold complexity and three-dimensionality from a functionalized precursor.
Rearrangement Reorganizes bonds within the ring system without net change in atom count. Includes pinacol, Wagner-Meerwein, and Beckmann rearrangements [33] [37]. Dramatically altering core connectivity and stereochemistry from a stable precursor.

The synthesis of medium-sized rings, particularly nine-membered carbocycles, remains a formidable challenge due to unfavorable transannular interactions and entropic factors during cyclization [36]. Ring distortion strategies, especially expansion and contraction, provide a critical solution. The strain energies for medium-sized rings, which peak at 9- and 10-membered systems, underscore the synthetic challenge [36].

Table 2: Strain Energies of Medium-Sized Carbocycles [36]

Ring Size 6 7 8 9 10 11 12
Strain Energy (kcal/mol) 1.4 7.6 11.9 15.5 16.4 15.3 11.8

Application Notes and Experimental Protocols

This general protocol combines site-selective C-H bond functionalization with subsequent ring expansion to access medium-sized rings from polycyclic natural products.

Concept: Install a functional handle via C-H oxidation, then use this handle to drive a ring expansion reaction. Workflow: Natural Product → Site-Selective C-H Oxidation → Functionalized Intermediate → Ring Expansion → Polycyclic Medium-Sized Ring.

G NP Polycyclic Natural Product (e.g., Steroid) OX Site-Selective C-H Oxidation NP->OX Electrochemical/Chemical Oxidation INT Functionalized Intermediate (Alcohol, Ketone) OX->INT RE Ring Expansion (e.g., Beckmann, Schmidt) INT->RE Reaction with Reagent (e.g., NH₂OH) FIN Product with Medium-Sized Ring RE->FIN

Diagram: Two-Phase Strategy for Medium-Sized Ring Synthesis

Detailed Procedure for Lactam Formation via Beckmann Rearrangement:

  • Starting Material: A ketone-functionalized steroid (e.g., derivative of dehydroepiandrosterone or estrone) [35].
  • Oxime Formation: Dissolve the ketone (1.0 equiv) in anhydrous pyridine. Add hydroxylamine hydrochloride (1.2 equiv) and heat to 80-90°C. Monitor reaction by TLC until ketone consumption is complete (typically 2-6 hours). Quench with water and extract with ethyl acetate. Wash the organic layer with brine, dry over MgSO₄, filter, and concentrate to obtain the crude oxime.
  • Beckmann Rearrangement: Dissolve the crude oxime in dry dichloromethane (0.1 M) under an inert atmosphere. Cool to 0°C. Add thionyl chloride (SOCl₂, 1.5 equiv) dropwise. Allow the reaction to warm to room temperature and stir until complete by TLC (1-3 hours). Caution: Reaction produces gases.
  • Work-up: Carefully quench the reaction by pouring onto crushed ice. Extract with DCM. Wash the combined organic layers with saturated NaHCO₃ solution, followed by brine. Dry over MgSO₄, filter, and concentrate.
  • Purification: Purify the residue via flash column chromatography (SiO₂, eluent gradient from hexanes to ethyl acetate) to yield the corresponding ε- or larger lactam.

Key Reagent Solutions & Materials:

  • Anhydrous Pyridine: Solvent and base for oxime formation. Must be distilled over CaH₂ and stored under argon.
  • Hydroxylamine Hydrochloride (NH₂OH·HCl): Source of the nucleophilic amine for oxime formation.
  • Thionyl Chloride (SOCl₂): Lewis acid reagent that activates the oxime for rearrangement. Highly moisture-sensitive and corrosive. Handle in a fume hood with appropriate PPE.
  • Anhydrous Dichloromethane (DCM): Solvent for rearrangement. Dry over CaH₂ or P₂O₅ and distill prior to use.

This protocol demonstrates how a single natural product with multiple reactive sites can be diverted down different ring distortion pathways.

Concept: Apply chemoselective reactions to different functional handles on gibberellic acid to trigger distinct ring distortion events (cleavage, expansion, rearrangement). Workflow: Divergent pathways from a common, complex natural product core.

G GA Gibberellic Acid (G) P1 Path A: Basic Conditions GA->P1 P2 Path B: Acidic Conditions GA->P2 P3 Path C: mCPBA/Oxidation GA->P3 I1 Intermediate G8/G9 (Lactone Rearrangement/Cleavage) P1->I1 I2 Allo-Gibberic Acid G10 (Aromatization) P2->I2 I3 Epoxide Intermediate P3->I3 OP1 Oper. 1: Amidation Oper. 2: Epoxidation Oper. 3: Wagner-Meerwein I1->OP1 OP2 Oper. 1: Esterification Oper. 2: Oxidative Rearrangement (DDQ) I2->OP2 OP3 Oper. 1: Oxidative Cleavage (PCC) Oper. 2: Ketalization I3->OP3 FIN1 Product G3 (Tricyclic Scaffold) OP1->FIN1 FIN2 Product G5 ([2.2.2]-Bicycle) OP2->FIN2 FIN3 Product G2 (Spiroketal) OP3->FIN3

Diagram: Divergent Ring Distortion Pathways from Gibberellic Acid

Detailed Procedure for the Synthesis of Spiroketal G2 from Gibberellic Acid [33]:

  • Starting Material: Gibberellic acid.
  • Epoxidation: Dissolve gibberellic acid (1.0 equiv) in dichloromethane (0.1 M). Cool to 0°C. Add meta-chloroperoxybenzoic acid (mCPBA, 1.1 equiv) portion-wise. Stir at 0°C for 1 hour, then allow to warm to room temperature and stir for 12 hours. The epoxidation is highly selective for the tetrasubstituted olefin.
  • Oxidative Cleavage & In Situ Ketalization: To the crude epoxide mixture, add pyridinium chlorochromate (PCC, 2.0 equiv) and activated molecular sieves (4Å). Stir vigorously at room temperature for 24 hours. PCC cleaves the diol to a diketone.
  • Acidic Work-up: Filter the reaction mixture through a pad of Celite. Concentrate the filtrate. Re-dissolve the residue in a mixture of tetrahydrofuran and 1M aqueous HCl (10:1). Stir at room temperature for 2 hours. This acidic treatment promotes tautomerization of the A-ring ketone and its nucleophilic attack on the C-ring ketone to form the spiroketal.
  • Purification: Quench with saturated NaHCO₃, extract with ethyl acetate, dry the combined organic layers (MgSO₄), and concentrate. Purify the crude product by flash chromatography (SiO₂, eluent gradient) to isolate spiroketal G2.

Key Reagent Solutions & Materials:

  • meta-Chloroperoxybenzoic Acid (mCPBA): Peroxyacid for selective epoxidation. Store cold and handle with care as a peroxide. Often used as a stabilized, technical grade solid; purity should be assayed.
  • Pyridinium Chlorochromate (PCC): Oxidant for the cleavage of 1,2-diols to diketones. Toxic and potentially explosive when dry. Always use moist PCC or dispose of old stocks properly. Reaction is performed with molecular sieves to absorb water and drive the oxidation.
  • Activated Molecular Sieves (4Å): Essential for scavenging water in PCC oxidations to prevent over-oxidation and side reactions. Must be activated by heating in a flame-dried flask under vacuum prior to use.

This protocol outlines a classical anionic ring contraction for converting cyclic α-haloketones to ring-contracted carboxylic acid derivatives.

Concept: A halogenated ketone undergoes nucleophilic attack, forming a strained cyclopropanone intermediate that is opened by a nucleophile, leading to a contracted ring. Workflow: α-Haloketone → Enolate Formation → Cyclopropanone Intermediate → Nucleophilic Attack → Ring-Contracted Product.

Detailed Procedure:

  • Starting Material: A cyclic α,α'-dibromoketone (e.g., derived from a cyclohexanone).
  • Enolate Formation: Dissolve the α-dibromoketone (1.0 equiv) in anhydrous methanol or ethanol (0.1 M). Cool the solution to 0°C.
  • Nucleophilic Addition: Add a solution of sodium methoxide or ethoxide (3.0 equiv, in the corresponding alcohol) dropwise. The alkoxide serves as both base and nucleophile.
  • Reaction: Allow the reaction to warm to room temperature and stir for 4-12 hours, monitoring by TLC.
  • Work-up and Purification: Quench carefully with a saturated aqueous NH₄Cl solution. Extract with ethyl acetate. Wash the organic layer with brine, dry (MgSO₄), and concentrate. Purify the residue via flash chromatography to yield the ring-contracted ester (e.g., methyl cyclopentanecarboxylate from cyclohexanone precursor).

Key Reagent Solutions & Materials:

  • Sodium Methoxide/Ethoxide Solution: A strong base and nucleophile. Typically prepared by carefully adding sodium metal to anhydrous alcohol under an inert atmosphere, or purchased as a standardized solution. Highly corrosive and moisture-sensitive.
  • Anhydrous Methanol/Ethanol: Solvent and nucleophile source. Must be dried over molecular sieves or distilled from Mg/I₂.

The Scientist's Toolkit: Essential Reagents for Ring Distortion

Table 3: Key Research Reagent Solutions for Ring Distortion Chemistry

Reagent/Category Primary Function in Ring Distortion Example Uses & Notes
Diacyl Peroxides & Peroxyacids (e.g., mCPBA, TFPA) Electrophilic oxidants for epoxidation and Baeyer-Villiger oxidation. Epoxidation of alkenes (e.g., in gibberellic acid) [33]; Baeyer-Villiger insertion of oxygen to convert ketones to esters/lactones [33] [37].
Diazocompounds (e.g., Ethyl Diazoacetate, TMSD) Sources of carbenes or metallocarbenoids for C-H insertion or cyclopropanation leading to expansion. Used in ring expansions (e.g., with Lewis acids like BF₃·Et₂O) to insert CHCO₂Et units [35]. Caution: Potentially explosive.
Oxidation States Manipulators (PCC, DDQ, NaIO₄/KMnO₄) Selective oxidation or oxidative cleavage to create new reactive handles. PCC: Diol cleavage [33]; DDQ: Dehydrogenation/oxidative rearrangement [33]; NaIO₄/KMnO₄: Oxidative cleavage of enones/α-diols [33].
Rearrangement Promoters (SOCl₂, POCl₃, NaN₃/H⁺) Lewis acids or reagents to activate substrates for skeletal rearrangement. SOCl₂: Beckmann rearrangement [35]; NaN₃/H⁺ (Schmidt conditions): Concurrent ring expansion and cleavage [33].
Strong Bases (NaH, KOtBu, n-BuLi) Generation of enolates or anions for fragmentation or contraction reactions. NaH/KOtBu: Base-induced Grob fragmentations [36]; n-BuLi: Halogen-lithium exchange for anionic cyclization/fragmentation [36].

Integration with Modern Drug Discovery

Ring distortion strategies directly address historical shortcomings in screening libraries, which have been dominated by planar, sp²-rich compounds [33]. The complex, three-dimensional architectures generated are particularly suited for probing "undruggable" targets. This is evidenced by their alignment with current trends in innovative drug development [38].

The pharmaceutical landscape is increasingly driven by new therapeutic modalities such as bifunctional degraders (PROTACs), advanced conjugates, and cell therapies [39] [40]. While not modalities themselves, the complex small molecules produced via ring distortion are ideal candidates for constituting the targeting ligands in these systems. For example, a sp³-rich, stereochemically defined macrocycle derived from quinine could serve as a superior binder for a protein-of-interest in a PROTAC design, improving degradation efficacy and selectivity [34].

Furthermore, the global push for first-in-class therapies creates a premium on novel chemical matter [38]. Compound libraries built via ring distortion of natural products occupy unique and underrepresented regions of chemical space, increasing the probability of identifying innovative hit compounds against novel biological targets. This positions ring distortion as a critical enabling methodology within a modern, diversity-driven drug discovery pipeline.

The exploration of biologically relevant chemical space remains a central challenge in modern drug discovery. Natural products (NPs) and their derivatives constitute a foundational source of therapeutics, accounting for approximately one-third of approved drugs since 1981 [41]. Their inherent biological relevance, encoded through co-evolution with biosynthetic proteins, makes them privileged starting points for discovery. However, their structural complexity often makes systematic diversification via traditional synthesis laborious and inefficient [13]. This creates a critical need for innovative synthetic strategies that can efficiently remodel NP-inspired scaffolds to explore uncharted regions of chemical space and accelerate the identification of new bioactive entities.

This article situates itself within a broader thesis on Diversity-Oriented Synthesis (DOS) from natural product scaffolds. DOS focuses on generating structural and stereochemical diversity, characteristics typical of NPs, but is not necessarily tied to a single target molecule [41]. Skeletal editing emerges as a paradigm-shifting tool perfectly aligned with this goal. It enables the direct, late-stage modification of a molecule's core framework through atom insertion, deletion, or exchange, moving beyond conventional peripheral functional group manipulations [42]. This capability allows researchers to treat complex, NP-derived lead compounds as advanced intermediates, rapidly generating skeletally diverse analogues for structure-activity relationship (SAR) studies without recourse to lengthy de novo synthesis [43] [44].

Recent breakthroughs in C-to-N atom swapping epitomize the power of this approach. Converting ubiquitous NP motifs like indoles and benzofurans into benzimidazoles, indazoles, benzoxazoles, and benzisoxazoles represents a profound change in molecular properties with minimal topological alteration [43] [45] [44]. Such transformations are invaluable for medicinal chemistry, enabling "nitrogen scans" to improve metabolic stability, fine-tune electronic properties, and potentially unlock new bioactivity [44]. This document provides detailed application notes and protocols for these advanced skeletal editing techniques, framing them as essential methodologies for diversifying natural product-inspired chemical libraries in a drug discovery context.

Foundational Concepts and Categorization of Skeletal Editing

Skeletal editing refers to the direct, precise modification of a molecule's core skeleton. It is analogous to performing "atom-level surgery" and represents a significant shift from traditional synthesis, which often builds complexity through sequential functional group transformations [42]. A clear categorization is essential for understanding the scope and application of these techniques.

Table: Categorization of Core Skeletal Editing Strategies

Strategy Description Key Transformation Impact on Core Scaffold
Atom Insertion Incorporation of a new atom (e.g., C, N, O) into the cyclic skeleton. Ring expansion. Increases scaffold size and alters ring strain. Example: Single-carbon insertion into indoles to form quinolines [46].
Atom Deletion Removal of an atom from the molecular core. Ring contraction. Decreases scaffold size and increases ring strain. Example: Nitrogen-atom deletion from primary amines for C–C bond formation [47].
Atom Exchange (Transmutation) Swap of one atom for another of a different element (e.g., C-to-N, O-to-N). Identity change without altering ring size. Changes electronic distribution and heteroatom content. Core Focus: C-to-N swap in indoles/benzofurans [43] [44].

A critical principle is chemodivergence, where a common intermediate can be selectively funneled toward distinct skeletal outcomes based on reaction conditions. For instance, a ring-opened oxime intermediate from a benzofuran can be directed to form either a benzisoxazole or a benzoxazole [43] [45]. This multiplies the structural diversity accessible from a single starting material, a feature highly advantageous for DOS campaigns.

skeletal_editing_workflow cluster_strat Skeletal Editing Strategy cluster_outcomes DOS Library Outcomes Start Natural Product-Inspired Lead Scaffold (e.g., Indole) Insertion Atom Insertion Start->Insertion Deletion Atom Deletion Start->Deletion Exchange Atom Exchange (Transmutation) Start->Exchange Lib1 Expanded Core Analogue Insertion->Lib1 Lib2 Contracted Core Analogue Deletion->Lib2 Lib3 Heteroatom-Swapped Analogue Exchange->Lib3 BioEval Biological Evaluation & SAR Analysis Lib1->BioEval Lib2->BioEval Lib3->BioEval

Diagram: Strategic Workflow for Skeletal Editing in DOS. The workflow demonstrates how a single natural product-inspired scaffold can be diversified through different skeletal editing strategies (Insertion, Deletion, Exchange) to generate a library of analogues with distinct core frameworks for biological evaluation.

The following table summarizes key recent advancements in skeletal editing, with a focus on transformations relevant to natural product-like scaffolds. The data highlights the efficiency, scope, and strategic value of these methods.

Table: Quantitative Summary of Key Skeletal Editing Methodologies (2024-2025)

Editing Type Core Transformation Typical Substrates Reported Yield Range Key Functional Group Tolerance Primary Reference
C-to-N Swap Indole → Benzimidazole N-Alkyl indoles 34-76% (av. ~55%) Ethers, halides, amides, esters, alkenes [44]. [44]
C-to-N Swap Indole → Indazole N-Protected indoles 38-78% (radical path) Alkyl, aryl, alkoxy at 5/6 position; sensitive to strong EWGs [43]. [43]
C-to-N Swap Benzofuran → Benzisoxazole/Benzoxazole Benzofurans 55-83% (ionic path) Halogen, alkyl, methoxy groups on arene ring [43] [45]. [43] [45]
Single-C Insertion Indole → Quinoline 3-Aryl indoles 45-92% (ee up to 99%) Aryl, heteroaryl at 3-position; enantioselective [46]. [46]
Ring Expansion Saturated amine → 7/8-membered aza-cycle Piperidines, pyrrolidines Not specified Method for underrepresented medium rings [47]. [47]
Chemo-enzymatic DOS Skeletal diversification via P450 oxidation Parthenolide derivatives Library of >50 scaffolds Demonstrated anticancer activity in library members [13]. [13]

Detailed Experimental Protocols

This one-pot protocol converts "native" N-alkyl indoles directly to benzimidazoles using commercially available reagents, making it highly practical for late-stage diversification.

Materials:

  • Substrate: N-Alkyl indole (1.0 equiv, 0.1 mmol scale).
  • Reagents: Phenyliodine(III) diacetate (PIDA, 4.0 equiv), Ammonium carbamate (8.0 equiv).
  • Solvent: Trifluoroethanol (TFE, 0.05 M concentration relative to substrate).
  • Equipment: 5 mL reaction vial with screw cap and PTFE septum, magnetic stirrer, heating block, argon/vacuum manifold for inert atmosphere.

Procedure:

  • Setup: In a flame-dried 5 mL vial equipped with a magnetic stir bar, charge the N-alkyl indole substrate (0.1 mmol). Seal the vial with a septum cap and purge the atmosphere with argon.
  • Reaction Assembly: Under a positive flow of argon, add anhydrous trifluoroethanol (2.0 mL) via syringe. Subsequently, add solid ammonium carbamate (8.0 equiv, 62 mg) and phenyliodine(III) diacetate (4.0 equiv, 129 mg). Ensure the solids are fully immersed.
  • Reaction Execution: Securely cap the vial and heat the reaction mixture with stirring at 80°C for 16 hours. Monitor reaction progress by TLC or LC-MS.
  • Work-up: After cooling to room temperature, dilute the reaction mixture with dichloromethane (10 mL). Transfer to a separatory funnel and wash sequentially with saturated aqueous sodium thiosulfate solution (10 mL, to reduce iodine byproducts) and brine (10 mL).
  • Isolation: Dry the organic layer over anhydrous sodium sulfate, filter, and concentrate under reduced pressure.
  • Purification: Purify the crude residue by flash column chromatography on silica gel (eluent: typically a gradient of ethyl acetate in hexanes) to afford the desired benzimidazole product.

Key Notes:

  • Mechanistic Pathway: The transformation is proposed to proceed through a cascade involving oxidative cleavage of the indole (Witkop-type oxidation), oxidative amidation, a Hofmann-type rearrangement, and final cyclization [44].
  • Scope & Limitations: Tolerates a wide range of functional groups including ethers, halides, and amides. The reaction is most effective for N-alkyl indoles; N-H indoles may require protection. The yield can be sensitive to concentration—maintaining a 0.05 M dilution is optimal.

This protocol illustrates chemodivergence, using a common intermediate (oxime I-3) to access two distinct heterocyclic cores.

Materials (Common to both paths):

  • Substrate: Benzofuran (1.0 equiv).
  • Reagent A (Oxidative Cleavage): Pyridinium chlorochromate (PCC, 1.2 equiv).
  • Solvent A: Dichloromethane (DCM), anhydrous.
  • Intermediate Formation: After PCC oxidation, aminolysis (e.g., with aqueous NH₃) yields ortho-hydroxyaryl ketimine I-4.

Procedure B1: Synthesis of Benzisoxazole from Intermediate I-4 [43]

  • Chlorination: To a solution of ketimine I-4 in DCM at 0°C, add N-chlorosuccinimide (NCS, 1.1 equiv) and a catalytic amount of base (e.g., pyridine, 0.1 equiv).
  • Cyclization: Allow the reaction to warm to room temperature and stir for 1-2 hours.
  • Work-up and Purification: Quench with water, extract with DCM, dry over Na₂SO₄, concentrate, and purify by flash chromatography to yield the benzisoxazole.

Procedure B2: Synthesis of Benzoxazole from Intermediate I-4 [43]

  • Alternative Chlorination/Cyclization: Treat ketimine I-4 with aqueous sodium hypochlorite (NaOCl, 1.5 equiv) in a mixture of DCM and water.
  • Reaction Conditions: Stir the biphasic mixture vigorously at room temperature for 3-5 hours.
  • Work-up and Purification: Separate the organic layer, wash with brine, dry over Na₂SO₄, concentrate, and purify by flash chromatography to yield the benzoxazole.

c_to_n_mechanism Indole N-Alkyl Indole (Starting Core) Step1 Oxidative Cleavage (PIDA, TFE) Indole->Step1 Int1 α-Dicarbonyl Intermediate Step1->Int1 Step2 Oxidative Amidation (NH₄ Carbamate) Int1->Step2 Int2 Primary Amide Intermediate Step2->Int2 Step3 Hofmann-Type Rearrangement Int2->Step3 Int3 Isocyanate Intermediate Step3->Int3 Step4 Tautomerization & Aromatization Int3->Step4 Benzimidazole Benzimidazole (Edited Core) Step4->Benzimidazole

Diagram: Mechanistic Pathway for Direct Indole-to-Benzimidazole C-to-N Swap. The diagram outlines the proposed multi-step cascade in a single pot: oxidative ring cleavage, amidation, rearrangement, and final cyclization to achieve the atom swap [44].

The Scientist's Toolkit: Essential Research Reagent Solutions

Successful implementation of skeletal editing protocols requires specific, high-quality reagents. The following table details essential items for the featured C-to-N swap reactions.

Table: Key Research Reagent Solutions for C-to-N Skeletal Editing

Reagent / Material Primary Function in Skeletal Editing Example Protocol Critical Notes for Use
Phenyliodine(III) Diacetate (PIDA) Hypervalent iodine oxidant. Used for both oxidative cleavage of indoles and to mediate Hofmann-type rearrangements [44]. Protocol A (Indole to Benzimidazole). Handle in a fume hood; moisture-sensitive. Store under inert atmosphere.
Ammonium Carbamate Dual-function nitrogen source. Provides both ammonia (for amidation) and carbamate (possible rearrangement facilitator) [44]. Protocol A (Indole to Benzimidazole). Inexpensive and commercial. Acts as a safer, solid alternative to gaseous ammonia.
N-Nitrosomorpholine Aminyl radical precursor. Undergoes light-mediated homolysis to generate radicals for C=C bond cleavage [43]. Radical cleavage of indoles/benzofurans [43]. Light-sensitive and potentially carcinogenic. Use with strict light protection and appropriate PPE.
Pyridinium Chlorochromate (PCC) Oxidizing agent. Selectively cleaves the C2=C3 bond of benzofurans to form diketone/ketoaldehyde intermediates [43]. Protocol B (Benzofuran editing). Moisture-sensitive and toxic. Avoid inhalation of dust.
Trifluoroethanol (TFE) Solvent. Promotes reactions mediated by hypervalent iodine reagents due to its polarity and ability to stabilize cationic intermediates [44]. Protocol A (Indole to Benzimidazole). High boiling point. Consider low-pressure concentration during work-up.
(S)-Di-tert-butyl Diaziridinylmethylphosphonate (Chiral Catalyst) Chiral dirhodium catalyst precursor. Generates chiral Rh-carbynoid for enantioselective carbon insertion [46]. Enantioselective C-insertion into indoles [46]. Air- and moisture-sensitive. Requires careful handling under inert atmosphere (glovebox/Schlenk techniques).

Within a thesis on diversity-oriented synthesis (DOS) from natural product scaffolds, the strategic use of multicomponent reactions (MCRs) and cascade reactions is paramount. These methodologies enable the rapid assembly of complex, polycyclic, and stereochemically dense architectures from simple building blocks in a single operation, efficiently populating chemical space around privileged natural product cores for drug discovery.

Table 1: Comparative Analysis of Key Reaction Platforms

Reaction Type / Name Key Starting Materials Number of Bonds Formed Typical Yield Range Complexity Indices (Avg. # Rings, Stereocenters) Primary Application in DOS
Ugi 4-Component Reaction Amine, Carbonyl, Isocyanide, Carboxylic Acid 4 (2 C-N, 1 C-C, 1 amide) 20-85% 0 new rings, 0-1 new stereocenters Peptidomimetic library generation from amino acid-derived scaffolds.
Passerini 3-Component Reaction Carbonyl, Isocyanide, Carboxylic Acid 3 (1 C-O, 1 C-C, 1 ester) 45-95% 0 new rings, 0 new stereocenters α-Acyloxy amide synthesis for fragment elaboration.
Domino Knoevenagel / Intramolecular Hetero-Diels-Alder Aldehyde, 1,3-Dicarbonyl, Electron-rich Diene 4-5 (2 C-C, 2 C-O/C-N) 40-75% 2-3 new fused rings, 2-4 new stereocenters Rapid construction of tetrahydrochromene / tetrahydroquinoline scaffolds.
Gold-Catalyzed Hydroamination / Cyclization Cascade Enyne with Tethered Nucleophile 2-3 (1 C-N, 1-2 C-C) 55-90% 1-2 new rings, 1-2 new stereocenters Access to complex polycyclic alkaloid-like structures.
Organocatalytic Michael/Aldol Cascade α,β-Unsaturated Aldehyde, Dual Donor Nucleophile 2-3 (2 C-C, 1 C-H) 60-95% (er: 90:10-99:1) 1-2 new rings, 2-3 new stereocenters Enantioselective synthesis of cyclohexene cores prevalent in terpenoids.

Detailed Experimental Protocols

Protocol 1: DOS of Tetrahydroquinoline Library via a Catalytic Three-Component Povarov Reaction

Objective: To generate a diverse library of tetrahydroquinoline-fused scaffolds, mimicking natural alkaloid cores, using a one-pot Lewis acid-catalyzed Povarov reaction.

Materials & Reagents: See "The Scientist's Toolkit" below.

Procedure:

  • In an oven-dried 5 mL microwave vial equipped with a magnetic stir bar, charge aniline derivative (1.0 mmol, 1.0 equiv) and aldehyde (1.2 mmol, 1.2 equiv) in anhydrous 1,2-dichloroethane (DCE, 2 mL).
  • Stir the mixture at room temperature under a nitrogen atmosphere for 30 minutes to pre-form the imine intermediate.
  • Add styrene-type dienophile (1.5 mmol, 1.5 equiv) followed by scandium(III) triflate (Sc(OTf)₃, 10 mol%, 0.1 mmol).
  • Seal the vial and heat the reaction mixture at 80°C with stirring for 12-16 hours (monitor by TLC/LCMS).
  • After completion, cool the mixture to 0°C and quench by addition of saturated aqueous sodium bicarbonate solution (5 mL).
  • Extract the aqueous mixture with ethyl acetate (3 x 10 mL). Combine the organic extracts, dry over anhydrous magnesium sulfate, filter, and concentrate in vacuo.
  • Purify the crude residue by flash column chromatography (silica gel, hexanes/ethyl acetate gradient) to obtain the desired tetrahydroquinoline product.

Protocol 2: Organocatalytic Michael-Michael-Aldol Cascade for Cyclohexene Formation

Objective: To execute an enantioselective, triple-cascade reaction constructing a cyclohexene ring with four contiguous stereocenters, relevant to steroidal and terpenoid synthesis.

Materials & Reagents: See "The Scientist's Toolkit" below.

Procedure:

  • In a 10 mL round-bottom flask, dissolve the primary amine catalyst (e.g., (S)-diphenylprolinol TMS ether, 20 mol%, 0.02 mmol) in anhydrous chloroform (1 mL).
  • Add α,β-unsaturated aldehyde (e.g., cinnamaldehyde, 0.1 mmol, 1.0 equiv) and stir at room temperature for 5 minutes to form the activated iminium intermediate.
  • Cool the reaction mixture to 4°C (ice-water bath).
  • In a separate vial, dissolve the dual Michael donor (e.g., 5-oxohexanal, 0.15 mmol, 1.5 equiv) in anhydrous chloroform (0.5 mL) and add it dropwise to the stirring catalyst/aldehyde mixture.
  • After the addition is complete, remove the cooling bath and allow the reaction to stir at room temperature for 48-72 hours.
  • Quench the reaction by adding a 1:1 mixture of trifluoroacetic acid (TFA) and water (0.2 mL) and stir for 10 minutes.
  • Dilute the mixture with dichloromethane (10 mL) and wash sequentially with water (5 mL) and brine (5 mL).
  • Dry the organic layer over sodium sulfate, filter, and concentrate.
  • Redissolve the crude material in methanol (2 mL) and add sodium borohydride (NaBH₄, 2.0 equiv) at 0°C to reduce any residual aldehyde. Stir for 1 hour, then quench carefully with water.
  • Extract with ethyl acetate, dry, concentrate, and purify by preparative TLC or flash chromatography to afford the polyfunctionalized cyclohexene product. Analyze enantiomeric excess by chiral HPLC.

Visualizations

G NP Natural Product Scaffold (e.g., Core Structure) DOS Diversity-Oriented Synthesis (DOS) Strategy NP->DOS MCR Multicomponent Reaction (MCR) DOS->MCR Rapid Scaffold Decor./Fusion Cascade Cascade Reaction (Sequential Steps) DOS->Cascade Rapid Scaffold Elaboration Lib Complex, Diverse Chemical Library MCR->Lib Cascade->Lib Screen Biological Screening (HTS, Phenotypic) Lib->Screen Lead Identified Lead Compounds Screen->Lead

Diagram Title: DOS Workflow from Natural Product Scaffolds

G cluster_0 Three-Component Povarov Reaction Protocol A Aniline Derivative (1.0 equiv) Step1 1. RT, 30 min (Iminine Formation) A->Step1 B Aldehyde (1.2 equiv) B->Step1 C Dienophile (1.5 equiv) Step2 2. 80°C, 12-16 h (Cycloaddition) C->Step2 Cat Sc(OTf) 3 (10 mol%) Cat->Step2 DCE Anhydrous DCE DCE->Step1 Step1->Step2 In situ imine Workup Quench, Extract, Purify (Chromatography) Step2->Workup Product Tetrahydroquinoline (Complex Polycycle) Workup->Product

Diagram Title: Povarov MCR Experimental Flow

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Materials for Featured Protocols

Reagent / Material Function & Rationale
Anhydrous 1,2-Dichloroethane (DCE) Aprotic solvent of choice for Lewis acid-catalyzed reactions (Povarov). Low polarity favors cycloaddition, inert under acidic conditions.
Scandium(III) Triflate [Sc(OTf)₃] Water-tolerant, strong Lewis acid catalyst. Activates the imine towards cycloaddition in the Povarov reaction; often recyclable.
(S)-Diphenylprolinol TMS Ether Versatile secondary amine organocatalyst. Forms reactive iminium (with enals) or enamine (with aldehydes) intermediates to catalyze cascades enantioselectively.
Anhydrous Chloroform Common solvent for organocatalytic cascades. Optimal polarity for amine catalyst activity and intermediate stability.
Trifluoroacetic Acid (TFA) Mild acid used to cleave the organocatalyst from the reaction intermediates during workup, quenching the catalysis.
Pre-coated TLC Plates (Silica) For reaction monitoring and preliminary purification. Essential for analyzing complex reaction mixtures from MCRs/cascades.
Flash Chromatography System Critical for purifying complex, polar products from MCRs. Automated systems with UV/ELSD detection are standard for library purification in DOS.
Chiral HPLC Column (e.g., AD-H, OD-H) For determining enantiomeric excess (ee) of products from asymmetric cascade reactions, ensuring fidelity of chiral induction.

Diversity-Oriented Synthesis (DOS) represents a foundational strategy in modern chemical biology and drug discovery, aimed at efficiently generating collections of small molecules with high levels of skeletal, stereochemical, and appendage diversity [2]. The ultimate goal is to create libraries that occupy broad regions of biologically relevant chemical space, thereby increasing the probability of discovering novel probes for chemical genetics or leads for therapeutic development [4] [2]. In contrast to target-oriented synthesis, DOS requires synthetic pathways that are robust and general enough to produce many distinct structural outcomes from common intermediates [4].

Natural products are pre-validated by evolution to interact with biological macromolecules and represent an unparalleled source of inspiration for DOS [4] [2]. Their inherent structural complexity, rich stereochemistry, and polycyclic frameworks are features often lacking in traditional combinatorial libraries [35]. Steroids and terpenes are exemplary classes for DOS applications due to their broad availability, structural rigidity, and proven history as privileged scaffolds in medicinal chemistry [48] [35]. However, directly modifying these complex scaffolds is challenging. Traditional functional group manipulations often yield limited diversity, as the inherent reactivity and stereoelectronic biases of the substrate can dominate outcomes [48].

This case study focuses on a powerful two-phase strategy to overcome these limitations: sequential C–H oxidation followed by ring expansion. This approach, positioned within the broader thesis of diversity-oriented synthesis from natural product scaffolds, first installs new functional handles via selective C–H activation, then leverages these handles to remodel the core scaffold itself [35]. By transforming ubiquitous C–H bonds into points of diversification and then using these to alter ring size and connectivity, this methodology can generate architecturally novel compounds that access underexplored chemical space, particularly polycyclic systems containing medium-sized rings (7-11 membered) [35].

Core Chemical Principles and Mechanisms

C–H Oxidation as a Functionalization Strategy

C–H bonds are the most abundant functionality in organic molecules and natural products. Their selective oxidation introduces oxygenated functional groups (e.g., alcohols, ketones) that serve as critical handles for downstream transformations [35]. The strategy emulates biosynthesis, where cytochrome P450 enzymes perform precise oxidations on terpene hydrocarbon skeletons [49]. Key methods applied to steroids and terpenes include:

  • Electrochemical Allylic C–H Oxidation: Enables oxidation of allylic positions with reduced byproduct formation [35].
  • Metal-mediated C(sp3)–H Oxidation: Employing catalysts based on copper, chromium, or iron for site-selective oxidation, often guided by substrate geometry [35].
  • Enzymatic Oxygen Activation: As exemplified by α-ketoglutarate-dependent nonheme iron enzymes (e.g., DAOCS), which use a concerted mechanism requiring simultaneous binding of cofactor and substrate to generate a high-valent iron-oxo (FeIV=O) intermediate capable of precise C–H abstraction and functionalization [50].

Ring Expansion for Skeletal Diversification

Ring expansion reactions alter the core scaffold of a molecule, directly generating skeletal diversity. Common mechanisms employed in natural product diversification include:

  • Beckmann and Schmidt Rearrangements: Transform ketones into lactams via the intermediacy of oximes or alkyl azides, resulting in a ring-expanded, nitrogen-incorporated skeleton [48] [35]. The regioselectivity (i.e., which adjacent bond migrates) is a major point of control.
  • Homologation with Diazo Compounds: Reactions of carbonyls with diazo reagents (e.g., α-diazoesters) can insert a carbon unit, leading to ring-expanded β-keto esters or derivatives [51] [35].
  • Carbocationic Rearrangements: Biomimetic processes involving alkyl or hydride shifts can mediate ring expansion, as observed in terpene biosynthesis. These are often multi-step concerted reactions that minimize high-energy intermediate states [52]. For example, during steroid biosynthesis, the formation of the D-ring from a protosterol carbocation involves a concerted C-ring expansion and D-ring formation [52].

Table 1: Key Ring Expansion Reactions for Natural Product Diversification

Reaction Type Key Reagent/Intermediate Product Core Change Primary Application in Case
Schmidt Reaction Alkyl azide / Nitrenium ion Ketone → Lactam (N-insertion, ring expansion) A- and D-ring expansion of steroids [48] [35]
Beckmann Rearrangement Ketoxime Ketone → Lactam (N-insertion, ring expansion) Synthesis of seven-membered lactams post C–H oxidation [35]
Homologation with α-Diazoesters Diazo compound (e.g., N2CHCO2R) Ketone → β-Keto Ester (C-insertion, ring expansion) Construction of benzocycloheptanes; two-carbon ring expansion [51] [35]
Carbocation Ring Expansion Generated in situ (e.g., via epoxide opening) Small ring (e.g., 4-membered) → Larger ring (e.g., 5-membered) Biomimetic skeletal reorganization in terpene synthesis [52] [53]

Regiochemical Control in Ring Expansion

A central challenge in applying ring expansions to complex molecules is controlling regioselectivity—determining which of two possible bonds adjacent to the reaction center will migrate. Steroids possess strong inherent stereoelectronic biases. For instance, in the D-ring of a 17-oxosteroid, classical reactions like the Beckmann rearrangement exclusively cause migration of the more substituted C13–C17 bond [48]. Overcoming this bias to achieve reagent-controlled regiodivergence is a hallmark of advanced DOS. This can be achieved using chiral hydroxyalkyl azides in intramolecular Schmidt reactions. The chirality of the reagent, through the defined stereochemistry of a transient spirocyclic oxazinane intermediate, dictates which carbon migrates, overriding the substrate's innate preference [48]. This allows access to complementary, isomeric ring-expanded scaffolds from a single starting material.

Application Notes & Experimental Protocols

Objective: To synthesize either lactam regioisomer A2 or B2 from a common steroidal ketone using enantiopure hydroxyalkyl azides to control migration selectivity.

Materials:

  • 5α-Cholestan-3-one (1)
  • (R)- or (S)-3-azido-1-phenylpropanol [(R)-7 or (S)-7]
  • Bronsted or Lewis acid (e.g., p-TsOH, BF₃·OEt₂)
  • Anhydrous dichloromethane (DCM) or 1,2-dichloroethane (DCE)
  • Standard workup and purification materials.

Procedure:

  • Reaction Setup: Under an inert atmosphere, dissolve ketone 1 (1.0 equiv) and the chosen chiral azide, e.g., (R)-7 (1.2-2.0 equiv), in anhydrous DCM (0.1 M relative to ketone).
  • Acid Activation: Cool the solution to 0°C. Add a catalytic amount of p-toluenesulfonic acid (p-TsOH, 0.1 equiv) or trimethylsilyl triflate (TMSOTf, 0.1 equiv).
  • Reaction Execution: Allow the reaction mixture to warm to room temperature and stir for 12-24 hours. Monitor by TLC or LC-MS for consumption of the starting ketone.
  • Workup: Quench the reaction by adding a saturated aqueous solution of sodium bicarbonate (NaHCO₃). Extract the aqueous layer three times with DCM.
  • Purification: Combine the organic extracts, dry over anhydrous sodium sulfate (Na₂SO₄), filter, and concentrate under reduced pressure. Purify the crude residue by flash column chromatography on silica gel to obtain the pure lactam.
  • Outcome: Using (R)-7 yields lactam A2 as the major product. Using (S)-7 yields lactam B2. The use of racemic azide (±)-7 yields a 1:1 mixture of isomers.

Key Notes:

  • The mechanism proceeds via the diastereoselective formation of a spiro-1,3-oxazinane. The phenyl group of the chiral reagent adopts an equatorial position, and the antiperiplanar carbon–carbon bond then migrates, with the reagent's stereochemistry dictating which bond is aligned for migration [48].
  • This protocol demonstrates full regiodivergent control, achieving selectivities often >19:1 for the desired isomer [48].

Objective: To diversify a steroid scaffold by first introducing a ketone via allylic C–H oxidation, then converting it to a ring-expanded lactam.

Materials:

  • Steroid substrate with allylic C–H position (e.g., dehydroepiandrosterone derivative)
  • Electrolyte: LiClO₄ or NBu₄PF₆
  • Solvent mixture: CH₃CN/H₂O/CH₂Cl₂
  • Electrochemical cell with graphite electrodes
  • Hydroxylamine hydrochloride (NH₂OH·HCl)
  • Acid for Beckmann rearrangement: e.g., PPA (polyphosphoric acid) or TsOH in toluene

Procedure: Part A: Electrochemical Allylic C–H Oxidation

  • Cell Preparation: In an undivided electrochemical cell, prepare a solution of the steroid substrate (0.1-0.2 mmol) and LiClO₄ (0.1 M) in a CH₃CN/H₂O/CH₂Cl₂ mixture.
  • Electrolysis: Place graphite electrodes and apply a constant current (e.g., 5-10 mA) at room temperature. Monitor reaction progress by TLC.
  • Workup: Upon completion, dilute the reaction mixture with water and extract with DCM. Dry, filter, and concentrate to obtain the allylic ketone intermediate.

Part B: Beckmann Rearrangement to Lactam

  • Oxime Formation: Dissolve the ketone from Part A in ethanol/pyridine. Add hydroxylamine hydrochloride (1.5 equiv) and heat to reflux for 2-4 hours. After standard workup, obtain the crude oxime.
  • Rearrangement: Dissolve the oxime in toluene and add a catalytic amount of p-TsOH. Alternatively, heat the oxime in PPA at 80-100°C.
  • Completion: Stir the reaction until complete by TLC. Pour into ice water, extract with ethyl acetate, dry, and concentrate.
  • Purification: Purify the crude material by flash chromatography to yield the ring-expanded steroidal lactam.

Key Notes:

  • This two-step, one-pot sequential strategy transforms an inert allylic C–H bond into a nitrogen-containing, medium-sized ring.
  • The electrochemical method offers a "greener" alternative to chemical oxidants and is compatible with a wide range of functional groups [35].

Objective: To construct chiral benzocycloheptanes from simple β-naphthols via a one-pot copper/Scandium catalyzed sequence.

Materials:

  • β-Naphthol substrate
  • Oxidant: Copper(I) chloride (CuCl) and tert-butyl hydroperoxide (TBHP)
  • Chiral Lewis Acid Catalyst: Scandium(III) triflate [Sc(OTf)₃] and chiral N,N′-dioxide ligand (e.g., L2-RaPr2 derived from ramipril)
  • α-Diazoester (e.g., methyl 2-diazo-2-phenylacetate)
  • Solvents: Ethyl acetate (EA) for oxidation, dichloromethane (DCM) for homologation
  • o-Diaminobenzene (for derivatization to stable quinoxaline for analysis)

Procedure:

  • Oxidative Dearomatization: In a vial, dissolve β-naphthol (0.1 mmol) in EA (1 mL). Add CuCl (10 mol%) and TBHP (4.0 equiv). Stir the mixture at 30°C for 2 hours to generate the intermediate 1,2-naphthoquinone.
  • Asymmetric Homologation: In a separate vial, prepare the chiral catalyst by mixing Sc(OTf)₃ (10 mol%) and chiral ligand L2-RaPr2 (10 mol%) in DCM (1 mL). Stir for 15 minutes.
  • Sequential Reaction: Transfer the catalyst solution to the reaction vial containing the in-situ generated quinone. Add the α-diazoester (1.2 equiv) to the combined mixture. Stir at 30°C for 12 hours.
  • Derivatization & Workup: Add o-diaminobenzene (1.5 equiv) and stir for an additional 1 hour to form the stable quinoxaline product. Quench with water, extract with DCM, dry, and concentrate.
  • Purification: Purify the crude product by preparative thin-layer chromatography (PTLC) or column chromatography to obtain the chiral benzocycloheptane derivative.

Key Notes:

  • This protocol highlights a tandem catalysis system (Cu/Sc) for sequential oxidation and carbon-insertion ring expansion.
  • The chiral N,N′-dioxide–Sc(III) complex is essential for high enantioselectivity (up to 97% ee), controlling the face of attack of the diazoester on the prochiral quinone intermediate [51].

Table 2: Quantitative Outcomes of Featured Diversification Protocols

Protocol (Starting Material → Product) Key Transformations Reported Yield Selectivity Achieved Chemical Space Accessed
A-Ring Expansion of 5α-Cholestan-3-one [48] Schmidt Reaction with Chiral Azide High (Yield not quantified, product isolated pure) Regioselectivity: >19:1 (controlled by reagent chirality) Isomeric 7-membered A-ring lactams
Sequential C–H Oxid./Beckmann [35] Electrochemical C–H Oxid. → Oxime Formation → Rearrangement Moderate to Good (over 2-3 steps) Site-Selectivity: Governed by electrochemical method 7-membered ring lactams from various ring positions
β-Naphthol to Benzocycloheptane [51] Oxidative Dearomatization → Homologation 57% (optimized yield for model substrate) Enantioselectivity: Up to 97% ee Chiral fused 6-7 bicyclic systems

Visualization of Strategies and Mechanisms

G cluster_0 Diversity-Oriented Synthesis (DOS) Workflow Start Steroid/Terpene Natural Product Scaffold Phase1 Phase 1: C-H Functionalization Start->Phase1 M1 Electrochemical Oxidation Phase1->M1 M2 Metal-Mediated Oxidation Phase1->M2 M3 Biomimetic Enzyme-like Oxidation Phase1->M3 Intermediate Functionalized Intermediate (Alcohol, Ketone) M1->Intermediate M2->Intermediate M3->Intermediate Phase2 Phase 2: Ring Expansion & Diversification Intermediate->Phase2 R1 Schmidt/Beckmann (N-Insertion) Phase2->R1 R2 Homologation (C-Insertion) Phase2->R2 R3 Reagent-Controlled Regiodivergent Expansion Phase2->R3 Lib Diverse Library of Polycyclic Compounds (Medium-Sized Rings, New Skeleta) R1->Lib R2->Lib R3->Lib

Diagram 1: Sequential C-H Oxidation and Ring Expansion DOS Workflow (76 chars)

G cluster_1 Mechanism of Reagent-Controlled Regiodivergence Substrate Steroidal Ketone (Chiral Substrate) TS Diastereomeric Transition State / Intermediate Substrate->TS  Binds with  defined geometry Reagent Chiral Hydroxyalkyl Azide (e.g., (S)-7) Reagent->TS  Chiral control  element ProductA Lactam Regioisomer A (Migration of C2) TS->ProductA  Reagent-controlled  path (S)-7 ProductB Lactam Regioisomer B (Migration of C4) TS->ProductB  Reagent-controlled  path (R)-7 Bias Substrate-Inherent Regiochemical Bias Bias->TS  Can be overridden

Diagram 2: Reagent Control Overrides Substrate Bias in Ring Expansion (67 chars)

The Scientist's Toolkit: Essential Research Reagents & Materials

Table 3: Key Reagent Solutions and Materials for C-H Oxidation & Ring Expansion

Category Item / Reagent Function & Role in Strategy Key Characteristics / Notes
C–H Oxidation Reagents Electrochemical Cell (C anode/graphite) Enables electrochemical allylic C–H oxidation [35]. Green alternative; requires electrolyte (e.g., LiClO₄).
Copper Salts (CuCl, CuBr) Catalyzes oxidative dearomatization (with TBHP) [51] or mediates specific C–H oxidations [35] [49]. Source of Cu(I) or Cu(II); choice affects yield.
Chiral N,N′-Dioxide Ligands Binds to Sc(III) to form chiral Lewis acid catalyst for asymmetric homologation [51]. Derived from amino acids (e.g., ramipril); controls enantioselectivity.
Ring Expansion Reagents Chiral Hydroxyalkyl Azides (e.g., (R)- or (S)-7) Key for regiodivergent Schmidt reactions; chirality dictates migration outcome [48]. Must be enantiomerically pure; phenyl group enhances stereocontrol.
α-Diazoesters (e.g., N2CHCO2R) One-carbon homologation agents for ring expansion with carbonyl compounds [51] [35]. Handle with care (potential explosivity); source of nucleophilic carbene.
Scandium(III) Triflate [Sc(OTf)₃] Strong, water-tolerant Lewis acid for activating carbonyls toward nucleophilic attack (e.g., by diazoesters) [51]. Compatible with many functional groups.
Catalysts & Additives Nonheme Iron Enzyme Mimics / Fe(II) complexes Model concerted O2 activation for biomimetic, selective C–H oxidation [50]. Requires α-ketoglutarate cofactor; studies mechanistic enzymology.
Bronsted/Lewis Acids (p-TsOH, BF₃·OEt₂, TMSOTf) Activates carbonyls toward addition (e.g., by azides) or promotes rearrangements (Beckmann) [48] [35]. Choice impacts efficiency and selectivity of ring-forming step.
Specialized Materials Anhydrous Solvents (DCM, DCE, Toluene) Medium for acid-catalyzed and Lewis acid-catalyzed reactions [51] [48]. Essential for moisture-sensitive reagents and intermediates.
Solid Support & Encoding Tags For split-pool synthesis of libraries from diversified scaffolds (mentioned in broader DOS context) [4]. Enables synthesis and tracking of large compound collections.

This case study is framed within the broader thesis that Diversity-Oriented Synthesis (DOS) from validated natural product scaffolds is a powerful strategy for populating biologically relevant chemical space and discovering novel bioactive small molecules [4] [2]. Natural products, characterized by enormous scaffold diversity and pre-validated biological relevance, provide ideal starting points for library generation [54] [55]. DOS aims to move beyond traditional combinatorial chemistry's focus on appendage diversity by deliberately incorporating skeletal, stereochemical, and functional group diversity, thereby creating structurally complex and functionally diverse compound collections [4] [2].

This work focuses on two privileged chemotypes: alkaloids and quinoneimines. Alkaloids, nitrogen-containing secondary metabolites, are a cornerstone of pharmacotherapy and share common biosynthetic logic centered around reactive iminium ions [55]. Quinoneimines, particularly the N-phenylquinoneimine (NPQ) scaffold, are versatile synthetic platforms with significant biological activities, including DNA intercalation and antimicrobial action [54]. By applying modern DOS principles—such as two-directional synthesis, domino reactions, and biocatalytic engineering—to these scaffolds, we can generate innovative chemical libraries. These libraries are designed to bridge the gap between the structural complexity of natural products and the need for novel, patentable chemical entities to probe "undruggable" biological targets [2].

Foundational Scaffolds: Alkaloids and Quinoneimines

2.1 Alkaloid Scaffolds and Biosynthetic Logic True alkaloids are defined as nitrogenous, heterocyclic compounds derived biosynthetically from amino acids [55]. Their biosynthesis often follows a convergent pattern involving: (i) accumulation of amine and aldehyde precursors, (ii) formation of an iminium ion, and (iii) a Mannich-like or Pictet-Spengler cyclization as the critical scaffold-forming step [55]. This logic is evident across major classes:

  • Benzylisoquinoline & Monoterpene Indole Alkaloids: Formed via an intermolecular condensation followed by an intramolecular Pictet-Spengler reaction [55].
  • Polyamine-Derived Alkaloids (e.g., Tropane, Quinolizidine): Formed via intramolecular cyclization to a cyclic iminium, followed by an intermolecular Mannich-like reaction [55].

This inherent reactivity of iminium intermediates makes alkaloid-inspired scaffolds highly amenable to DOS planning, enabling the synthesis of polycyclic, stereochemically rich architectures through biomimetic or two-directional synthetic approaches [56].

2.2 Quinoneimine Scaffolds: Reactivity and Biological Significance Quinone imines are highly reactive electrophiles derived from quinones, where one or more carbonyl oxygens are replaced by an imine (=NR) group [57]. Their reactivity stems from the tendency of nucleophilic attack to drive aromatization of the quinoid system [57]. Subtypes are classified based on the number and position of imine groups (ortho/para, mono/diimine), each with distinct reactivity profiles ideal for DOS [57].

  • Biological Precedent: Quinoneimine cores are found in significant natural products and drugs, such as the antibiotic exfoliazone, the antitumor agent actinomycin D, and the antifungal chandrananimycins [54].
  • DOS Utility: They serve as excellent substrates for complexity-generating domino annulation reactions ([3+2], [4+2], [5+2] cycloadditions) to rapidly assemble diverse nitrogen- and oxygen-containing heterocycles, which are underrepresented in many commercial screening collections [57] [2].

Table 1: Biological Activities of Representative Quinoneimine-Based Natural Products [54]

Natural Product Core Scaffold Reported Biological Activities
Exfoliazone Phenoxazine Antibiotic, antifungal, antitumor, growth-promoting
Venezuelines A–G Phenoxazinone Cytotoxic, antitumor
Chandrananimycins A–C Phenoxazinone Antibacterial, antifungal, antialgal, anticancer
Actinomycin D Phenoxazinone chromophore Antitumor, anticancer (clinical use), inhibits HIV-1
Pitucamycin Not specified Antiproliferative, weak cytotoxicity

Application Notes & Experimental Protocols

Protocol 1: Generating a Quinoneimine-Based Library via Domino Annulation This protocol outlines the synthesis of a 1,4-benzoxazine library via an oxidative [4+2] cycloaddition, a key DOS transformation for ortho-quinone monoimines [57].

  • Objective: To generate skeletally diverse 1,4-benzoxazines from a common orth-aminophenol precursor.

  • Reaction Principle: In situ oxidation of an ortho-aminophenol generates a highly reactive ortho-quinone monoimine. This intermediate acts as an aza-diene in an inverse-electron-demand hetero-Diels-Alder reaction with a dienophile (e.g., cyclic enamine), followed by rearomatization to furnish the tricyclic product [57].

  • Materials:

    • ortho-Aminophenol starting materials (varied substitution).
    • Cyclic enamine dienophiles (e.g., 1-pyrroline, morpholine derivatives).
    • Manganese(III) acetate dihydrate (Mn(OAc)₃·2H₂O) as oxidant/catalyst.
    • Acetic acid (AcOH) as solvent.
    • Molecular sieves (4Å).
    • Dichloromethane (DCM), ethyl acetate (EtOAc), hexanes for workup and chromatography.

  • Step-by-Step Procedure:

    • Reaction Setup: In a flame-dried Schlenk tube under nitrogen, combine the ortho-aminophenol (1.0 equiv) and cyclic enamine (1.2 equiv) in glacial AcOH (0.1 M).
    • Additive: Add activated 4Å molecular sieves (50 mg/mmol of substrate).
    • Oxidation/Cyclization: Add Mn(OAc)₃·2H₂O (1.5 equiv) in one portion at room temperature.
    • Stirring: Stir the reaction mixture at 80°C for 12-16 hours, monitoring by TLC.
    • Work-up: Cool to room temperature. Dilute with DCM and filter through a Celite pad. Wash the filtrate sequentially with saturated aqueous NaHCO₃ solution and brine.
    • Purification: Dry the organic layer over anhydrous Na₂SO₄, filter, and concentrate under reduced pressure. Purify the crude residue by flash column chromatography (SiO₂, gradient elution from hexanes to EtOAc) to obtain the desired 1,4-benzoxazine derivatives.
    • Analysis: Characterize all library members by ( ^1 )H NMR, ( ^{13} )C NMR, and HRMS. Expected yields range from moderate to excellent (up to 94%) [57].

Protocol 2: Generating Unnatural Alkaloid Scaffolds via Engineered Type III PKS (Precursor-Directed Biosynthesis) This protocol describes the use of engineered type III polyketide synthase (PKS) HsPKS1 to generate unnatural polyketide-alkaloid hybrids, a biocatalytic DOS strategy [58].

  • Objective: To synthesize novel pyridoisoindole scaffolds using an enzyme-catalyzed cascade.

  • Biosynthetic Principle: The engineered PKS accepts a synthetic, nitrogen-containing starter substrate (2-carbamoylbenzoyl-CoA). Iterative condensation with malonyl-CoA extender units forms a reactive poly-β-keto intermediate. The basic nitrogen atom within the same intermediate facilitates an intramolecular Schiff base formation and subsequent cyclizations, creating a new C–N bond and a novel heterocyclic scaffold [58].

  • Materials:

    • Purified recombinant HsPKS1 S348G mutant enzyme [58].
    • Synthetic starter substrate: 2-carbamoylbenzoyl-CoA.
    • Extender substrate: Malonyl-CoA.
    • Reaction buffer: 100 mM potassium phosphate buffer, pH 6.0.
    • Quenching solution: 1 M HCl.
    • Ethyl acetate for extraction.
    • Analytical tools: LC-MS, NMR.

  • Step-by-Step Procedure:

    • Enzyme Reaction: In a 1.5 mL microcentrifuge tube, combine 100 mM potassium phosphate buffer (pH 6.0), 2-carbamoylbenzoyl-CoA (50 µM, 1.0 equiv), and malonyl-CoA (200 µM, 4.0 equiv).
    • Initiation: Start the reaction by adding the HsPKS1 S348G mutant enzyme (final concentration 10 µM).
    • Incubation: Incubate the reaction mixture at 30°C for 90 minutes.
    • Quenching: Stop the reaction by adding 50 µL of 1 M HCl.
    • Extraction: Extract the product three times with equal volumes of ethyl acetate. Combine the organic layers and dry under a gentle stream of nitrogen.
    • Purification: Redissolve the residue in a minimal volume of methanol and purify by preparative reverse-phase HPLC.
    • Characterization: Analyze the purified product (e.g., 2-hydroxypyrido[2,1-a]isoindole-4,6-dione) by LC-ESIMS (([M+H]^+) m/z 214) and NMR spectroscopy [58]. The S348G mutation alters the cyclization mechanism to produce a ring-expanded 6.7.6-fused dibenzoazepine scaffold when three extenders are incorporated [58].

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Key Reagents for Library Synthesis from Featured Scaffolds

Reagent / Material Function in DOS Protocol/Context
Manganese(III) Acetate [Mn(OAc)₃] One-electron oxidant. Generates reactive ortho-quinone monoimine intermediates from aminophenols in situ [57]. Protocol 1: Quinoneimine Annulation
Phenyliodine Diacetate (PIDA) Hypervalent iodine oxidant. Used for selective oxidation of phenols/aminophenols to quinone imines [57]. General Quinoneimine Synthesis
2-Indolylmethanols Versatile C3-nucleophilic building blocks. Participate in formal [3+3] cyclizations with quinone imines to build fused indole scaffolds [59]. Indole-Quinoneimine Hybrid Synthesis [59]
Engineered Type III PKS (e.g., HsPKS1 S348G) Biocatalyst for C–C and C–N bond formation. Accepts unnatural starter substrates to catalyze scaffold-forming cascade reactions [58]. Protocol 2: Unnatural Alkaloid Synthesis
2-Carbamoylbenzoyl-CoA Synthetic, nitrogen-containing starter substrate for PKS. Designed to intramolecularly trap the poly-β-keto intermediate via Schiff base formation [58]. Protocol 2: Unnatural Alkaloid Synthesis
Diacetoxyiodobenzene (DAIB) Oxidizing agent for the generation of ortho-quinone monoimines from ortho-aminophenols [57]. General Quinoneimine Synthesis

Visualization of Strategies and Mechanisms

G Start DOS Planning Algorithm NP Natural Product Inspiration Start->NP S1 Scaffold Selection (Alkaloid / Quinoneimine) NP->S1 Strat DOS Strategy Selection S1->Strat BB Building Block Variation Strat->BB Appendage Diversity CG Complexity-Generating Reaction Strat->CG Skeletal Diversity Domino Rxn Biocatalysis BP Branch Point Strat->BP Stereochemical Diversity Lib Diverse Chemical Library BB->Lib CG->Lib BP->Lib Screen Biological Screening & Probe Discovery Lib->Screen

Title: DOS Workflow from Natural Product Scaffolds

G Aminophenol ortho-Aminophenol (Substituted) Ox Oxidation (Mn(III) or PIDA) Aminophenol->Ox QI ortho-Quinone Monoimine (Reactive Aza-Diene) Ox->QI Cycloadd [4+2] Cycloaddition QI->Cycloadd Inverse Electron-Demand Dienophile Dienophile (e.g., Cyclic Enamine) Dienophile->Cycloadd Intermed Cycloadd->Intermed Arom Aromatization Intermed->Arom Product 1,4-Benzoxazine (Tricyclic Product) Arom->Product

Title: Domino Annulation Mechanism to 1,4-Benzoxazines

G StartC Unnatural Starter 2-Carbamoylbenzoyl-CoA PKS Engineered Type III PKS (HsPKS1 S348G) StartC->PKS Extend Iterative Condensation with Malonyl-CoA (x3) PKS->Extend PKI Poly-β-Keto Intermediate Extend->PKI Schiff Intramolecular Schiff Base Formation PKI->Schiff Nucleophilic N Iminium Iminium Ion Schiff->Iminium Cyclize1 C-C Bond Formation (6-endo-trig) Iminium->Cyclize1 Cyclize2 C-N Bond Formation & Tautomerization Cyclize1->Cyclize2 ProductC Novel Alkaloid Scaffold (6.7.6-Dibenzoazepine) Cyclize2->ProductC

Title: PKS Engineering for Unnatural Alkaloid Synthesis

Comparative Analysis of DOS Strategies

Table 3: Comparative Analysis of DOS Strategies for Scaffold Diversification

DOS Strategy Core Principle Application to Scaffolds Key Advantage Representative Outcome
Build/Couple/Pair Sequential build of functionalized skeletons, couple fragments, then pair functional groups for cyclization [4] [2]. Applicable to alkaloid synthesis via late-stage cyclization of linear precursors [56]. High degree of skeletal planning and diversity from common intermediates. Libraries of polycyclic alkaloid-like scaffolds [56].
Domino Reactions Multi-bond forming processes where subsequent reactions are a consequence of functionality formed in prior step [57]. Ideal for quinoneimines, leveraging their inherent electrophilicity to trigger cascades [57] [59]. Rapid increase in molecular complexity and efficiency in one pot. Fused heterocycles (e.g., 1,4-benzoxazines, indole-quinones) [57] [59].
Biocatalytic Engineering Use or engineered enzymes to catalyze transformations with high selectivity and novel mechanisms [58]. Generation of "unnatural natural products" by feeding synthetic precursors to engineered PKS [58]. Access to chemically challenging scaffolds and green chemistry credentials. Novel polyketide-alkaloid hybrid scaffolds (e.g., pyridoisoindoles) [58].
Two-Directional Synthesis Simultaneous elaboration of a symmetrical starting material from two termini [56]. Efficient synthesis of symmetrical or pseudo-symmetrical alkaloid cores [56]. Efficient and rapid generation of complexity from simple materials. Complex polycyclic alkaloid scaffolds with reduced step count [56].

Navigating Synthetic Challenges: Optimization and Problem-Solving in DOS Campaigns

Controlling Diastereoselectivity and Regioselectivity in Complex Polycyclic Systems

Within the strategic framework of diversity-oriented synthesis (DOS), the deliberate control of diastereoselectivity and regioselectivity is not merely a synthetic goal but a foundational tool for efficiently accessing architecturally diverse and biologically relevant chemical space [2]. DOS aims to generate small-molecule libraries with high skeletal, stereochemical, and appendage diversity to populate broad regions of bio-relevant chemistry, thereby accelerating the discovery of novel probes and therapeutic leads [2] [4]. This approach stands in contrast to traditional combinatorial libraries, which often lack scaffold diversity and complexity [2].

Natural products, with their inherent structural complexity, polycyclic frameworks, and validated biological relevance, serve as quintessential inspirations for DOS campaigns [4]. They reside in biologically relevant chemical space, possessing the three-dimensionality and functional group density often required to modulate challenging biological targets, including protein-protein interactions [2] [4]. Therefore, developing methodologies that construct natural product-like polycyclic systems with precise control over stereochemistry and regiochemistry is central to a modern DOS strategy. This article details practical protocols and analyzes contemporary strategies for exerting such control, providing researchers with actionable insights for library design and synthesis.

Foundational Principles and Strategic Approaches

Achieving selectivity in polycyclic systems hinges on understanding and manipulating the factors that govern reaction pathways. The following strategies, illustrated by recent advances, are central to modern protocol design.

  • Substrate Control: The innate steric and electronic profile of a starting material can dictate the trajectory of a reaction. A powerful demonstration is the switchable annulation of ninhydrin-derived Morita–Baylis–Hillman (MBH) adducts. Here, a simple change in the leaving group (hydroxyl vs. carbonate) on the same core scaffold redirects the reaction between [4+2] and [3+2] pathways, leading to skeletally distinct polycyclic products (e.g., spirooxazinoisoquinolines vs. spiropyrroloisoquinolines) with excellent diastereoselectivity [60].
  • Catalyst Control: Catalysts can override inherent substrate biases to enforce desired selectivity. A seminal example is the use of chiral Co(II)-metalloradical catalysis to govern both enantioselectivity and diastereoselectivity in radical cascade bicyclizations of 1,6-enynes. Fine-tuning the chiral amidoporphyrin ligand enables the construction of cyclopropane-fused tetrahydrofurans with three contiguous stereocenters in high stereoselectivity, a feat challenging to achieve with other methods [61].
  • Reagent-Based Control: The choice of reaction partner can fundamentally alter regiochemical outcomes. In the three-component reaction of α-amino acids, acetylenedicarboxylates, and arylideneindanediones, the structure of the amino acid (primary, secondary, cyclic) determines the regioisomeric and diastereoisomeric form of the resulting spiro-pyrrolidine or pyrrolizine product [62].

The following workflow diagram synthesizes these strategic concepts into a unified decision-making framework for planning DOS campaigns aimed at complex polycyclic systems.

G Start Natural Product-Inspired Polycyclic Scaffold Goal Goal: Library of Diverse Polycyclic Skeletons Start->Goal DOS Strategy Substrate Substrate Control Goal->Substrate Catalyst Catalyst Control Goal->Catalyst Reagent Reagent Control Goal->Reagent Strat1 Modify leaving group/ protecting group Substrate->Strat1 Strat2 Tune chiral ligand/ metal center Catalyst->Strat2 Strat3 Vary nucleophile/ 1,3-dipole precursor Reagent->Strat3 Outcome1 Switchable Annulation Pathways [60] Strat1->Outcome1 Outcome2 Enantio- & Diastereoselective Radical Cascade [61] Strat2->Outcome2 Outcome3 Regio- & Diastereodivergent Spirocyclization [62] Strat3->Outcome3

The following tables summarize key quantitative data on yield and selectivity from representative methodologies for constructing complex polycyclic systems.

Table 1: Substrate-Controlled Switchable Annulations of MBH Adducts [60]

MBH Adduct Type Annulation Mode Product Scaffold Yield Range Diastereoselectivity (dr)
MBH Alcohol (R = H) [4+2] Cycloaddition Spiro[indene-2,2'-[1,3]oxazino[2,3-a]isoquinoline] Up to 87% >25:1
MBH Carbonate (R = CO₂Me) [3+2] Cycloaddition Spiro[indene-2,1'-pyrrolo[2,1-a]isoquinoline] Up to 90% >25:1

This work demonstrates how a minimal substrate alteration (OH vs. OCO₂R) completely redirects the cycloaddition pathway, delivering two distinct, complex spiro-heterocycles with exceptional selectivity.

Table 2: Amino Acid-Directed Regio- and Diastereoselectivity in Spirocyclization [62]

α-Amino Acid Used Product Type (Skeleton) Representative Yield Observed Selectivity
Sarcosine (N-methylglycine) Spiro[indene-2,3'-pyrrolidine] Type I 72-80% Single diastereomer
Glycine (R = H) Spiro[indene-2,3'-pyrrolidine] Type II (with maleate appendage) 68-75% Single diastereomer
Alanine/Phenylalanine (Primary, R ≠ H) Spiro[indene-2,3'-pyrrolidine] Type III (Regioisomer of Type II) 65-78% Single diastereomer
L-Proline (Cyclic) Spiro[indene-2,2'-pyrrolizine] 69-78% Single diastereomer
Thiazolidine-4-carboxylic acid (Cyclic) Spiro[indene-2,6'-pyrrolo[1,2-c]thiazole] 71-76% Single diastereomer

The identity of the amino acid precisely controls the regiochemistry of the 1,3-dipolar cycloaddition and the resulting scaffold, providing a powerful tool for generating spirocyclic diversity from common reagents.

Table 3: Catalytically Controlled Radical Bicyclization [61]

Chiral Ligand System Product Framework Yield Stereoselectivity
D₂-Symmetric Chiral Amidoporphyrin-Co(II) Cyclopropane-fused Tetrahydrofuran (3 contiguous stereocenters) High Excellent enantioselectivity and diastereoselectivity

Detailed Experimental Protocols

Objective: To synthesize either spirooxazinoisoquinoline (3a) or spiropyrroloisoquinoline (5a) from ninhydrin-derived MBH adducts and 3,4-dihydroisoquinoline via a tunable annulation process.

  • Materials:

    • MBH Alcohol 1a: (Z)-2-((Hydroxy(phenyl)methyl)ene)-1H-indene-1,3(2H)-dione.
    • MBH Carbonate 4a: (Z)-2-(((Methoxycarbonyl)oxy)(phenyl)methyl)ene)-1H-indene-1,3(2H)-dione.
    • 3,4-Dihydroisoquinoline (2a).
    • Anhydrous solvents: Dichloromethane (CH₂Cl₂), Acetonitrile (CH₃CN).
    • Base: 1,4-Diazabicyclo[2.2.2]octane (DABCO).

  • Procedure for [4+2] Annulation (Synthesis of 3a):

    • In an oven-dried reaction vial, charge MBH alcohol 1a (0.2 mmol, 1.0 equiv) and 3,4-dihydroisoquinoline 2a (0.22 mmol, 1.1 equiv).
    • Add anhydrous acetonitrile (CH₃CN, 2.0 mL) as solvent.
    • Add DABCO (0.02 mmol, 10 mol%) to the reaction mixture.
    • Stir the reaction at room temperature (25 °C) and monitor by TLC until the starting materials are consumed (typically 10-12 hours).
    • Upon completion, concentrate the reaction mixture under reduced pressure.
    • Purify the crude residue by flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate gradient) to afford the desired spirooxazinoisoquinoline 3a as a solid in up to 85% yield with >25:1 dr.

  • Procedure for [3+2] Annulation (Synthesis of 5a):

    • In an oven-dried reaction vial, charge MBH carbonate 4a (0.2 mmol, 1.0 equiv) and 3,4-dihydroisoquinoline 2a (0.22 mmol, 1.1 equiv).
    • Add anhydrous dichloromethane (CH₂Cl₂, 2.0 mL) as solvent. Note: No added base is required.
    • Stir the reaction at room temperature (25 °C) for 5-7 hours, monitoring by TLC.
    • Upon completion, concentrate the reaction mixture under reduced pressure.
    • Purify the crude residue by flash column chromatography to afford the desired spiropyrroloisoquinoline 5a in up to 90% yield with >25:1 dr.

  • Key Analysis: Characterize products by ¹H NMR, ¹³C NMR, and HRMS. The relative configuration is confirmed by X-ray crystallography. The exclusive formation of one diastereomer is evident from the clean ¹H NMR spectrum.

Objective: To synthesize diverse spiro[indene-pyrrolidine/pyrrolizine] derivatives and investigate the role of the α-amino acid on regioselectivity.

  • Materials:

    • α-Amino Acid (e.g., L-proline, sarcosine, alanine, phenylalanine).
    • Dialkyl acetylenedicarboxylate (e.g., dimethyl acetylenedicarboxylate, DMAD).
    • 2-Arylidene-1,3-indanedione.
    • Absolute ethanol.

  • General Procedure:

    • In a round-bottom flask, combine the α-amino acid (1.0 mmol), dialkyl acetylenedicarboxylate (1.05 mmol), and 2-arylidene-1,3-indanedione (1.0 mmol).
    • Add absolute ethanol (10 mL) as the solvent.
    • Heat the reaction mixture to 50 °C with stirring. The reaction time varies (8-15 hours) depending on the amino acid used.
    • Monitor the reaction progress by TLC. A color change is often observed.
    • After completion, cool the reaction mixture to room temperature.
    • Filter the precipitated solid or concentrate the mixture if no solid forms.
    • Recrystallize the crude product from a suitable solvent (e.g., ethanol/dichloromethane) or purify by flash chromatography to obtain the pure spirocyclic compound in good yield (65-80%) and as a single detectable diastereomer.

  • Key Observations & Safety Notes:

    • Safety: Perform all operations in a fume hood. Use appropriate personal protective equipment (PPE) when handling chemicals.
    • Selectivity: As per Table 2, the product skeleton is dictated by the amino acid. Primary amino acids with substituents (Ala, Phe) yield a different regioisomer compared to glycine [62].
    • Analysis: Characterization by ¹H NMR, ¹³C NMR, HRMS, and IR is essential. The high diastereoselectivity is confirmed by the simplicity of the ¹H NMR spectrum. Single-crystal X-ray diffraction was used to unambiguously assign the regiochemistry and stereochemistry of each product type [62].

The Scientist's Toolkit: Key Reagents for Selectivity Control

Table 4: Essential Research Reagents and Their Functions

Reagent/Catalyst Primary Function in Selectivity Control Exemplary Use Case
Ninhydrin-derived MBH Adducts (Alcohols & Carbonates) Substrate-controlled reaction pathway switching. The leaving group dictates whether the adduct acts as a C4 or C3 synthon in annulations [60]. Diversity-oriented synthesis of skeletally distinct spiro-heterocycles [60].
Chiral Amidoporphyrin-Co(II) Complex Catalyst-controlled enantioselective radical formation and trapping. The chiral environment governs the stereochemistry of C-centered radical intermediates in cascade cyclizations [61]. Asymmetric construction of cyclopropane-fused tetrahydrofurans with multiple stereocenters [61].
Varied α-Amino Acids (Glycine, Proline, Sarcosine, etc.) Reagent-controlled regioselectivity in 1,3-dipole formation and cycloaddition. Steric and conformational properties of the amino acid dictate the geometry and reactivity of the in situ generated azomethine ylide [62]. Regiodivergent synthesis of spiro-pyrrolidines and pyrrolizines from common starting materials [62].
3,4-Dihydroisoquinolines Versatile cyclic imine dipolarophiles/nucleophiles. Their electrophilicity and conformation are pivotal for selective annulation with MBH-derived zwitterions [60]. Incorporation of the privileged tetrahydroisoquinoline motif into complex polycyclic systems [60].

The precise control of diastereoselectivity and regioselectivity is a critical engine driving the success of diversity-oriented synthesis, particularly when targeting natural product-inspired polycyclic systems. As demonstrated, strategic deployment of substrate control [60], catalyst control [61], and reagent control [62] allows synthetic chemists to navigate complex reaction landscapes and channel transformations toward diverse polycyclic architectures with high fidelity.

The future of this field lies in the further integration of these principles with predictive tools and automated synthesis platforms. Advances in computational modeling to predict selectivity outcomes, coupled with machine learning for reaction optimization, will accelerate the design of next-generation DOS libraries. Furthermore, developing new catalytic systems—particularly for challenging transformations like asymmetric radical processes [61]—and exploring broader ranges of biomimetic complexity-generating reactions will continue to expand the accessible chemical universe. By systematically applying the protocols and strategies outlined herein, researchers can more effectively harness the power of selectivity to construct rich, functionally diverse compound collections for discovering novel biological probes and therapeutic agents.

Overcoming the Thermodynamic and Kinetic Hurdles of Medium-Sized Ring Synthesis

Medium-sized rings (8–11-membered cycles) occupy a critical but underexplored region of chemical space in medicinal chemistry and diversity-oriented synthesis (DOS). While prevalent in numerous bioactive natural products and offering a unique balance of structural rigidity and conformational diversity that is favorable for target binding, their presence in synthetic screening libraries and marketed drugs remains disproportionately low [63] [64]. This scarcity is a direct consequence of the significant thermodynamic and kinetic barriers associated with their construction. Unlike smaller rings (5–7 members), which benefit from favorable kinetics of cyclization, or larger macrocycles (≥12 members), medium-sized rings suffer from destabilizing transannular strain and entropic penalties during direct cyclization from linear precursors [63] [65]. These hurdles render traditional cyclization methods inefficient, necessitating innovative synthetic strategies.

Within the framework of diversity-oriented synthesis from natural product scaffolds, accessing medium-sized rings is paramount. Natural products are a prime source of novel, biologically validated scaffolds, and DOS aims to build structurally diverse libraries around these privileged cores to explore uncharted chemical space and identify new bioactive entities [13] [65]. The inability to readily incorporate medium-sized rings into such libraries represents a major gap. This application note details contemporary strategies—primarily ring-expansion reactions and catalytic cyclizations—designed to overcome these fundamental challenges. It provides researchers with a practical guide, including comparative data, detailed protocols, and a toolkit for implementing these methods to diversify natural product-inspired compound collections.

Strategic Frameworks for Synthesis

Overcoming the hurdles of medium-sized ring formation requires bypassing the high-energy transition states of direct cyclization. The two most effective strategic paradigms are Ring Expansion from Pre-formed Smaller Cycles and Catalytic Cyclization via Reactive Intermediates.

Ring Expansion Strategies: This approach transforms a less-strained, kinetically accessible smaller ring (typically 5-7 membered) into a medium-sized ring. The critical design principle is to couple the ring expansion step with a strong, independent thermodynamic driving force that compensates for the inherent strain of the product [64]. As summarized in Table 1, common driving forces include the formation of stable bonds (e.g., amides), the neutralization of charged intermediates, and aromatization [65] [64].

Table 1: Thermodynamic Driving Forces in Ring-Expansion Strategies for Medium-Sized Ring Synthesis

Driving Force Mechanistic Basis Example Transformation Key Advantage
Bond Formation Conversion of a higher-energy functional group (e.g., ynamide, imidazoline) into a more stable bond (e.g., amide, lactam) [64]. Yttrium-catalyzed rearrangement of ynamides to 8-9 membered lactams [64]. High yields; predictable by computational analysis of relative isomer stability.
Charge Neutralization Relief of strain or stabilization via rearrangement of a charged reactive intermediate (e.g., carbanion, acyl ammonium ion) [64]. Acyl ammonium ion cascade from linear precursors to 8-11 membered lactams/lactones [64]. Avoids medium-sized transition states; uses internal catalysis.
Aromatization Regaining aromaticity in an expanded ring system provides a powerful energetic payoff [65] [64]. Oxidative Dearomatization-Ring Expansion (ODRE) of phenols to benzannulated medium rings [65]. Biomimetic; accesses complex scaffolds found in natural products.

Catalytic Cyclization Strategies: These methods facilitate the direct ring closure of acyclic precursors by stabilizing the key cyclization transition state. A prominent example is the vinyl carbocation cyclization, where a Lewis acid catalyst generates a persistent electrophilic intermediate that undergoes intramolecular Friedel-Crafts reaction [63]. This method is particularly effective for forming 8- and 9-membered rings with fused arenes.

The conceptual relationship between the synthesis challenge and the strategic solutions is outlined in the following workflow.

G Challenge Core Challenge: Medium-Sized Ring (8-11) Synthesis Hurdle1 Kinetic Hurdle: Unfavorable Entropy of Direct Cyclization Challenge->Hurdle1 Hurdle2 Thermodynamic Hurdle: Transannular Strain & High Ring Strain Challenge->Hurdle2 Strategy1 Strategy 1: Ring Expansion Hurdle1->Strategy1 Bypasses High-TS Strategy2 Strategy 2: Catalytic Cyclization Hurdle1->Strategy2 Catalyst Lowers TS Hurdle2->Strategy1 Paid by Driving Force Hurdle2->Strategy2 Product Stabilized Mech1 Grow from Pre-formed Small Ring Strategy1->Mech1 Force1 Driving Force: Bond Formation / Aromatization Mech1->Force1 Outcome Outcome: Access to Diverse Medium-Sized Scaffolds Force1->Outcome Mech2 Stabilize Cyclization Transition State Strategy2->Mech2 Force2 e.g., Vinyl Cation Intermediate Mech2->Force2 Force2->Outcome

Diagram 1: Strategic Framework for Overcoming Synthesis Hurdles (83 characters)

Application Notes & Comparative Analysis

The choice of synthetic strategy depends on the target scaffold, available precursors, and required functional group tolerance. The following analysis compares two leading methods.

Table 2: Comparative Analysis of Medium-Sized Ring Synthesis Strategies

Parameter Ring Expansion (e.g., ODRE, Acyl Ammonium Cascade) Vinyl Carbocation Cyclization
Typical Ring Sizes Accessed Broad scope (7-11+ members); highly method-dependent [64]. Primarily 8- and 9-membered rings effectively [63].
Key Thermodynamic Driver Aromatization, amide/lactone formation, charge neutralization [65] [64]. Formation of stable exo-cyclic alkene and rearomatization of fused arene [63].
Kinetic Advantage Proceeds via normal-sized ring transition states or intermediates [64]. Lewis acid catalysis lowers barrier for C-C bond formation [63].
Functional Group Tolerance Varies; ODRE tolerant of many nucleophiles (acids, phenols) [65]. Tolerant of sulfonamides, thioethers, electron-donating arenes; sensitive to strong electron-withdrawing groups [63].
Fit for DOS from NP Scaffolds Excellent. Can transform phenolic or heterocyclic cores common in NPs into diverse analogues [13] [65]. Good. Builds onto arene-rich scaffolds, common in NP alkaloids, to create novel fused ring systems [63].

Detailed Experimental Protocols

This protocol describes the formation of an 8-membered ring via Li–WCA catalyzed intramolecular Friedel–Crafts alkylation, optimized to a 73% yield.

Materials & Setup:

  • Substrate: Vinyl tosylate precursor (e.g., compound 1 from [63]).
  • Catalyst: Lithium tetrakis(pentafluorophenyl)borate etherate {[Li(OEt₂)]₊[B(C₆F₅)₄]₋} (10 mol%).
  • Additive: Lithium hydride (LiH, 5.0 equiv).
  • Solvent: Anhydrous 1,2-dichlorobenzene (o-DCB).
  • Reaction Vessel: Schlenk tube or sealed microwave vial equipped with a stir bar.
  • Atmosphere: Reaction performed under an inert nitrogen or argon atmosphere.
  • Heating: Oil bath or heating block at 140 °C.

Procedure:

  • Preparation: In a glovebox, charge the reaction vessel with vinyl tosylate substrate (1.0 equiv, typically 0.1 mmol scale), [Li(OEt₂)]₊[B(C₆F₅)₄]₋ (0.1 equiv), and LiH (5.0 equiv).
  • Solvent Addition: Add anhydrous o-DCB (0.1 M concentration relative to substrate) and seal the vessel.
  • Reaction: Remove the vessel from the glovebox and heat with vigorous stirring at 140 °C for 16-24 hours. Monitor reaction progress by TLC or LC-MS.
  • Work-up: After cooling to room temperature, carefully quench the reaction by adding a saturated aqueous solution of ammonium chloride (NH₄Cl). Extract the aqueous layer three times with ethyl acetate (EtOAc).
  • Purification: Combine the organic extracts, dry over anhydrous magnesium sulfate (MgSO₄), filter, and concentrate under reduced pressure. Purify the crude residue by flash column chromatography on silica gel to obtain the desired tetrahydroazocine product.

Critical Notes:

  • Catalyst loading below 10 mol% leads to significantly diminished yields [63].
  • The choice of base is crucial. LiHMDS is detrimental, while LiH is essential for good yield [63].
  • Solvent is critical. o-DCB gave optimal results; DMF or o-DFB failed [63].

This biomimetic protocol diversifies phenolic natural product scaffolds by cleaving a C–C bond and inserting a new fragment to form a medium-sized ring.

Materials & Setup:

  • Substrate: Polycyclic phenol precursor.
  • Oxidizing Agent: (Diacetoxyiodo)benzene (PIDA) or similar hypervalent iodine reagent.
  • Promoter/Reagent: Triflic anhydride (Tf₂O), Copper(II) tetrafluoroborate (Cu(BF₄)₂), or p-toluenesulfonic acid (TsOH) to trigger fragmentation [65].
  • Nucleophile: Alcohol, carboxylic acid, or arene (depending on desired linkage).
  • Solvent: Dichloromethane (DCM) or acetonitrile (MeCN), anhydrous.

General Workflow: The ODRE sequence involves three key operational stages, as visualized below.

G A Step 1: Oxidative Dearomatization B Intermediate: Polycyclic Cyclohexadienone A->B PIDA Oxidant C Step 2: Reagent-Induced Fragmentation B->C Add Tf2O/TsOH D Key Intermediate: Cationic Species C->D C-C Cleavage E Step 3: Trapping & Rearomatization D->E + NuH (Nucleophile) F Product: Benzannulated Medium-Sized Ring E->F Rearomatizes

Diagram 2: ODRE Reaction Sequence (56 characters)

Procedure:

  • Dearomatization: Cool a solution of the phenol substrate (1.0 equiv) in anhydrous DCM to 0°C. Add the oxidant (PIDA, 1.1 equiv) and stir until complete conversion to the cyclohexadienone intermediate (monitor by TLC).
  • Fragmentation & Ring Expansion: To the same reaction mixture, add the promoter (e.g., Tf₂O, 1.5 equiv) to activate the dienone towards C–C bond cleavage. This generates a reactive cationic or ketene intermediate.
  • Nucleophilic Trapping: Immediately add the desired nucleophile (e.g., a carboxylic acid or alcohol, 2.0 equiv). The nucleophile attacks the intermediate, initiating bond formation and simultaneous ring expansion.
  • Rearomatization: The final step is spontaneous or mild-acid promoted rearomatization of the arene, delivering the expanded, benzannulated product.
  • Work-up & Purification: Quench with aqueous sodium thiosulfate (if using iodine reagents) or saturated NaHCO₃, extract with DCM, dry, concentrate, and purify by chromatography.

Critical Notes:

  • The choice of promoter (Tf₂O vs. TsOH vs. Cu²⁺) dictates the fragmentation pathway and the type of nucleophile that can be incorporated [65].
  • Competing dienone-phenol rearrangements must be suppressed by optimized conditions [65].

The Scientist's Toolkit: Essential Reagents & Materials

Table 3: Key Reagent Solutions for Medium-Sized Ring Synthesis

Reagent/Material Function in Synthesis Application Note
Lithium Tetrakis(pentafluorophenyl)borate {[Li]+[B(C₆F₅)₄]−} Lewis acid–weakly coordinating anion (WCA) catalyst. Ionizes vinyl sulfonates to generate persistent vinyl carbocation intermediates for cyclization [63]. Critical for Protocol A. Must be handled under inert atmosphere. LiH co-additive is essential for good yield [63].
Vinyl Tosylates Vinyl carbocation precursors. More stable and easier to prepare than analogous vinyl triflates for electron-rich systems [63]. The electrophilic core in vinyl carbocation cyclization. Requires an appropriate tethered arene or heteroarene nucleophile.
(Diacetoxyiodo)benzene (PIDA) Hypervalent iodine oxidant. Mediates the selective oxidative dearomatization of phenols to cyclohexadienones [65]. Used in the first step of ODRE protocols (Protocol B).
Triflic Anhydride (Tf₂O) Strong electrophilic promoter. Activates cyclohexadienone intermediates towards C–C bond cleavage and fragmentation in ODRE sequences [65]. Highly moisture-sensitive. Determines one major pathway in ODRE diversification.
1,2-Dichlorobenzene (o-DCB) High-boiling-point aromatic solvent. Provides a high-temperature reaction environment necessary for some vinyl carbocation cyclizations [63]. Essential for optimal yields in Protocol A. Not interchangeable with other common solvents like DMF or toluene [63].

Integration with Diversity-Oriented Synthesis from Natural Product Scaffolds

The synthesis of medium-sized rings is not merely a technical challenge but a strategic imperative for effective diversity-oriented synthesis (DOS) campaigns aimed at natural product (NP) scaffolds. Modern DOS increasingly moves beyond simple peripheral decoration towards skeletal diversity, altering the core scaffold itself to access entirely new regions of chemical space [13] [47]. The strategies outlined here are perfectly suited for this goal.

  • Complexity-to-Diversity (CtD): Ring expansion methods like ODRE exemplify the CtD strategy. They start with a complex, natural product-inspired polycyclic core (the "complexity") and systematically rearrange it through predictable bond-cleavage and reformation processes to generate a diverse family of novel scaffolds (the "diversity") that retain biological relevance [65].
  • Chemoenzymatic Diversification: Recent advances integrate synthetic chemistry with enzymatic catalysis. For example, late-stage, P450-catalyzed oxyfunctionalization can introduce hydroxyl groups at unactivated C-H bonds on a core scaffold [13]. These new hydroxyl groups, particularly phenols, can then serve as direct handles for downstream diversification via methods like ODRE, exponentially increasing accessible skeletal diversity from a single precursor [13].
  • Accessing Underexplored Chemical Space: By enabling the reliable construction of 8-11 membered rings, these methods allow medicinal chemists to populate screening libraries with compounds that mimic the three-dimensionality and stereochemical complexity of natural products but are not found in nature. This increases the probability of discovering novel bioactive agents with unique modes of action, particularly against challenging "undruggable" targets [65] [64].

In conclusion, overcoming the thermodynamic and kinetic hurdles of medium-sized ring synthesis through ring expansion and catalytic cyclization is a cornerstone for the next generation of diversity-oriented synthesis. By providing robust, practical methodologies, as detailed in these application notes, researchers can now more confidently incorporate these privileged yet elusive ring systems into their drug discovery campaigns, unlocking new avenues inspired by natural product architecture.

Balancing Molecular Complexity with Synthetic Feasibility and Yield

Diversity-oriented synthesis (DOS) aims to produce chemical libraries that rapidly explore large, biologically relevant portions of chemical space, often taking inspiration from the structural complexity and pre-validated bioactivity of natural products (NPs) [47] [4]. A central, persistent challenge in this field is the inherent trade-off between designing molecules of sufficient complexity to interact with challenging biological targets and ensuring those molecules are synthetically accessible in yields that enable practical screening and development [8] [66]. This balance is critical for the efficient discovery of bioactive probes and lead compounds.

This application note details integrated computational and experimental strategies for navigating this design paradox. Framed within the broader thesis of diversity-oriented synthesis from natural product scaffolds, we present protocols centered on two innovative concepts: 1) the use of machine learning-powered synthetic feasibility scores that incorporate human expertise, and 2) the "diverse Pseudo-Natural Product (dPNP)" strategy, which builds complex, NP-inspired scaffolds from a common, synthetically tractable intermediate [67] [8]. The goal is to provide researchers with a actionable framework for maximizing output in DOS campaigns directed at novel biological space.

Core Concepts and Quantitative Metrics

Effective balancing requires quantifiable metrics for both molecular complexity and synthetic feasibility. Below is a comparison of key computational tools and metrics relevant to DOS planning.

Table 1: Comparison of Synthetic Feasibility and Complexity Assessment Tools

Tool/Metric Name Core Methodology Output Range Key Strengths for DOS Primary Limitations
FSscore [67] Graph Neural Network trained on reaction data, fine-tuned with human feedback. Continuous ranking. Differentiates subtle stereochemical differences; adaptable to specific chemical spaces (e.g., macrocycles, NPs) via fine-tuning. Requires labeled data for fine-tuning; performance gains challenging on very complex scopes with limited labels.
SAscore [66] Rule-based: Fragment contribution from PubChem prevalence + complexity penalties (rings, stereocenters, etc.). 1 (easy) to 10 (hard). Fast, interpretable; explains ~90% of variance in human chemist rankings; good for high-throughput prioritization. Over-penalizes symmetrical molecules; ignores commercial availability of complex building blocks.
Molecular Complexity (ML Model) [68] Learning-to-Rank (LTR) model trained on ~300k human pairwise comparisons. Continuous ranking relative to training set. Digitizes human intuition; key features (MW, aromatic rings, TPSA) align with medicinal chemistry principles. Model is a relative ranker, not an absolute metric; dependent on quality and scope of training data.
Derivatization Design [69] Rule-based AI forward synthesis engine evaluating reagent compatibility and reaction rules. Binary (feasible/infeasible) with suggested route. Guarantees synthetic feasibility and provides route; incorporates reagent cost/availability data. Limited to known reaction rules in its knowledge base; may lack truly novel disconnections.

Integrated Protocol: From Design to Synthesis

This protocol outlines a cyclical workflow for designing and synthesizing a DOS library based on natural product fragments, integrating computational feasibility assessment with practical synthesis.

G Start Start: NP Scaffold & Target Profile C1 Step 1: Computational Design & Feasibility Filtering Start->C1 C2 Step 2: Retrosynthetic & Route Planning with AI Tools C1->C2 C3 Step 3: Synthesis of Divergent Intermediate C2->C3 C4 Step 4: DOS Library Synthesis & Diversification C3->C4 C5 Step 5: Biological Screening C4->C5 Feedback Feedback Loop: Yield/Feasibility Data C4->Feedback End End: Hit Identification & Validation C5->End ML_Update Fine-tune FSscore Model Feedback->ML_Update ML_Update->C1 Improved Prediction

Diagram 1: Integrated workflow for balancing complexity and synthetic yield in DOS [67] [8] [69].

Protocol 1: Computational Design & Prioritization with FSscore

Objective: To filter and rank a virtual library of NP-inspired designs based on predicted synthetic feasibility.

Materials & Software:

  • Virtual Library: SMILES strings of designed molecules.
  • FSscore Model: Pre-trained graph attention network model [67].
  • Fine-tuning Dataset: (Optional) 20-50 expert-ranked molecule pairs from your target chemical space.
  • Python Environment with deep learning libraries (PyTorch, DGL/RDKit).

Procedure:

  • Baseline Scoring: Input SMILES strings into the pre-trained FSscore model to obtain an initial synthetic feasibility ranking.
  • Expert Evaluation (Critical Step): Select the top 100 and bottom 100 ranked molecules. Have 2-3 expert medicinal chemists perform pairwise comparisons (A vs. B) on a subset of these, focusing on molecules near the feasibility threshold for your project.
  • Model Fine-Tuning: Use the collected pairwise preference data (approximately 20-50 pairs is sufficient [67]) to fine-tune the FSscore model. This adapts the model to your team's expertise and specific chemical space (e.g., spirocycles, macrocycles).
  • Final Prioritization: Re-score the entire virtual library with the fine-tuned FSscore. Select the top-ranked compounds that also meet other criteria (e.g., calculated properties, structural diversity) for synthesis.
Protocol 2: Synthesis of Diverse PNPs via a Divergent Intermediate

Objective: To synthesize a library of complex, three-dimensional pseudo-natural products from a common, synthetically accessible intermediate, maximizing scaffold diversity and yield [8].

Conceptual Model of the dPNP Strategy

G NP_Frag_A NP Fragment A (e.g., Indole) Div_Int Common Planar Divergent Intermediate NP_Frag_A->Div_Int NP_Frag_B NP Fragment B (e.g., Aryl Bromide) NP_Frag_B->Div_Int Rx1 Dearomatization/ Carbonylation Div_Int->Rx1 ClassA Class A Spiroindolylindanone Rx1->ClassA Pd/Xantphos N-formyl saccharin Rx2 Reduction ClassB Class B Spiro-indoline-indanone Rx2->ClassB Hantzsch ester PPTS Rx3 Functionalization/ Annulation ClassE Class E Indoline-isoquinolinone Rx3->ClassE Methyl 2-bromobenzoate Pd/Xantphos ClassA->Rx2 ClassA->Rx3

Diagram 2: The dPNP strategy: generating multiple complex classes from one intermediate [8].

Materials:

  • Key Reagent: N-formyl saccharin (safe, efficient CO surrogate) [8].
  • Catalyst System: Palladium acetate (Pd(OAc)₂), Xantphos ligand.
  • Solvents: Anhydrous DMF, benzene.
  • Building Blocks: Substituted indole derivatives with tethered aryl bromides.

Part A: Synthesis of the Core Spiroindolylindanone (Class A)

  • In a flame-dried Schlenk tube under inert atmosphere, combine the indole substrate (1.0 equiv), Pd(OAc)₂ (5 mol%), Xantphos (10 mol%), and Na₂CO₃ (2.0 equiv).
  • Add anhydrous DMF (0.1 M concentration relative to substrate).
  • Add N-formyl saccharin (1.5 equiv) as a solid.
  • Heat the reaction mixture to 100°C and stir for 12-16 hours.
  • Cool to room temperature, dilute with ethyl acetate, and wash with water and brine.
  • Purify the crude product by flash chromatography to obtain the dearomatized spiroindolylindanone (Class A). Expected yields: Moderate to excellent (50-86%) with broad functional group tolerance [8].

Part B: Diversification to Access Additional Scaffolds

  • To Class B (Spiro-indoline-indanone): Dissolve Class A compound in DCM (0.05 M). Add Hantzsch ester (2.0 equiv) and a catalytic amount of pyridinium p-toluenesulfonate (PPTS, 0.1 equiv). Stir at room temperature for 2-4 hours. Purify via flash chromatography to obtain the reduced product with high diastereoselectivity (d.r. ≥ 6:1) [8].
  • To Class E (Indoline-isoquinolinone): Combine Class A compound (1.0 equiv), methyl 2-bromobenzoate (1.5 equiv), Pd(OAc)₂ (5 mol%), Xantphos (10 mol%), and K₃PO₄ (2.0 equiv) in toluene. Heat to 110°C for 18 hours. Work up and purify to obtain the fused isoquinolinone product [8].
Protocol 3: AI-Assisted Derivatization Design for Lead Optimization

Objective: To generate synthetically feasible analogues around a DOS-derived hit for preliminary SAR exploration [69].

Materials & Software:

  • Hit Molecule: SMILES structure of the confirmed hit.
  • Derivatization Design Software: e.g., SynSpace or similar rule-based AI forward synthesis platform [69].
  • Reagent Database: Integrated database of commercially available building blocks.

Procedure:

  • Define Constraints: Input the hit structure and specify design parameters (e.g., maximize diversity at R1/R2, maintain core scaffold, limit synthesis to ≤3 steps).
  • Execute In Silico Forward Synthesis: The AI engine systematically evaluates compatible reagents and reaction rules from its library (>300 transformations) to generate virtual products [69].
  • Filter and Select: The output is automatically annotated with predicted synthetic feasibility, reagent availability, and estimated cost. Filter based on:
    • Synthetic accessibility score (SAscore < 5).
    • Compatibility with parallel synthesis formats.
    • Structural novelty and property predictions.
  • Route Review: Examine the suggested synthetic route for each selected analogue. The rule-based system provides specific reagents and reaction conditions.

The Scientist's Toolkit: Essential Reagents & Solutions

Table 2: Key Research Reagent Solutions for DOS Based on NP Scaffolds

Item Function/Application Example/Note Relevance to Balance
N-Formyl Saccharin [8] Safe, solid CO surrogate for carbonylation reactions. Enables high-yield (86%) Pd-catalyzed dearomatization/carbonylation cascade. Replaces hazardous CO gas; improves yield and operational safety in complex step.
Hantzsch Ester Biomimetic transfer hydrogenation agent. Used for diastereoselective reduction of indolenine to indoline in dPNP synthesis [8]. Provides mild, selective reduction to access new chiral centers without over-reduction.
Xantphos Ligand Bulky, electron-rich bisphosphine ligand for Pd catalysis. Essential for successful carbonylation and annulation steps in dPNP synthesis [8]. Stabilizes Pd intermediates in complex transformations, enabling key bond-forming steps.
FSscore Fine-Tuning Dataset Curated set of molecular pairs with expert preference labels. ~50 pairs can significantly adapt model to specific project chemistry [67]. Directly incorporates synthetic team's intuition into computational design, aligning predictions with practical feasibility.
Rule-Based AI Forward Synthesis Engine [69] Software for predicting feasible reactions and routes. Evaluates >300 reaction types with functional group tolerance rules. Guarantees that designed analogues are tied to a known, viable synthetic pathway, minimizing dead ends.

The pursuit of novel biologically active small molecules through diversity-oriented synthesis (DOS) presents a unique convergence of synthetic creativity and practical efficiency. DOS aims to generate structurally and stereochemically diverse compound libraries, often inspired by the pre-validated, biologically relevant chemical space of natural product scaffolds [4] [2]. However, the traditional focus on maximizing structural diversity must now be harmonized with the imperative of sustainable practice. The integration of green chemistry principles is not merely an ethical addendum but a critical strategy for enhancing the feasibility, scalability, and environmental responsibility of DOS campaigns within natural product-based drug discovery [70].

Green chemistry, defined as the design of chemical products and processes that reduce or eliminate hazardous substances, provides a foundational framework [70]. Its twelve principles—including waste prevention, the use of safer solvents, increased energy efficiency, and the preferential use of catalytic reagents—offer a direct roadmap for improving synthetic protocols [70]. This article details practical applications of these principles, focusing on rational solvent selection, innovative catalyst recovery, and the development of sustainable workflows. By embedding these considerations early in the library design phase, researchers can build efficiency and sustainability into the very foundation of their discovery pipeline, ensuring that the quest for novel chemical probes and drug leads aligns with broader environmental and economic goals.

Strategic Solvent Selection for Sustainable Synthesis

The choice of solvent is one of the most impactful decisions in chemical synthesis, influencing reaction efficiency, workup, waste, and operator safety. Strategic solvent selection moves beyond simple solubility to a holistic analysis of environmental, health, and lifecycle impacts.

Quantitative Assessment Tools and Comparative Data

Modern solvent selection is guided by comprehensive tools that quantify multiple parameters. The ACS GCI Pharmaceutical Roundtable Solvent Selection Tool enables interactive selection based on the Principal Component Analysis (PCA) of 70 physical properties for 272 solvents, including research, process, and next-generation green solvents [71]. It incorporates data on functional group compatibility, ICH classification, and environmental impact categories (health, air, water, lifecycle) [71]. Similarly, the GreenSOL guide provides a lifecycle assessment tailored for analytical chemistry, evaluating 58 solvents (including deuterated varieties) across production, use, and waste phases, assigning a composite greenness score from 1 to 10 [72].

Table 1: Greenness Scoring for Common Solvents in Synthesis (Representative Examples)

Solvent ICH Class [71] Principal Green Concern Suggested Green(er) Alternative Key Consideration for DOS
N,N-Dimethylformamide (DMF) Class 2 Reproductive toxicity, poor biodegradability Cyrene (dihydrolevoglucosenone) High boiling point can complicate product isolation in parallel synthesis.
Dichloromethane (DCM) Class 2 Carcinogenicity, high volatility 2-Methyltetrahydrofuran (2-MeTHF) Excellent solvating power but poses significant inhalation risks.
Dimethyl Sulfoxide (DMSO) Class 3 Difficult to remove, penetrates skin N-Butylpyrrolidinone (NBP) Ideal for high-temperature reactions but can interfere with biological screening if carried over.
n-Hexane Class 2 Neurotoxicity, high flammability Heptane Often used for chromatography; less toxic alkanes are preferable.
Tetrahydrofuran (THF) Class 3 Peroxide formation, derived from fossil fuels 2-MeTHF (bio-derived) Widely used in organometallic chemistry; bio-derived versions improve sustainability.

A Workflow for Rational Solvent Choice

The following workflow provides a systematic approach to solvent selection for DOS planning.

G Start Define Reaction & Solvent Requirements Step1 Consult Selection Guides (ACS Tool, GreenSOL) Start->Step1 Step2 Filter by ICH Class & Hazard Profile Step1->Step2 Step3 Evaluate Performance: Solubility, B.P., Inertness Step2->Step3 Step4 Assess Workup & Recovery Potential Step3->Step4 Decision Optimal for Reaction & Workup? Step4->Decision Decision:s->Step1:s No End Implement & Document in Protocol Decision->End Yes Recycle Plan for Solvent Recycling/Disposal End->Recycle

Diagram 1: Systematic solvent selection workflow (73 characters)

Advanced Catalyst Recovery and Reuse

The use of catalysts is a cornerstone of green chemistry (Principle 9), but their sustainability hinges on efficient recovery and reuse, especially for expensive and potentially toxic homogeneous transition metal catalysts [70].

Organic Solvent Nanofiltration (OSN) for Homogeneous Catalysis

Traditional separation methods like distillation are energy-intensive and can degrade sensitive catalysts [73]. Organic Solvent Nanofiltration (OSN) has emerged as a transformative technology for catalyst recovery. OSN uses pressure-driven membranes stable in organic solvents to separate molecules based on size and shape, allowing small product molecules to pass through while retaining larger catalyst complexes [74] [73].

A landmark 2025 study demonstrated the recovery and five-time reuse of a homogeneous palladium catalyst in the synthesis of the active pharmaceutical ingredient AZD4625 using commercial OSN membranes [74]. The process maintained >90% conversion in each cycle without altering the catalyst/ligand system, showcasing its practical robustness [74].

Table 2: Comparison of Catalyst Recovery Methods

Method Key Principle Advantages Limitations for Homogeneous Catalysis
Distillation Separation by boiling point Well-established, scalable High energy cost, unsuitable for heat-sensitive catalysts [73].
Liquid-Liquid Extraction Partitioning between immiscible solvents Can be very selective Often requires large solvent volumes, can lead to catalyst loss [73].
Immobilization (Heterogenization) Anchor catalyst to solid support Easy filtration Can reduce activity/selectivity; leaching is a concern.
Organic Solvent Nanofiltration (OSN) Size-exclusion in solvent-resistant membranes Low energy, mild conditions, high selectivity Membrane compatibility and long-term stability require validation [74] [73].

Detailed Protocol: OSN-Assisted Recovery of a Homogeneous Palladium Catalyst

This protocol is adapted from the work by Xiao et al. (2025) on the synthesis of AZD4625 [74].

Materials: Reaction mixture containing product and Pd catalyst complex (MW ~1-3 kDa); OSN membrane module (e.g., StarMem 240, GMT oNF-2); compatible solvent for diafiltration (e.g., toluene, methanol); pressure source (nitrogen or pump).

Procedure:

  • Reaction Completion & Quenching: Conduct the palladium-catalyzed reaction as per standard conditions. Quench the reaction appropriately to stop catalytic activity.
  • Initial Filtration: Pass the crude reaction mixture through a basic filter to remove any particulate matter that could foul the OSN membrane.
  • OSN Setup & Concentration: Install the selected OSN membrane in its holder. Feed the filtered reaction mixture into the system. Apply pressure (typically 10-30 bar) to initiate permeation. The permeate, containing the product and solvent, is collected. The retentate, containing the concentrated catalyst, is recycled back to the feed tank.
  • Diafiltration: Once the initial volume is reduced, begin adding a clean, process-compatible solvent to the retentate tank at the same rate as permeation. This displaces residual product from the retentate, increasing product yield and catalyst purity. Continue for 3-5 volume equivalents.
  • Catalyst Reconditioning & Reuse: The final retentate is a concentrated solution of the recovered catalyst and ligand. Analyze for palladium content and activity (e.g., via a test reaction). Adjust concentration with fresh solvent as needed and reintroduce directly into a new reaction cycle.
  • Membrane Regeneration: After operation, flush the membrane system with clean solvent to preserve its lifespan.

G Reaction Catalytic Reaction Mixture Crude Mixture: Product + Catalyst Reaction->Mixture OSN OSN Membrane Unit Mixture->OSN Permeate Permeate: Pure Product in Solvent OSN->Permeate Permeates Retentate Concentrated Retentate: Catalyst OSN->Retentate Retained Reuse Catalyst Reuse in New Cycle Retentate->Reuse Reuse->Reaction Solvent Make-up Solvent Solvent->OSN Diafiltration

Diagram 2: OSN catalyst recycling loop (37 characters)

Sustainable Protocols for Library Synthesis

Implementing green chemistry in DOS requires rethinking entire workflows, from the source of starting materials to the final workup.

Leveraging Renewable Feedstocks: Biomass-Derived Materials

Principle 7 advocates for renewable feedstocks [70]. Crop residues (e.g., husks, straw, bagasse) are abundant sources of cellulose, lignin, and silica that can be transformed into sustainable materials for synthesis. Green synthesis methods using these residues can yield catalytic nanoparticles or porous supports for catalysis [75].

Protocol: Preparation of a Silica-Supported Catalyst from Rice Husk Ash

  • Pretreatment: Wash rice husks thoroughly with water and dry. Perform an acid wash (e.g., 1M HCl) to remove metal impurities.
  • Combustion: Calcine the cleaned husks in a muffle furnace at 600°C for 6 hours to obtain silica-rich ash.
  • Activation: Treat the ash with sodium hydroxide solution to form sodium silicate, followed by acid precipitation to generate mesoporous silica gel.
  • Functionalization: Impregnate the silica with an aqueous solution of a metal salt (e.g., PdCl₂, Cu(NO₃)₂). Dry and reduce under a hydrogen atmosphere to yield metal nanoparticles on the silica support.
  • Application: This heterogeneous catalyst can be used in various DOS transformations (e.g., coupling reactions) and recovered by simple filtration.

Process Intensification: Continuous Flow Systems

Moving from batch to continuous flow processing aligns with multiple green principles. It enhances heat/mass transfer, improves safety with hazardous reagents, enables precise reaction control, and facilitates in-line purification and solvent recycling. This is ideal for key steps in a DOS library synthesis, such as heterocycle formation or catalytic hydrogenation.

G P1 Precursors in Solvent A Mix Static Mixer P1->Mix P2 Reagent in Solvent B P2->Mix Reactor Tube Reactor (Heated/Cooled) Mix->Reactor Sep In-line Separator (e.g., Membrane) Reactor->Sep Quench In-line Quench Stream Quench->Sep Product Purified Product Stream Sep->Product Waste Solvent/Catalyst Recycle Sep->Waste Retentate

Diagram 3: Simplified continuous flow system (38 characters)

The Scientist's Toolkit: Essential Reagents & Materials

Table 3: Key Research Reagent Solutions for Green DOS

Item Function/Description Green Chemistry Rationale
2-Methyltetrahydrofuran (2-MeTHF) Renewable solvent (from biomass) for extractions, organometallics. Replaces THF and halogenated solvents; better biodegradability [71].
Cyrene (Dihydrolevoglucosenone) Dipolar aprotic solvent from cellulose. Direct replacement for toxic DMF and NMP [71].
Ethyl Lactate Ester solvent derived from fermentation. Biodegradable, low toxicity solvent for chromatography and reactions.
Polymer-Supported Reagents & Scavengers Immobilized reactants or purification agents on solid support. Simplify workup, reduce waste, enable automation in parallel synthesis.
OSN Membrane Modules Solvent-resistant membranes for molecular separation. Enable low-energy catalyst and solvent recycling [74] [73].
Solid Acid/Base Catalysts (e.g., Amberlyst resins, supported amines) Heterogeneous alternatives to corrosive acids/bases. Recyclable, simplify workup, reduce corrosive waste streams.
Biomass-Derived Feedstocks (e.g., chitosan, levulinic acid) Renewable building blocks for library synthesis. Reduce reliance on petrochemicals, incorporate degradable motifs [75].

Integrating Chemoenzymatic and Photobiocatalytic Steps with Traditional Synthesis

The pursuit of novel bioactive compounds in drug discovery is increasingly directed toward the expansive, biologically relevant chemical space surrounding natural products (NPs) [76]. Diversity-oriented synthesis (DOS) from natural product scaffolds represents a powerful paradigm within this pursuit, aiming to generate structurally complex and diverse compound libraries that mimic the favorable pharmacological properties of NPs while exploring new structural territories [47] [41]. Traditional synthetic chemistry, while robust, often encounters limitations in achieving selective functionalization of complex scaffolds under mild conditions, particularly in late-stage diversification where sensitive functional groups are present [47].

This article frames the integration of chemoenzymatic and photobiocatalytic steps with traditional synthesis within the context of a broader thesis on DOS from NP scaffolds. The core thesis posits that the strategic merger of these disciplines can overcome key bottlenecks in library generation. Specifically, biocatalysis offers unmatched regio-, stereo-, and chemoselectivity for transforming multifunctional NP scaffolds, while photocatalysis provides unique activation modes to access novel reactive intermediates [77] [78]. When seamlessly combined with traditional synthetic steps, this integrated approach enables the efficient, sustainable, and divergent synthesis of NP-inspired libraries, accelerating the discovery of new probes and therapeutic leads [41].

Conceptual Foundations and Strategic Integration

The design of NP-inspired compound collections exists on a continuum from purely synthetic molecules to the NPs themselves [41]. Strategies like biology-oriented synthesis (BIOS) or pharmacophore-directed retrosynthesis (PDR) start from a known NP scaffold or pharmacophore, aiming to simplify or diversify the structure to explore structure-activity relationships (SAR) [76] [41]. Integrating modern catalytic technologies into these strategies enhances their scope and efficiency.

  • Chemoenzymatic Synthesis combines the precision of enzymatic catalysis with the broad scope of traditional chemical reactions. Enzymes, particularly when engineered or used under non-natural conditions, can perform selective transformations—such as kinetic resolutions, asymmetric reductions, or site-specific hydroxylations—on intermediates prepared by synthetic chemistry, setting stereocenters or introducing functionalities that are challenging to access chemically [77]. A prime example is dynamic kinetic resolution, which can theoretically provide 100% yield of a single enantiomer from a racemic mixture, surpassing the limits of traditional resolution [77].
  • Photobiocatalysis represents the merger of photocatalysis with enzymatic catalysis [78]. This field leverages light to drive enzymatic cofactor regeneration (e.g., NAD(P)H) or to create unique enzyme-substrate complexes that undergo "new-to-nature" reactions, such as asymmetric radical additions or C-H functionalizations [78] [79]. This allows for reaction pathways that are inaccessible to either catalysis alone.
  • Integration with Traditional Synthesis: Traditional synthesis provides the foundational scaffold, often derived from or inspired by an NP core (e.g., tetrahydropyridine, N-phenylquinoneimine) [47] [54]. Chemoenzymatic and photobiocatalytic steps are then inserted at strategic points in the synthetic sequence, often to introduce diversity or complexity in a selective manner. For instance, a traditional coupling reaction might construct a core, which is then diversified via enzymatic asymmetric reduction, followed by a photobiocatalytic late-stage C-H functionalization to create a final library.

G Start Natural Product (NP) Scaffold (e.g., N-Phenylquinoneimine, Tetrahydropyridine) TS Traditional Synthesis (TS) Scaffold Construction & Initial Functionalization Start->TS CE Chemoenzymatic Step (Selective Functional Group Interconversion, Resolution) TS->CE Provides chiral/ multifunctional intermediate PBC Photobiocatalytic Step ('New-to-Nature' C-H Activation, Radical Coupling) CE->PBC Enables selective activation under mild conditions Lib Diverse NP-Inspired Compound Library PBC->Lib Eval Biological Evaluation & SAR Analysis Lib->Eval Eval->TS Feedback for library redesign p1

Diagram 1: Integrated workflow for DOS from NP scaffolds. This diagram outlines the strategic sequence of methodologies, where traditional synthesis builds the core scaffold for selective diversification via chemoenzymatic and photobiocatalytic steps [47] [77] [78].

Application Notes in Diversity-Oriented Synthesis

The integrated approach finds practical application in several key areas of DOS from NP scaffolds.

Case Study 1: Diversification of Reactive NP Scaffolds. The N-phenylquinoneimine (NPQ) scaffold is a reactive platform found in bioactive natural products like actinomycin D [54]. Its α,β-unsaturated carbonyl/imino system is prone to selective attack but can be sensitive to harsh conditions. A strategic integration could involve:

  • Traditional Synthesis: Construct the NPQ core via oxidative coupling [54].
  • Chemoenzymatic Step: Use an engineered reductase to selectively reduce one of the carbonyl groups to generate a chiral alcohol handle with high enantiomeric excess [77].
  • Photobiocatalytic Step: Employ an enzyme-photocatalyst duo to perform an enantioselective radical conjugate addition to the remaining unsaturated system, installing a diverse alkyl or aryl group from a pool of HAT donors [79]. This sequence rapidly generates a library of complex, chiral NPQ analogues with multiple points of diversity for screening against biological targets like DNA or specific enzymes [54].

Case Study 2: Building Complexity in Saturated N-Heterocycles. Saturated aza-heterocycles (e.g., 7- and 8-membered rings) are valuable but synthetically challenging scaffolds in medicinal chemistry [47]. An integrated approach could enable their diversification:

  • Traditional Synthesis: Provide a functionalized cyclic amine via ring expansion or cyclization [47].
  • Photobiocatalytic Step: Use a visible-light-mediated enzyme system to selectively abstract a hydrogen atom from a C-H bond adjacent to nitrogen, generating a radical site [78].
  • Chemoenzymatic Step: Trap the radical intermediate with a cofactor-regenerated enzyme (e.g., a ketoreductase) to stereoselectively install a new functional group, or use a transaminase to further modify the amine group itself [77]. This allows for the late-stage, stereocontrolled functionalization of otherwise inert positions in complex amines.

Detailed Experimental Protocols

Protocol 4.1: Compartmentalized Photobiocatalytic Cofactor Regeneration for Sustained Biocatalysis

Based on the engineered artificial cell system for alcohol metabolism [80].

Objective: To achieve sustained enzymatic cascade reactions by physically separating photocatalytic NAD+ regeneration from ROS-sensitive enzymes using silica nano-organelles (SiNOs).

Materials:

  • Photocatalytic Polymer (PC): Poly[(9,9-bis(6-N,N-diethyl-N-methylammoniumhexyl)fluorene)-alt-benzothiadiazole] (P-BT-QA) [80].
  • Enzymes: Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH).
  • Chemicals: Tetraethyl orthosilicate (TEOS), (3-aminopropyl)triethoxysilane (APTES), cyclohexane, Lutensol AT 50 surfactant, NAD+, ethanol, acetaldehyde (for activity assays).
  • Equipment: Microfluidizer, dynamic light scatterer (DLS), UV-Vis spectrophotometer, fluorescent plate reader, TEM.

Procedure:

  • Synthesis of Photocatalytic Nano-organelles (SiNO@PC): a. Prepare an aqueous solution of P-BT-QA PC. b. Disperge this solution in cyclohexane using a microfluidizer to form a stable inverse miniemulsion. c. Add APTES and TEOS to the emulsion. APTES anchors at the water/oil interface, catalyzing the sol-gel condensation of TEOS to form a silica shell around the PC-containing water droplets. d. Recover the SiNO@PC nanoparticles by centrifugation and transfer to aqueous buffer using Lutensol AT 50 [80].
  • Synthesis of Biocatalytic Nano-organelles (SiNO@ADH/ALDH): a. Follow a similar inverse miniemulsion process, using an aqueous solution containing a optimized molar ratio of ADH and ALDH (e.g., 1:1) instead of the PC. b. After silica shell formation, purify the SiNO@ADH/ALDH.
  • Assembly of Artificial Cells: a. Mix SiNO@PC and SiNO@ADH/ALDH in an aqueous solution. b. Use a gentle film hydration or electroformation method to encapsulate the mixed nano-organelles within polymeric giant unilamellar vesicles (pGUVs) [80].
  • Photobiocatalytic Reaction: a. Suspend the artificial cells in buffer containing ethanol (substrate) and a catalytic amount of NAD+. b. Illuminate the suspension with visible light (e.g., 460 nm LED, 10 mW/cm²) to activate the PC. c. The PC photo-regenerates NAD+ from NADH. NAD+ diffuses into the SiNO@ADH/ALDH to drive the oxidation of ethanol to acetate, which is detected via assay or HPLC. The semi-permeable silica shells allow substrate/product diffusion while protecting enzymes from ROS generated by the PC [80].

G cluster_0 Light Visible Light PC Photocatalytic Polymer (P-BT-QA) Light->PC SiNO_PC Silica Nano-Organelle (SiNO@PC) PC->SiNO_PC NAD NAD+ SiNO_PC->NAD Regenerates NADH NADH NADH->SiNO_PC Diffuses SiNO_Enz Silica Nano-Organelle (SiNO@ADH/ALDH) NAD->SiNO_Enz Diffuses Sub Ethanol ADH ADH Sub->ADH Oxidizes Int Acetaldehyde ALDH ALDH Int->ALDH Oxidizes Prod Acetate SiNO_Enz->NADH Generates ADH->Int ALDH->Prod pGUV Polymeric Giant Unilamellar Vesicle (Artificial Cell)

Diagram 2: Engineered artificial cell with segregated photobiocatalysis. This system spatially separates photocatalytic NAD+ regeneration from enzymatic alcohol oxidation to prevent enzyme deactivation by reactive oxygen species (ROS), enabling sustained cascade reactions [80].

Protocol 4.2: Photobiocatalytic Stereoselective Acylation of C(sp³)-H Bonds

Adapted from the merging of thiamine-dependent enzymes with HAT catalysis [79].

Objective: To achieve enantioselective acylation of benzylic and aliphatic C-H bonds using a combined photobiocatalytic system.

Materials:

  • Enzyme: Recombinant benzaldehyde lyase (BAL) or related thiamine diphosphate (ThDP)-dependent enzyme.
  • Photocatalyst/HAT Reagent: N-fluoroamide (e.g., N-fluoro-2,4,6-trimethylpyridinium triflate).
  • Substrates: Aromatic aldehyde (acyl donor), substrate with activated C(sp³)-H bond (e.g., tetralin, alkylated heterocycles).
  • Cofactor: ThDP, MgCl₂.
  • Equipment: Schlenk line for inert atmosphere, blue LED array (450 nm), chiral HPLC, NMR.

Procedure:

  • Reaction Setup: In a dried Schlenk tube under nitrogen, combine the following in a suitable buffer (e.g., potassium phosphate, pH 7.5):
    • ThDP (1.2 equiv), MgCl₂ (2.0 equiv).
    • Aromatic aldehyde (1.0 equiv).
    • C-H substrate (2.0-5.0 equiv).
    • N-fluoroamide HAT reagent (2.0 equiv).
    • Recombinant BAL enzyme (10-20 mg/mL).
  • Photoreaction: Seal the tube and degass the mixture via freeze-pump-thaw cycles. Place the tube under an atmosphere of nitrogen and irradiate with a blue LED array (450 nm, ~20 W) while stirring vigorously. Maintain the temperature at 25-30°C using a cooling fan or water bath.
  • Monitoring & Workup: Monitor reaction progress by TLC or HPLC. After completion (typically 24-48 hours), quench by diluting with ethyl acetate. Centrifuge to remove precipitated protein.
  • Product Isolation: Separate the organic layer, dry over Na₂SO₄, and concentrate. Purify the resulting chiral ketone via flash chromatography on silica gel.
  • Analysis: Determine enantiomeric excess (ee) by chiral HPLC or SFC analysis. Assign absolute configuration by comparison to known standards or optical rotation.

Key Considerations: Enzyme stability under photochemical conditions is critical. Optimization of light intensity, enzyme-to-photocatalyst ratio, and the use of sacrificial electron donors may be necessary. The mechanism involves photoexcitation of the enzyme-bound Breslow intermediate (formed from BAL and the aldehyde), which interacts with the HAT reagent to generate an amidyl radical. This radical abstracts hydrogen from the substrate, and the resulting carbon radical couples with the enzyme-bound radical intermediate under stereochemical control of the enzyme pocket [79].

The Scientist's Toolkit: Essential Research Reagents & Materials

Item Category Specific Example Function in Integrated DOS Key Property / Note
Enzymes for Chemoenzymatic Steps Immobilized Lipases (e.g., Eversa Transform 2.0) [77] Hydrolysis, esterification, transesterification of NP scaffold intermediates. High stability, solvent tolerance, reusability.
Ketoreductases (KREDs) Asymmetric reduction of ketones on NP-derived scaffolds to set stereocenters. High enantioselectivity, often cofactor-dependent (NAD(P)H).
Engineered Cytochrome P450s Selective C-H hydroxylation at late-stage, complex molecules. Can functionalize unactivated C-H bonds.
Photocatalysts for Photobiocatalysis Conjugated Polymers (e.g., P-BT-QA) [80] Visible-light-driven cofactor (NAD+/NADH) regeneration. Biocompatible, hydrophilic, tunable bandgap.
Metal Complexes (e.g., [Ir(ppy)₃]) General photocatalyst for generating reactive radical species. Requires careful pairing with enzyme to avoid deactivation.
HAT Reagents & Mediators N-Fluoroamides [79] Hydrogen atom abstraction to generate substrate radicals in photobiocatalytic C-H functionalization. Selectivity for weaker C-H bonds.
Cofactors Thiamine Diphosphate (ThDP) [79] Essential cofactor for decarboxylases/lyases (e.g., BAL) in Umpolung catalysis. Enzyme-bound, forms reactive ylide.
Nicotinamide Cofactors (NAD+/NADP+) Electron carriers for oxidoreductases; required for redox biocatalysis. Often need in situ regeneration systems.
Scaffold Materials Silica Nano-organelles (SiNOs) [80] Compartmentalization to segregate incompatible catalytic modules (e.g., photocatalyst from enzyme). Semi-permeable shell, protects enzymes from ROS.
NP Scaffold Starting Materials N-Phenylquinoneimine derivatives [54] Privileged, bioactive core for library generation via sequential functionalization. Reactive α,β-unsaturated system.
Saturated Aza-heterocycles [47] Underrepresented medicinally relevant cores for diversification via C-H activation. Synthetically challenging to functionalize selectively.

Data Presentation and Comparative Analysis

Table 1: Performance Metrics of Integrated Methodologies vs. Traditional Steps

Metric Traditional Chemical Step (e.g., Pd-catalyzed cross-coupling) Chemoenzymatic Step (e.g., KRED reduction) Photobiocatalytic Step (e.g., BAL/HAT acylation) Advantage of Integrated Approach
Stereoselectivity (ee) Often requires chiral ligands; moderate to high ee possible. Typically very high (>99% ee) with native or engineered enzymes [77]. High ee achieved via enzyme control of radical coupling [79]. Superior & predictable stereocontrol for complex molecules.
Functional Group Tolerance Can be limited by catalyst poisoning (e.g., by amines, thiols). Generally excellent; enzymes operate in aqueous or mild conditions [77]. Good; radical pathways often tolerate many functional groups. Enables late-stage diversification of multifunctional scaffolds.
C-H Functionalization Selectivity Directivity controlled by sterics/electronics; can lack regioselectivity. Limited to specific activated positions (e.g., benzylic via P450s). High selectivity guided by HAT reagent and enzyme cavity [79]. Access to new, selective disconnections on NP cores.
Environmental Impact Can involve heavy metals, toxic ligands, and hazardous solvents. Aqueous buffers, biodegradable catalysts, mild temps [77]. Light as renewable energy source; typically ambient conditions. Greener, more sustainable synthesis aligning with Green Chemistry principles.
Step Economy in DOS Excellent for rapid scaffold assembly. Can combine multiple steps (e.g., resolution and transformation). Enables direct, one-step conversion of C-H to C-C bonds. Increases efficiency by reducing protection/deprotection steps.

Table 2: Exemplary Library Diversification from a Single NP-like Scaffold

Parent Scaffold Traditional Synthesis Step Integrated Catalytic Diversification Step Number of Analogues Generated* Key Structural Feature Introduced
Tetrahydropyridine [47] CoH-mediated reductive hydroarylation. Chemoenzymatic: Lipase-mediated kinetic resolution of a racemic precursor. 2 (enantiomers) Absolute configuration at a specific ring carbon.
Photobiocatalytic: Enantioselective radical C-H acylation at the benzylic position [79]. 10+ (from different acyl donors) Chiral ketone functionality with diverse R-groups.
N-Phenylquinoneimine [54] Oxidative coupling of aniline/quinone. Chemoenzymatic: P450-catalyzed hydroxylation on the phenyl ring. 1-2 (regioisomers) Phenol group for further derivatization (e.g., glycosylation).
Photobiocatalytic: Decarboxylative radical addition to the quinoneimine core. 10+ (from different carboxylic acids) Alkyl/aryl appendages at the electrophilic core.

*Number is illustrative for a single diversification step; combining steps multiplicatively expands library size.

The integration of chemoenzymatic and photobiocatalytic steps with traditional synthesis represents a frontier methodology for advancing the core thesis of diversity-oriented synthesis from natural product scaffolds. This synergy directly addresses the challenge of efficiently exploring the vast, biologically relevant chemical space around NPs by providing tools for selective, sustainable, and innovative scaffold functionalization.

The future of this field hinges on several key developments:

  • Robustness and Scale: Moving from proof-of-concept to preparative scale requires further engineering of enzyme stability under non-native conditions (e.g., organic solvents, light irradiation) and the development of continuous flow systems to integrate photochemical and enzymatic modules [81].
  • Expanding the Enzyme Toolbox: Discovering and engineering new enzymes compatible with photocatalysis or capable of catalyzing a broader range of "new-to-nature" radical reactions will be crucial [78].
  • Computational-Guided Integration: Machine learning and quantum mechanics/molecular mechanics (QM/MM) simulations will play an increasing role in predicting enzyme-substrate-photocatalyst interactions, designing optimal HAT reagents, and planning efficient synthetic sequences that maximize diversity and complexity [41] [79].
  • Standardized Metrics: As highlighted in recent critiques, the field must adopt standardized performance indicators—such as total turnover numbers (TTN) for enzymes, photon efficiency, and holistic environmental impact assessments—to critically evaluate and compare integrated systems, ensuring they offer real practical advantages [81].

By embracing these challenges, the integrated approach will solidify its role as an indispensable strategy for generating high-quality, NP-inspired chemical libraries. This will accelerate the discovery of novel bioactive compounds, ultimately contributing to the development of new therapeutic agents and chemical probes that address unmet medical needs.

Leveraging Computational and Chemoinformatic Analysis for Library Design and Route Planning

The field of drug discovery is increasingly defined by the integration of computational and experimental sciences. Within this paradigm, Diversity-Oriented Synthesis (DOS) emerges as a powerful strategy to construct structurally complex and skeletally diverse small-molecule libraries, particularly those inspired by the privileged architectures of natural products (NPs) [82] [2]. Natural products have historically been a prolific source of drug leads, with complex three-dimensional shapes, high sp³-carbon content (Fsp3), and a propensity for modulating challenging biological targets like protein-protein interactions [76] [2]. The central thesis of modern DOS research is to capture this "biological relevance" of NPs while overcoming their inherent limitations—such as synthetic complexity, scarcity, and difficult derivatization—through systematic, synthetic, and computational planning [82] [76].

Computational and chemoinformatic analyses are indispensable for realizing this goal. They provide the frameworks for designing novel NP-inspired scaffolds, planning efficient synthetic routes, analyzing the resulting chemical space, and prioritizing compounds for synthesis and screening [83] [84]. This document provides detailed application notes and protocols for leveraging these computational tools to design DOS libraries based on natural product scaffolds and to plan their synthetic realization, thereby bridging the gap between conceptual library design and practical laboratory execution.

Integrated Computational-Experimental Workflow

A successful DOS campaign from NP scaffolds follows an iterative cycle of computational design and experimental validation. The workflow integrates several key computational modules, as illustrated in the following diagram.

G NP_Database Natural Product & Bioactive Compound Databases (PubChem, ChEMBL, NP Atlas) Target_Analysis Target & Pharmacophore Analysis NP_Database->Target_Analysis Scaffold_Hopping Computational Scaffold Hopping & De Novo Design Target_Analysis->Scaffold_Hopping Library_Enum Virtual Library Enumeration & Property Filtering Scaffold_Hopping->Library_Enum Route_Planning Synthetic Route Planning & SAscore Evaluation Library_Enum->Route_Planning DOS_Synthesis DOS Execution: Build/Couple/Pair Route_Planning->DOS_Synthesis Chem_Analysis Chemoinformatic Analysis (PCA, PMI, Diversity Metrics) DOS_Synthesis->Chem_Analysis Bio_Screening Biological Screening & Hit Identification Chem_Analysis->Bio_Screening Feedback Data Analysis & Iterative Design Loop Bio_Screening->Feedback SAR Data Feedback->Target_Analysis Validate Target Feedback->Scaffold_Hopping Refine Design

Diagram 1: Integrated Workflow for NP-Inspired DOS Library Design and Synthesis (Max Width: 760px). The diagram depicts the cyclical workflow from NP-inspired design to biological screening, highlighting the integration of computational (red/orange) and experimental (blue) modules with analytical feedback (yellow).

Computational Strategies for Library Design and Analysis

Core Computational Tools and Comparative Analysis

The computational phase relies on specialized tools for scaffold manipulation, property prediction, and library enumeration. The selection of an appropriate tool depends on the specific design strategy (e.g., scaffold hopping vs. de novo growth).

Table 1: Comparative Analysis of Key Computational Tools for Scaffold-Centric Library Design

Tool Name Primary Function Key Algorithm/Feature Synthetic Accessibility (SA) Consideration Source/Availability
ChemBounce [85] Scaffold Hopping HierS fragmentation, Tanimoto/ElectroShape similarity, curated 3.2M scaffold library from ChEMBL High (uses synthesis-validated fragments) Open-source (GitHub, Google Colab)
V-SYNTHES [86] Ultra-large virtual screening via synthons Modular synthon-based screening of >11B compounds Implicit via pre-defined reaction rules Proprietary/Published method
Reactor, KNIME [84] Virtual library enumeration Application of pre-validated chemical reaction rules to reagent lists High (built on reliable reactions) Open-source / Freemium
FTrees, SpaceLight [85] Scaffold hopping & bioisostere replacement Pharmacophore and shape-based searching Variable Commercial (BioSolveIT)
AlphaFold2/3 [87] Target structure prediction AI-based protein structure prediction Not applicable Open-source (for non-commercial use)
ChemGPS-NP [82] Chemical space navigation PCA-based mapping on 8D property space Not applicable Web-based public tool
Protocols for Computational Design

Protocol 1: Performing Scaffold Hopping with ChemBounce on a Natural Product Core Objective: To generate novel, synthetically accessible analogs of a bioactive natural product core while preserving its key pharmacophoric elements.

  • Input Preparation: Obtain the SMILES string of the NP core or a simplified derivative. Validate the SMILES for correct syntax, stereochemistry, and valence. Remove any salts or solvents [85].
  • Scaffold Fragmentation: Run ChemBounce with the -i flag for the input SMILES. The tool uses the HierS algorithm to systematically fragment the molecule into its ring systems and linkers, identifying the "query scaffold" [85].

  • Scaffold Replacement: ChemBounce queries its curated library of ~3.2 million synthetically feasible scaffolds from ChEMBL. It identifies candidate scaffolds with high topological (Tanimoto) and 3D electron shape similarity to the query scaffold [85].
  • Output & Filtering: The tool generates output SMILES of new hybrid molecules. Filter results based on:
    • Similarity Threshold (-t): Adjust to balance novelty and activity retention.
    • Property Filters: Apply calculated properties like SAscore (synthetic accessibility score), QED (drug-likeness), and Lipinski's Rule of Five to prioritize lead-like compounds [85] [86].
    • Custom Constraints: Use the --core_smiles option to preserve critical substructures from the original NP.

Protocol 2: Enumerating a Virtual DOS Library using KNIME & Reaction Rules Objective: To computationally generate a full virtual library based on a validated DOS "Build/Couple/Pair" reaction sequence.

  • Define Core Scaffold and Variation Points: Using a sketcher (e.g., MarvinSketch), draw the core NP-inspired scaffold (e.g., a morpholine derivative [82]) and annotate the R-group attachment points (e.g., R1, R2).
  • Curate Building Block Lists: Compile SMILES files for each set of commercially available or easily synthesizable building blocks (e.g., amino acids, aldehydes, boronic acids) that will attach to the defined R-groups. Ensure they contain the correct reactive functional groups [84].
  • Implement Reaction in KNIME:
    • Use the RDKit Node suite. Load the scaffold as an SDF file and building blocks as SMILES files.
    • Employ the "Combinatorial Enumeration" node or the "Reaction" node. For the latter, define the reaction using SMARTS notation (e.g., [#6;R:1]-[C;H1:2]=[O:3].[N;H2:4]>>[#6;R:1]-[C:2](-[O:3])(-[N:4]) for an amidation).
    • Connect the scaffold and building block inputs to the reaction node to generate all combinatorial products [84].
  • Post-Enumeration Filtering:
    • Calculate molecular properties (molecular weight, LogP, H-bond donors/acceptors) for all enumerated compounds.
    • Apply substructure filters to remove molecules containing undesirable motifs (e.g., PAINS - pan-assay interference compounds).
    • Use a Diversity Picker node (e.g., MaxMin picking based on molecular fingerprints) to select a maximally diverse subset for physical synthesis [84].

Experimental Protocols for DOS from Natural Product Scaffolds

Key Stages and Strategies in DOS

DOS aims to maximize skeletal diversity from minimal starting materials. The following table outlines the core strategies, particularly relevant to NP-inspired synthesis.

Table 2: Key Stages and Strategies in Diversity-Oriented Synthesis from Natural Product Scaffolds

Stage Strategy Description Example from NP-inspired Chemistry
1. Building Block Selection Use of Chiral Pool Employing readily available, enantiopure NP-derived fragments (e.g., sugars, amino acids) as starting points. Using D-mannose or L-proline to impart stereochemistry and polyfunctionality [82].
2. Skeletal Construction Build/Couple/Pair Build: Create functionalized intermediates. Couple: Join them via reliable reactions. Pair: Induce cyclization or further diversification. Coupling amino acetaldehyde derivatives with dimethoxyacetaldehyde, then pairing via acid-catalyzed cyclization to form morpholine scaffolds [82].
3. Appendage Diversification Late-Stage Functionalization Introducing diversity at the final stages through reactions like amidation, alkylation, or cross-coupling on a pre-formed core. Decorating a spiro-β-lactam morpholinone core through selective alkylation at a quaternary center [82].
4. Complexity Generation Post-Coupling Cyclizations Using reactions like ring-closing metathesis, intramolecular aldol, or 1,3-dipolar cycloadditions after the coupling step. Transforming a linear Petasis coupling product into bicyclic structures via trans-acetalization or lactone formation [82].

Diagram 2: Visualizing the DOS Build/Couple/Pair Strategy (Max Width: 760px). This flowchart details the core synthetic logic for generating skeletal diversity from simple, NP-derived building blocks.

G BuildingBlocks Polyfunctional Building Blocks (e.g., Amino Acids, Sugars) Build BUILD Create functionalized intermediates (A, B) BuildingBlocks->Build Couple COUPLE Join A + B via robust reaction (e.g., Petasis, Ugi, Amidation) Build->Couple LinearIntermediate Linear or Simple Cyclic Intermediate Couple->LinearIntermediate Pair1 PAIR (Pathway 1) Cyclization / Rearrangement LinearIntermediate->Pair1 Pair2 PAIR (Pathway 2) Different cyclization or functionalization LinearIntermediate->Pair2 Scaffold1 Complex Scaffold 1 (e.g., Spirocycle) Pair1->Scaffold1 Scaffold2 Complex Scaffold 2 (e.g., Bridged Bicycle) Pair2->Scaffold2

Detailed Synthetic Protocol

Protocol 3: Synthesis of a Spiro-β-lactam Morpholinone via Staudinger Reaction [82] Objective: To install a quaternary stereocenter and generate skeletal complexity on a morpholin-3-one core, inspired by the spirocyclic motifs found in many NPs. Materials:

  • Starting Material: N-protected morpholin-3-one derivative (e.g., with carbomethoxy group at Cα).
  • Reagents: Imine (e.g., N-(p-methoxybenzylidene)-4-methylbenzenesulfonamide), triethylamine, anhydrous dichloromethane (DCM) or toluene.
  • Procedure:
    • Under an inert atmosphere (N₂ or Ar), charge a dry round-bottom flask with the morpholinone starting material (1.0 equiv) and the chosen imine (1.2 equiv).
    • Add anhydrous DCM (0.1 M concentration relative to morpholinone) and cool the reaction mixture to 0°C in an ice bath.
    • Add triethylamine (1.5 equiv) dropwise via syringe. After addition, remove the ice bath and allow the reaction to warm to room temperature.
    • Stir the reaction mixture for 12-24 hours, monitoring by TLC or LC-MS for consumption of the starting material.
    • Upon completion, quench the reaction by adding a saturated aqueous solution of ammonium chloride.
    • Extract the aqueous layer with DCM (3 x 20 mL). Combine the organic layers, dry over anhydrous magnesium sulfate, and filter.
    • Concentrate the filtrate under reduced pressure. Purify the crude residue via flash column chromatography (SiO₂, hexanes/ethyl acetate gradient) to obtain the desired spiro-β-lactam product. Characterization: Confirm structure by ¹H NMR, ¹³C NMR, and HRMS. Determine stereochemistry via NOESY experiments or X-ray crystallography if possible [82].

Chemoinformatic Analysis of DOS Libraries

Protocols for Chemical Space Analysis

Protocol 4: Mapping Library Diversity using Principal Moment of Inertia (PMI) and ChemGPS-NP Objective: To quantitatively assess the shape diversity and property distribution of a synthesized NP-inspired DOS library compared to known chemical space.

  • Data Preparation: Generate canonical SMILES for all compounds in your library and a reference set (e.g., known drugs, original NP scaffolds).
  • Conformational Sampling: For each compound, generate a low-energy 3D conformation using software like RDKit, Open Babel, or VegaZZ [82].
  • PMI Calculation & Plotting:
    • For the lowest energy conformer, calculate the three principal moments of inertia (Ixx, Iyy, Izz).
    • Normalize them as ratios: I1/I3 and I2/I3 (where I1 ≤ I2 ≤ I3).
    • Plot these normalized ratios on a triangular PMI graph. The corners represent rod-like (I1/I3 ≈ 0), disc-like (I2/I3 ≈ 1), and sphere-like (I1/I3 ≈ 1, I2/I3 ≈ 1) shapes. A library covering a broad area of the triangle possesses high shape diversity [82].
  • ChemGPS-NP Analysis:
    • Submit the SMILES strings of your library to the ChemGPS-NP web server.
    • The tool projects each compound into an 8-dimensional chemical property map derived from principal component analysis (PCA) of a vast compound collection.
    • Analyze the resulting scores, typically by plotting PC1 (size, polarizability) vs. PC2 (aromaticity, conjugation). This visualization shows how your library occupies chemical space relative to drugs and NPs, confirming if it explores novel, yet biologically relevant, regions [82].
Case Study and Data Interpretation

A research group synthesized 186 morpholine-based peptidomimetics inspired by natural product structures [82]. Chemoinformatic analysis revealed:

  • High sp³ Character: The library had a high average Fsp3, correlating with NP-like complexity and improved prospects for modulating difficult targets.
  • Shape Diversity: PMI analysis showed the library occupied a region distinct from typical flat, aromatic combinatorial compounds, trending towards more three-dimensional, sphere-like shapes.
  • Novel Chemical Space: ChemGPS-NP mapping positioned the library in a region adjacent to, but distinct from, clusters of common drugs and the original NP starting materials, indicating successful generation of novel yet biomimetic chemotypes.

Implementation Toolkit and Concluding Remarks

The Scientist's Toolkit: Research Reagent Solutions

Successful implementation of the above protocols requires access to specific computational and chemical resources.

Table 3: Essential Research Reagent Solutions for Computational DOS

Category Item/Resource Function/Purpose Example/Supplier
Computational Tools RDKit Open-source cheminformatics toolkit for molecule manipulation, fingerprinting, and property calculation. www.rdkit.org
KNIME Analytics Platform Visual workflow environment for data integration, library enumeration, and analysis. www.knime.com
Google Colaboratory Cloud-based platform for running Python scripts (e.g., ChemBounce) without local setup. colab.research.google.com
Chemical Databases ChEMBL Database Curated database of bioactive molecules with drug-like properties, used for scaffold sourcing. www.ebi.ac.uk/chembl/
ZINC / REAL Space Commercially available "make-on-demand" virtual compound libraries for screening ideas. zinc.docking.org / enamine.net
Building Blocks NP-derived Chiral Pool Enantiopure amino acids, sugars, and hydroxy acids for use as DOS starting materials. Sigma-Aldrich, Combi-Blocks
Custom Scaffold Library Pre-synthesized, decorated heterocyclic cores for focused library production. Life Chemicals (e.g., 1580 scaffold-based collection) [88]
Analysis Software DataWarrior Free tool for interactive filtering, visualization, and profiling of chemical libraries. www.openmolecules.org/datawarrior/
PyMOL / ChimeraX Molecular visualization for analyzing protein-ligand docking poses from virtual screens. pymol.org / www.cgl.ucsf.edu/chimerax/

In conclusion, the synergy of computational design and DOS principles provides a robust, rational framework for exploring NP-inspired chemical space. By following the detailed application notes and protocols outlined herein—from virtual scaffold hopping and library enumeration to practical synthetic execution and chemoinformatic analysis—researchers can systematically generate novel, complex, and biologically relevant small-molecule libraries. This integrated approach directly addresses the core challenges of modern drug discovery, offering a path to interrogate new biological targets and develop innovative therapeutics.

Proof of Concept: Biological Validation, Chemical Space Analysis, and Comparative Impact

The escalating threat of antimicrobial resistance in Mycobacterium tuberculosis and the persistent challenges in oncology, such as tumor heterogeneity and therapeutic resistance, underscore an urgent need for new pharmacophores with novel mechanisms of action [89] [90]. Natural products (NPs) have historically served as an unparalleled source of drug leads, with one-third of all new small-molecule drugs approved since 1981 being NP-derived or inspired [41]. Their inherent structural complexity and evolutionary optimization for bioactivity make them ideal starting points for drug discovery [41].

This work is framed within the broader thesis of Diversity-Oriented Synthesis (DOS) from Natural Product Scaffolds. Traditional target-oriented synthesis often lacks the structural diversity needed to probe complex biological systems or overcome resistance mechanisms. In contrast, DOS aims to synthesize collections of structurally complex and diverse small molecules, efficiently exploring chemical space around privileged NP cores [41]. This strategy bridges the gap between the rich bioactivity of natural products and the practical demands of modern drug discovery—such as synthetic accessibility, lead optimization, and thorough structure-activity relationship (SAR) analysis [91] [41]. This article details the application notes and protocols for identifying and developing novel antitubercular and anticancer agents from NP-inspired libraries, providing a practical roadmap for researchers in drug development.

Key Lead Compounds and Their Mechanisms of Action

The screening of NP libraries has yielded potent leads for both antitubercular and anticancer applications. The following table summarizes key lead compounds, their origins, bioactivity, and primary mechanisms of action, providing a direct comparison of their potential.

Table 1: Key Natural Product Leads for Antitubercular and Anticancer Development

Compound Class & Name Source Target Indication & Model Key Activity (MIC or IC₅₀) Postulated Primary Mechanism of Action
Rufomycin I (cyclic heptapeptide) [89] Streptomyces sp. Tuberculosis (Drug-sensitive & INH-resistant M. tb H37Rv) MIC < 0.004 µM Inhibition of ClpC1 protease, disrupting protein homeostasis [89].
Hapalindole A [89] Not specified Tuberculosis (M. tuberculosis) MIC < 0.6 µM Potent whole-cell activity; precise target under investigation [89].
Bengamide A [92] Marine sponge Jaspis sp. Tuberculosis (M. tuberculosis) MIC ~0.04 µg/mL [92] Inhibition of methionine aminopeptidases (MetAPs), essential for bacterial protein maturation [92].
Crassolide [93] Soft coral Lobophytum michaelae Breast Cancer (Murine 4T1-luc2 cells) Cytotoxic; induces ICD [93] Catalytic inhibition of p38α MAPK, inducing immunogenic cell death (ICD) [93].
Palytoxin [93] Soft coral Palythoa aff. clavata Leukemia (Various cell lines) Cytotoxic at pM concentrations [93] Modulation of ion channels (Na+/K+-ATPase), leading to apoptosis [93].
F12 Fraction [94] Mushroom Astraeus asiaticus (ethyl acetate extract) Cervical (HeLa), Breast (MCF-7), Lung (A549) Cancer IC₅₀ 701 - 807 µg/mL [94] Upregulation of pro-apoptotic (Caspase 3/9, p53) and downregulation of anti-apoptotic (Bcl-2) proteins [94].
Gnetin C [90] Plant (Stilbene polyphenol) Advanced Prostate Cancer (Genetically engineered mouse model) Suppresses proliferation & angiogenesis [90] Inhibition of the MTA1/PTEN/Akt/mTOR signaling pathway [90].
Oleanolic Acid & Ursolic Acid [90] Plants (Triterpenoids) Breast Cancer (MCF-7, MDA-MB-231 cells) Combination induces excessive autophagy [90] Inhibition of PI3K/Akt/mTOR pathway, leading to cytotoxic autophagy [90].

Chemical Synthesis and Library Generation Strategies

Moving from a bioactive natural product isolate to a viable lead requires the generation of analogue libraries for SAR studies. DOS provides powerful strategies to efficiently build complexity and diversity from NP scaffolds [41].

3.1. Diversity-Oriented Clicking (DOC) for Modular Synthesis A cutting-edge strategy for library generation is Diversity-Oriented Clicking (DOC), which combines click chemistry with fluoride exchange (SuFEx) reactions [95]. This modular approach uses "hubs" like 2-Substituted-Alkynyl-1-Sulfonyl Fluoride (SASF) to rapidly generate diverse pharmacophores under mild, biocompatible conditions [95].

  • Principle: A central SASF hub contains two orthogonal reactive handles: an alkyne for copper-catalyzed azide-alkyne cycloaddition (CuAAC) and a sulfonyl fluoride for SuFEx reactions with amines or phenols.
  • Protocol (Conceptual Workflow):
    • Hub Synthesis: Synthesize or procure the core SASF scaffold.
    • Diversification Phase 1 (π-Bond Click): React the alkyne handle with a library of organic azides via CuAAC to generate triazole-containing intermediates.
    • Diversification Phase 2 (SuFEx Click): React the sulfonyl fluoride handle of the intermediate with a library of nucleophiles (e.g., diverse amines, phenols) via SuFEx chemistry.
    • Purification & Analysis: Purify compounds using automated flash chromatography or preparative HPLC. Confirm structures via LC-MS and NMR.

3.2. Complementary DOS Strategies Other synergistic strategies from the DOS framework include [41]:

  • Biology-Oriented Synthesis (BIOS): Uses the core scaffold of a bioactive NP as a starting point for diversification, preserving biologically relevant architecture.
  • Pseudo-Natural Product (PNP) Synthesis: Recombines distinct NP-derived fragments to create novel hybrid scaffolds not found in nature, exploring new regions of chemical space.
  • Function-Oriented Synthesis (FOS): Aims to simplify the complex NP structure while retaining or enhancing its biological function, improving synthetic feasibility.

workflow NP_Scaffold Natural Product (NP) Scaffold Strategy Synthesis Strategy Selection NP_Scaffold->Strategy BIOS Biology-Oriented Synthesis (BIOS) Strategy->BIOS PNP Pseudo-Natural Product (PNP) Synthesis Strategy->PNP DOC Diversity-Oriented Clicking (DOC) Strategy->DOC Modular FOS Function-Oriented Synthesis (FOS) Strategy->FOS Library Diverse Compound Library BIOS->Library PNP->Library DOC->Library FOS->Library Screen Biological Screening Library->Screen Lead Optimized Lead Candidate Screen->Lead SAR Analysis & Iteration

Diagram 1: DOS Strategy Flow from Scaffold to Lead Candidate (Max width: 760px)

Experimental Protocols: From Screening to Characterization

4.1. Protocol 1: Primary Antimycobacterial Screening (Microbroth Dilution for MIC) This standard protocol determines the Minimum Inhibitory Concentration (MIC) of compounds against Mycobacterium tuberculosis and surrogate models [89] [91].

  • Bacterial Strain Preparation: Use M. tuberculosis H37Ra (biosafety level 2) or the surrogate M. smegmatis mc²155 (biosafety level 1) [89]. Grow in Middlebrook 7H9 broth supplemented with OADC and 0.05% Tween 80 to mid-log phase (OD₅₈₀ ~0.6-0.8).
  • Compound Dilution: Prepare a 2 mg/mL stock of test compound in DMSO. Perform serial two-fold dilutions in 7H9 broth in a 96-well plate, ensuring a final DMSO concentration ≤2% (v/v).
  • Inoculation: Dilute bacterial culture to ~1×10⁵ CFU/mL in fresh broth. Add 100 µL to each well containing 100 µL of diluted compound. Include growth control (bacteria, no compound) and sterile control (broth only).
  • Incubation: Seal plates and incubate at 37°C. Incubate M. smegmatis for 48-72 hours and M. tuberculosis H37Ra for 7-10 days.
  • MIC Determination: Visualize growth or add 30 µL of 0.01% resazurin solution to each well. Incubate for an additional 24-48 hours. The MIC is the lowest compound concentration that prevents a color change from blue to pink (resazurin) or shows no visible turbidity.

4.2. Protocol 2: In Vitro Cytotoxicity and Anticancer Screening (MTT Assay) This protocol assesses compound cytotoxicity and anticancer activity against mammalian cell lines [94].

  • Cell Seeding: Harvest adherent cancer cells (e.g., HeLa, MCF-7) and seed into a 96-well plate at an optimal density (e.g., 5-10×10³ cells/well) in complete growth medium. Incubate for 24 hours at 37°C, 5% CO₂ for attachment.
  • Compound Treatment: Prepare serial dilutions of test compound in DMSO and further dilute in growth medium (final DMSO ≤0.5%). Aspirate medium from the plate and add 100 µL of compound-containing medium to respective wells. Include vehicle control (DMSO only) and blank control (medium only).
  • Incubation: Incubate the plate for a determined period (e.g., 24, 48, or 72 hours).
  • MTT Development: Add 10 µL of MTT solution (5 mg/mL in PBS) to each well. Incubate for 3-4 hours.
  • Solubilization & Measurement: Carefully aspirate the medium. Add 100 µL of DMSO to each well to dissolve the formazan crystals. Shake the plate gently for 10 minutes. Measure the absorbance at 570 nm (reference 630-650 nm) using a microplate reader.
  • Data Analysis: Calculate cell viability percentage relative to the vehicle control. Determine the half-maximal inhibitory concentration (IC₅₀) using non-linear regression analysis (e.g., GraphPad Prism).

4.3. Protocol 3: Mechanism Studies – Apoptosis via Western Blot To confirm pro-apoptotic mechanisms observed in Table 1 (e.g., for F12 fraction) [94].

  • Cell Lysis: Treat cells with compound at IC₅₀ and 2xIC₅₀ concentrations for 24-48 hours. Harvest cells and lyse in RIPA buffer containing protease and phosphatase inhibitors on ice.
  • Protein Quantification: Determine protein concentration using a BCA assay.
  • Gel Electrophoresis & Transfer: Load equal amounts of protein (20-40 µg) onto an SDS-PAGE gel. Electrophorese and transfer proteins to a PVDF membrane.
  • Immunoblotting: Block membrane with 5% non-fat milk. Probe overnight at 4°C with primary antibodies against target proteins (e.g., Cleaved Caspase-3, Bcl-2, p53, β-actin loading control). Incubate with appropriate HRP-conjugated secondary antibody for 1 hour at room temperature.
  • Detection: Develop blots using enhanced chemiluminescence (ECL) substrate and visualize with a digital imaging system.

cancer_pathway NP Natural Product Lead PI3K PI3K NP->PI3K Inhibits BCL2 Bcl-2 (Anti-apoptotic) NP->BCL2 Downregulates Caspase Caspase 3/9 (Pro-apoptotic) NP->Caspase Upregulates p53 p53 NP->p53 Upregulates Akt Akt PI3K->Akt Activates mTOR mTOR Akt->mTOR Activates Autophagy Cytotoxic Autophagy mTOR->Autophagy Suppresses Apoptosis Apoptosis Induction BCL2->Apoptosis Inhibits Caspase->Apoptosis Executes p53->Apoptosis Promotes

Diagram 2: Key Cancer Signaling Pathways Targeted by NP Leads (Max width: 760px)

The Scientist's Toolkit: Essential Research Reagent Solutions

Table 2: Key Research Reagents and Materials for NP-Based Drug Discovery

Category Item Function / Purpose Key Considerations / Examples
Biological Models M. smegmatis mc²155 [89] Non-pathogenic, fast-growing surrogate for M. tuberculosis in primary screening. Biosafety Level 1. Provides a rapid initial activity readout [89].
M. tuberculosis H37Ra [89] Attenuated strain for confirmatory screening with a drug sensitivity profile similar to virulent strains. Requires Biosafety Level 2/3 facilities.
Cancer Cell Line Panel (e.g., NCI-60) Panel of human cancer cell lines for profiling cytotoxicity and selectivity. Includes diverse cancer types (breast, lung, prostate, leukemia).
Assay Kits & Reagents Alamar Blue (Resazurin) [89] Redox indicator for determining bacterial or cell viability in microtiter plates. Used in MIC assays; color change indicates metabolic activity.
MTT Reagent [94] Tetrazolium salt reduced to purple formazan by metabolically active cells. Standard for mammalian cell cytotoxicity/viability assays.
Caspase-3/9 Activity Assay Kits Fluorometric or colorimetric kits to measure apoptosis induction. Confirms mechanism of action for anticancer leads.
Chemistry & Synthesis SASF (2-Substituted-Alkynyl-1-Sulfonyl Fluoride) Hubs [95] Core building blocks for Diversity-Oriented Clicking (DOC). Enable modular, rapid generation of diverse compound libraries.
CuAAC & SuFEx Reagent Kits Pre-packaged catalysts and reagents for click chemistry reactions. Ensure reproducibility and efficiency in library synthesis.
Software & Databases AutoDock Vina / MOE Molecular docking software for in silico target prediction and SAR analysis [91]. Predicts binding affinity and orientation of compounds to protein targets.
SwissADME / pkCSM [94] Online platforms for predicting pharmacokinetic and toxicity profiles. Used early in discovery to filter compounds with poor drug-like properties.

The integration of natural product discovery with rational chemical synthesis strategies like DOS and DOC provides a powerful engine for generating novel leads against intractable diseases like tuberculosis and cancer. The protocols outlined here—from primary screening and mechanism elucidation to library synthesis—form a foundational workflow for translational research in this field.

Future advancements will be driven by deeper integration of computational methods (AI/ML for virtual screening and SAR prediction) [90], advanced delivery systems (nanoparticles for ocular TB or tumor targeting) [96], and a continued focus on diversity-oriented approaches to efficiently explore the vast, untapped chemical space around natural product scaffolds [41]. By systematically applying these principles, the journey from a natural product in a library to a optimized clinical lead can be significantly accelerated.

1. Introduction

The discovery of novel bioactive small molecules is fundamentally limited by the quality and diversity of the chemical libraries screened. Diversity-oriented synthesis (DOS), particularly when inspired by the structural complexity of natural product scaffolds, aims to populate biologically relevant regions of chemical space that are often under-represented in conventional synthetic libraries [4] [2]. Assessing the success of such library design strategies requires robust analytical methods. Principal Component Analysis (PCA) has emerged as a critical cheminformatic tool for this purpose, enabling the multidimensional visualization and quantitative assessment of a library's position and coverage within the broader chemical universe [97] [98]. By reducing complex physicochemical and structural descriptors to interpretable principal components, PCA allows researchers to compare synthetic libraries directly against reference sets of natural products and drugs, identify structural biases, and guide iterative design to improve scaffold diversity and natural product-likeness [97]. This protocol details the integrated application of PCA for assessing library quality within a research thesis focused on diversity-oriented synthesis from natural product scaffolds, providing a framework for objective evaluation and optimization.

2. Application Notes & Data Interpretation

PCA transforms a high-dimensional dataset of molecular descriptors into a lower-dimensional space defined by principal components (PCs), which are orthogonal axes that capture the maximum variance within the data [97]. In library assessment, this allows for the visual clustering of compounds based on shared structural features and the identification of overarching trends that differentiate compound classes.

Table 1: Key Physicochemical Descriptors for PCA in Library Assessment [97] [99]

Descriptor Description Role in Differentiating Chemical Space
Molecular Weight (MW) Mass of the molecule. Distinguishes small drug-like molecules from macrocycles and complex natural products.
Fraction of sp³ Carbons (Fsp³) Ratio of sp³-hybridized carbons to total carbon count. Higher values correlate with 3D shape complexity and natural product-likeness [2].
Topological Polar Surface Area (TPSA) Surface area contributed by polar atoms. Indicator of membrane permeability and solubility; differs between drug and natural product classes.
Number of Rotatable Bonds Count of single bonds allowing free rotation. Proxy for molecular flexibility; often lower in conformationally constrained natural products.
Hydrogen Bond Donors/Acceptors Count of functional groups that can donate/accept H-bonds. Critical for target interaction; distribution varies across chemical classes.
Octanol-Water Partition Coefficient (LogP/D) Measure of lipophilicity. Fundamental property separating hydrophilic and hydrophobic chemical regions.

Table 2: Interpreting PCA Results for Library Design

PCA Observation Chemical Implication Actionable Guidance for DOS
Library clusters tightly, away from natural product (NP) reference space. Low scaffold diversity and insufficient NP-like character (e.g., low Fsp³, high flatness). Prioritize synthesis of sp³-rich, complex scaffolds via ring-expansion or biomimetic cyclization [97].
Library overlaps with drug-like space but not NP space. "Drug-like" bias; may miss opportunities for novel target (e.g., protein-protein interaction) modulation [2]. Introduce structural features prevalent in NPs (e.g., macrocycles, stereogenic centers) to bridge the gap [4].
Library shows broad dispersion across multiple PCs. High skeletal and shape diversity, covering a wide swath of chemical space [98]. Focus on filling specific, vacant sub-regions adjacent to bioactive NP clusters identified in the analysis.
Specific descriptors show high loading on a key PC. Those descriptors are major drivers of variance and differentiation between classes [97]. Use synthetic chemistry to deliberately modulate these key parameters (e.g., increasing oxygen count or stereocenters).

Recent large-scale analyses underscore the necessity of such assessments. A 2025 benchmark study evaluating commercial libraries and combinatorial chemical spaces revealed significant blind spots, particularly in regions occupied by complex, hydrophilic compounds (e.g., nucleotides) and sp³-rich, natural-product-like molecules [100]. This systematic gap highlights the critical role of DOS to fill these underexplored but biologically relevant areas of chemical space. Furthermore, analyses of microbial natural products show that chemical diversity in nature is often organized into distinct structural "hotspots" or clusters (e.g., microcystins, peptaibols), which are highly interconnected internally but distinct from other scaffolds [101]. A high-quality DOS library should aim to generate scaffolds that populate these distinct regions rather than converging on a single, common chemical area.

3. Experimental Protocols

Protocol 1: Calculating Descriptors and Performing PCA

This protocol details the steps for generating principal component analysis plots to compare a new DOS library against reference compound sets.

1. Compound Curation and Standardization

  • Input: Compile SMILES (Simplified Molecular Input Line Entry System) strings for three compound sets: 1) Your DOS library, 2) A reference set of approved drugs (e.g., from DrugBank), and 3) A reference set of natural products (e.g., from the Natural Products Atlas) [101].
  • Software: Use a cheminformatics toolkit like RDKit in Python or CDK (Chemistry Development Kit) in Java for programmatic processing [99].
  • Steps: a. Load all SMILES strings. b. Standardize molecules: neutralize charges, remove solvents, and generate canonical tautomers. c. Calculate a consistent set of 2D and 3D molecular descriptors for each compound. The core set should include, at minimum: Molecular Weight, LogP, H-Bond Donors, H-Bond Acceptors, Topological Polar Surface Area (TPSA), Fraction of sp³ Carbons (Fsp³), Rotatable Bond Count, and Ring Count [97] [99]. d. Export the data as a tab-delimited file with compounds as rows and descriptors as columns.

2. Data Preprocessing and PCA Execution

  • Software: Use statistical software R or Python's scikit-learn library.
  • Steps: a. Import the descriptor table. b. Handle missing values (e.g., remove compounds or impute using column median). c. Scale the data: This is critical, as descriptors are on different scales. Use standardization (subtract mean, divide by standard deviation) for each descriptor column. d. Perform PCA on the scaled matrix. The analysis will generate new variables (Principal Components, PCs). e. Extract the variance explained by each PC (typically, PC1 and PC2 explain the most variance). Also extract the loadings, which indicate how much each original descriptor contributes to each PC.

3. Visualization and Interpretation

  • Software: Use ggplot2 in R or matplotlib/seaborn in Python.
  • Steps: a. Generate a 2D scatter plot with PC1 on the x-axis and PC2 on the y-axis. b. Color the data points by their source (DOS library, Drugs, NPs). c. Analyze the plot: * Clustering: Do the DOS compounds cluster together or intermingle with NPs? * Coverage: What area of the chemical map defined by Drugs and NPs does your library occupy? * Gaps: Are there regions populated by bioactive NPs that your library does not reach? d. Create a loading plot (or bar chart) to see which descriptors (e.g., Fsp³, O count) are the primary drivers for PC1 and PC2. This informs which chemical features to modify in future design [97].

Protocol 2: Iterative Library Design Based on PCA Feedback

Use PCA results to plan the synthesis of a subsequent, improved library.

1. Target Identification

  • Action: From the initial PCA plot, identify a cluster of natural products that is distant from your current library's cluster. Select 3-5 representative NP structures from this target region.

2. Feature Analysis

  • Action: Calculate the average descriptor profile for the target NP cluster. Compare it to the average profile of your first-generation library. Identify the 2-3 descriptors with the largest difference (e.g., target NPs have significantly higher Fsp³ and more oxygen atoms) [97].

3. Synthetic Planning

  • Action: Design a new DOS pathway or modify an existing one to systematically increase the identified target descriptors in the products. For example, to increase Fsp³, incorporate aliphatic ring-forming steps or sp³-rich building blocks. To increase oxygen count, employ oxidation reactions or use oxygenated starting materials [4].

4. Validation Cycle

  • Action: Synthesize the proposed second-generation library (or a representative pilot set). Run it through Protocol 1 again. The new compounds should show a vectorial shift in the PCA plot toward the target natural product cluster, confirming an increase in natural product-likeness and improved coverage of the desired chemical space [97].

4. Workflow & Pathway Diagrams

G cluster_legend Process Stage A Input: Compound Collections (DOS Lib, Drugs, NPs) B Descriptor Calculation (MW, LogP, TPSA, Fsp³, etc.) A->B SMILES C Data Preprocessing (Standardization, Scaling) B->C Descriptor Table D Principal Component Analysis (PCA) C->D Scaled Data E PCA Output: Scores & Loadings D->E F Visualization: 2D/3D Chemical Space Plot E->F Scores G Interpretation & Design (Identify Gaps & Biases) E->G Loadings F->G H Output: Guidance for Iterative Library Design G->H L1 Data Input L2 Computational Step L3 Analysis & Output L4 Decision & Action

Diagram 1: PCA Workflow for Library Assessment. This flowchart outlines the sequential steps from data collection to actionable design insights.

G cluster_plot PCA Map of Chemical Space axis_x PC1 (e.g., Polarity/Size) region_drug Drug-Like Space (High MW, Low Fsp³) axis_y PC2 (e.g., Complexity/Fsp³) region_np Natural Product Space (High Fsp³, Complex) lib_v1 Gen 1 DOS Library region_gap Identified Coverage Gap arrow Design Vector (Increase Fsp³, Add Oxygen) lib_v1->arrow lib_v2 Gen 2 Target arrow->lib_v2

Diagram 2: Interpreting Chemical Space Coverage. This conceptual PCA plot shows library positioning and the iterative design process to fill gaps.

5. The Scientist's Toolkit

Table 3: Essential Research Reagents & Software for PCA-Based Library Assessment

Item Name Type Function in Protocol Key Features / Notes
RDKit Open-Source Cheminformatics Library Core engine for reading SMILES, standardizing molecules, and calculating 2D/3D molecular descriptors [99]. Python-based; integrates seamlessly with data science stacks; essential for Protocol 1, Step 1.
scikit-learn Open-Source ML Library Provides robust, simple functions for data scaling, PCA, and other dimensionality reduction techniques [99]. Used in Protocol 1, Step 2; industry standard for preprocessing and PCA in Python.
Instant JChem / ChemAxon Commercial Cheminformatics Suite Alternative platform for compound registration, descriptor calculation, and batch processing of chemical data [97]. User-friendly GUI; useful for managing large compound collections and calculating specific chemical terms.
R / RStudio Statistical Programming Environment Powerful platform for statistical analysis, PCA, and advanced plotting (via ggplot2) [97]. Preferred by many statisticians; offers extensive packages for chemical data analysis.
Natural Products Atlas Curated Database Reference database of microbial natural product structures used as a benchmark for NP-like chemical space [101]. Critical for defining the target chemical space in Protocol 1; provides authentic NP scaffolds for comparison.
ChEMBL / PubChem Bioactivity Databases Sources for reference drug molecules and bioactivity data, used to compile drug-like reference sets [100]. Provide large, publicly available sets of known bioactive molecules for benchmarking.
Python (Jupyter Notebook) Programming Environment Interactive coding environment ideal for developing, documenting, and sharing the reproducible analysis workflow [99]. Combines code execution, visualization, and text in a single document; perfect for collaborative analysis.

The continuous decline in drug-discovery successes highlights deficiencies in conventional compound collections, which are often dominated by large numbers of structurally similar, "flat" molecules [2]. This underscores a consensus that library diversity, rather than sheer size, is paramount for accessing novel biological function [2]. This analysis is framed within a broader thesis on diversity-oriented synthesis (DOS) from natural product scaffolds, which posits that inspiration from nature's evolutionarily validated architectures is a powerful strategy to access biologically relevant and underexplored chemical space [4].

DOS aims to generate small-molecule libraries with high skeletal (scaffold) diversity, directly linked to molecular shape and functional diversity [2]. In contrast, traditional combinatorial chemistry and commercially available collections have historically prioritized appendage diversity around a limited set of simple cores [2] [102]. This fundamental difference in design philosophy leads to distinct outcomes in screening campaigns against conventional versus "undruggable" targets, such as protein-protein interactions [2]. This document provides detailed application notes and protocols to elucidate these comparative advantages.

Comparative Quantitative Analysis

The following tables summarize the core characteristics, performance, and strategic outputs of the different library paradigms.

Table 1: Foundational Characteristics of Compound Library Types

Characteristic DOS Libraries (Natural Product-Inspired) Traditional Combinatorial Libraries Commercial/Corporate Collections
Primary Design Goal Maximize skeletal/scaffold and stereochemical diversity for novel probe/drug discovery [2] [4]. Generate large numbers (millions) of compounds for high-throughput screening (HTS), often around single scaffolds [103] [104]. Archive large numbers of "drug-like" compounds for target-focused screening; built from historic and combinatorial sources [2] [102].
Key Diversity Type Skeletal > Stereochemical > Appendage [2]. Primarily Appendage (Building-Block) [2] [4]. Appendage, with limited scaffold diversity; bias toward known bioactive space [2].
Structural Complexity High; features sp3-richness, stereocenters, and macrocyclic elements inspired by natural products [2] [4]. Typically low to moderate; often "flat," aromatic-heavy structures [2] [102]. Variable, but filtered for "drug-likeness" (e.g., Lipinski's Rule of 5), often reducing complexity [2] [102].
Typical Library Size Smaller (hundreds to tens of thousands) [4]. Very large (hundreds of thousands to billions, especially with DNA-encoding) [103] [104]. Very large (millions to tens of millions) [2] [102].
Synthesis Strategy Branching pathways using complexity-generating reactions; often iterative, multicomponent [4]. Linear, sequential addition of building blocks via robust, high-yielding reactions (e.g., amide coupling) [103]. Aggregated from various sources; synthesis not unified [102].
Inspiration/Validation Pre-validated by nature; scaffolds possess inherent bio-relevance [4]. Focused on target families (e.g., kinases) or driven by available building blocks and chemistry [103]. Heavily biased toward historical medicinal chemistry targets and rules [2].

Table 2: Screening Performance and Strategic Output

Aspect DOS Libraries Traditional/Commercial Collections
Hit Rate vs. Novel Targets Higher potential for novel, especially "undruggable," targets due to shape diversity [2]. Lower for novel target classes; higher for well-precedented target families [2].
Nature of Hits Often provide novel chemotypes and mechanisms of action; high information content [2] [4]. May yield known chemotypes; prone to identifying false positives (e.g., PAINS) if not filtered [102] [105].
Lead Optimization Path Can be more challenging due to complexity; requires sophisticated synthesis [4]. Typically more straightforward due to simpler, modular scaffolds [103].
Intellectual Property (IP) Potential High. Novel scaffolds create strong, broad composition-of-matter patent positions [2] [106]. Lower/Crowded. Incremental modifications to known cores lead to dense, narrow IP landscapes [106].
Primary Utility Chemical biology probe discovery, pioneering new target classes, filling white space in chemical libraries [2] [4]. Lead optimization (focused libraries), large-scale HTS campaigns for established targets [103] [102].

Table 3: Benchmarking Data on Library Scaffold Diversity

Metric Representative DOS Library (from literature) Typical Commercial HTS Library [102] Implication
Number of Unique Bemis-Murcko (BM) Scaffolds ~50-150 from a library of 1,000-10,000 compounds (High ratio) [4]. ~100,000 from 1-2 million compounds (Low ratio) [102]. DOS achieves higher scaffold density, meaning each compound sampled adds a distinct core shape.
Shape Complexity (Fraction of sp3 Carbons, Fsp3) Often >0.5 [4]. Typically ~0.3-0.4 [102]. Higher Fsp3 correlates with better 3D coverage and increased success in clinical development [2].
Success in Identifying Probes for Novel Biology Documented cases (e.g., Secramine, Uretupamine) [4]. Fewer documented cases for first-in-class, novel mechanism probes [2]. DOS is engineered for phenotypic and novel target discovery.

Detailed Experimental Protocols

Protocol: Synthesis of a Skeletal-Diverse DOS Library from a Natural Product-Inspired Scaffold

Application Note: This protocol outlines the synthesis of a library featuring multiple distinct cores from common intermediates, a hallmark of the "branching" DOS strategy inspired by natural product architectures [4].

Materials:

  • Starting Materials: See 'The Scientist's Toolkit' Section 5.
  • Equipment: Standard Schlenk and glassware for inert atmosphere, automated flash chromatography system, LC-MS for reaction monitoring, HPLC for purification.

Procedure:

  • Common Intermediate Synthesis: Prepare a polyfunctionalized, advanced intermediate (e.g., 1) containing multiple orthogonal reactive sites (e.g., alkene, epoxide, ketone) from a chiral pool starting material or via an asymmetric catalytic key step in 3-5 linear steps [4].
  • Split-Pool Diversification (Appendage): Divide the resin-bound or solution-phase intermediate 1 into portions. Subject each to a different high-yielding reaction (e.g., amine acylation, Suzuki coupling, reductive amination) to introduce appendage diversity (R¹) and produce intermediates 2a-2d [103].
  • Divergent Skeleton-Forming Reactions (Branching): Subject each intermediate 2a-2d to a different skeleton-diversifying reaction under distinct conditions.
    • Path A (for 2a): Ring-closing metathesis (RCM). Use Grubbs II catalyst (5 mol%) in DCM (0.01 M) under N₂, stir at 40°C for 12h. Purify to yield macrocyclic scaffold A [4].
    • Path B (for 2b): Intramolecular epoxide opening. Treat with BF₃•OEt₂ (1.1 eq) in DCM at -78°C to 0°C. Quench with sat. NaHCO₃ to yield fused polycyclic scaffold B [4].
    • Path C (for 2c): Cycloaddition (e.g., [4+2]). Heat in toluene at 110°C for 8h to yield bridged scaffold C.
    • Path D (for 2d): Reductive rearrangement. Use NaBH₄ in MeOH/THF followed by acid catalysis (PPTS) to yield scaffold D.
  • Final Functionalization: Perform a final step of diversification (e.g., amide coupling, sulfonylation) on each distinct scaffold (A-D) to introduce a second layer of appendage diversity (R²).
  • Quality Control: Analyze all final library members by UPLC-MS. Purity is assessed by evaporative light-scattering detection (ELSD) or diode array detector (DAD). Accept compounds with >90% purity (by ELSD) and correct mass. Compounds are formatted into 96- or 384-well plates in DMSO at a standard concentration (e.g., 10 mM) for screening.

Diagram: Branching DOS Synthesis Workflow

G Start Polyfunctional Intermediate 1 Div1 Split & Appendage Diversify (e.g., introduce R¹) Start->Div1 A Intermediate 2a with Alkene Div1->A B Intermediate 2b with Epoxide Div1->B C Intermediate 2c Diene/Dienophile Div1->C D Intermediate 2d with Ketone Div1->D PathA Path A: RCM Macrocyclic Scaffold A A->PathA PathB Path B: Epoxide Opening Fused Scaffold B B->PathB PathC Path C: Cycloaddition Bridged Scaffold C C->PathC PathD Path D: Reductive Rearrangement Scaffold D D->PathD LibA Library A1-An PathA->LibA Final Diversify R² LibB Library B1-Bn PathB->LibB Final Diversify R² LibC Library C1-Cn PathC->LibC Final Diversify R² LibD Library D1-Dn PathD->LibD Final Diversify R²

Protocol: High-Throughput Screening (HTS) & Hit Triage Protocol

Application Note: This protocol is tailored for screening complex DOS libraries, where hit validation must rigorously exclude false positives and prioritize novel chemotypes [105].

Materials:

  • Library Plates: DOS library (10 mM in DMSO).
  • Assay Reagents: Target protein, fluorescent/ luminescent substrate, control inhibitors/activators.
  • Equipment: Automated liquid handler, multimode plate reader, LC-MS, SPR or ITC instrument.

Procedure:

  • Primary HTS: Perform assay in 384-well format. Test compounds at a single concentration (e.g., 10 µM) in duplicate. Include controls (no compound, no enzyme, reference inhibitor). Calculate % inhibition/activation [105].
  • Hit Identification: Apply a primary hit threshold (e.g., >50% inhibition). Use stringent in silico filtering on all primary hits:
    • Remove compounds matching PAINS (Pan-Assay Interference Compounds) substructures [102] [105].
    • Filter for undesirable functionalities (reactive groups, unstable esters).
    • Assess chemical novelty via scaffold analysis against internal and commercial databases.
  • Dose-Response Confirmation: Re-test remaining hits in an 8-point dose-response curve (e.g., from 30 µM to 1 nM) to obtain IC₅₀/EC₅₀ values. Use freshly prepared compound solutions to exclude DMSO degradation artifacts.
  • Orthogonal Assay & Counter-Screen:
    • Orthogonal Assay: Confirm activity in a biophysical assay (e.g., SPR to measure binding KD, or thermal shift assay ΔTm) [105].
    • Counter-Screen: Test against a related but off-target protein (e.g., another kinase isoform) or a general assay interference panel (e.g., fluorescence quenching, redox activity) to assess selectivity and rule out assay artifacts [105].
  • Hit Validation & Prioritization: Compounds passing steps 3-4 are considered validated hits. Prioritize based on:
    • Potency (IC₅₀/EC₅₀, KD).
    • Selectivity ratio (on-target vs. counter-screen).
    • Novelty of the chemotype (prioritize compounds from under-represented or new scaffolds in the library).
    • Synthetic tractability for analoguing.

Visualization of Discovery Pathways

Diagram: Comparative Screening & Validation Workflow

G LibDOS DOS Library (High Skeletal Diversity) HTS Primary HTS (Single Concentration) LibDOS->HTS LibTrad Traditional/Commercial Library (High Appendage Diversity) LibTrad->HTS Tri Hit Triage & In-Silico PAINS Filter HTS->Tri DR Dose-Response (IC₅₀/EC₅₀) Tri->DR Ortho Orthogonal Biophysical Validation (SPR, ITC) DR->Ortho Count Selectivity Counter-Screen Ortho->Count OutputDOS Output: Validated Hits • Novel Chemotype • Possible New MOA • High IP Potential Count->OutputDOS OutputTrad Output: Validated Hits • Known/Likely Chemotype • Potency/Optimization Focus Count->OutputTrad

The Scientist's Toolkit: Essential Research Reagent Solutions

Table 4: Key Reagents and Materials for DOS and Screening

Item Function/Application Key Considerations
Chiral Pool Starting Materials (e.g., amino acids, sugars, terpenes) Provide stereochemical complexity and natural product-like functional group handles for DOS library synthesis [4]. Source optically pure materials. Enables rapid access to complex, bioactive-like scaffolds.
Robust, Tolerant Catalysts (e.g., Grubbs II, Pd PEPPSI, Organocatalysts) Enable the key skeleton-forming and diversification reactions (e.g., RCM, cross-coupling, asymmetric induction) on diverse polyfunctional intermediates [4]. Select for air/moisture stability and functional group tolerance to ensure high yields across library.
Solid-Phase Synthesis Resins & Linkers Facilitate split-pool synthesis and purification by filtration, enabling generation of large, diverse libraries [103] [4]. Choose linker chemistry (e.g., Rink amide, Wang alcohol) compatible with reaction conditions and final cleavage method.
Validated PAINS Filtering Software/Scripts Critical computational tool for triaging HTS hits to remove promiscuous, artifact-causing compounds, improving hit list quality [102] [105]. Implement as a mandatory step in hit analysis workflow. Use updated substructure lists.
Orthogonal Assay Reagents (e.g., SPR Chips, Label-Free Detection Kits) Provide biophysical confirmation of binding, moving beyond functional assays to validate target engagement and measure affinity (KD) [105]. Essential for de-risking hits before costly chemical optimization.
Benchmarking Datasets (e.g., WelQrate, CANDO libraries) Curated, high-quality datasets for validating computational screening methods and assessing library coverage of bioactive chemical space [107] [105]. Use to benchmark in-house library designs and virtual screening protocols against established standards.

Diversity-Oriented Synthesis (DOS) represents a foundational strategy in modern chemical biology and drug discovery, deliberately aiming to generate collections of small molecules that span broad regions of chemical space by applying varied reaction pathways to multifunctional starting materials [47]. This approach stands in contrast to target-oriented or combinatorial synthesis, focusing instead on maximizing skeletal, stereochemical, and appendage diversity within a library [4]. The primary goal is to enable the discovery of novel probes and therapeutics with previously unknown biological functions by exploring wider swaths of chemical diversity [4].

Natural products serve as a critical inspiration for DOS library design. These evolved biological probes inherently reside in biologically relevant chemical space, as they must bind their biosynthetic enzymes and their target macromolecules [4]. Consequently, natural product scaffolds are "pre-validated" for biological interaction. Libraries inspired by these privileged scaffolds, such as tetrahydroquinolines derived from natural product models, are more likely to yield bioactive compounds [108] [4]. This strategy merges the evolutionary optimization of natural products with the deliberate, expansive exploration of synthetic chemistry.

Phenotypic screening, a target-agnostic discovery approach, provides a powerful complementary method to leverage DOS libraries [109]. Instead of screening compounds against a predefined, purified protein target, phenotypic screening assays compound activity in cells or whole organisms, monitoring for a desired change in observable traits (phenotypes) such as cell viability, morphology, or reporter gene expression [109]. This approach is particularly valuable for complex diseases where the underlying mechanisms or a single "druggable" target are not well-defined [109]. When a DOS library rich in natural product-inspired complexity is screened in a phenotypic assay, it creates a powerful engine for discovering novel chemical probes and therapeutic mechanisms. A successful hit can simultaneously identify a bioactive compound and implicate a novel biological pathway or target, serving both hit and target identification purposes [109].

Core Principles and Framework

The Target-Agnostic Screening Paradigm

Target-agnostic phenotypic screening reverses the traditional drug discovery logic. It begins with a physiologically relevant disease model and asks which compounds can elicit a therapeutic phenotype, without prior assumptions about the molecular target [109]. The key advantages of this approach include:

  • Physiological Relevance: Compounds are tested in a complex cellular environment, preserving critical context like protein-protein interactions, compartmentalization, and metabolic pathways.
  • Discovery of Novel Mechanisms: The process is open to identifying compounds that act through previously unknown or undruggable targets.
  • Functional Readout: The assay endpoint is directly linked to a therapeutic outcome (e.g., cell death in cancer, reduced protein aggregation in neurodegeneration).

A major historical challenge has been the subsequent mechanism of action (MoA) deconvolution for identified hits [109]. However, strategies such as screening libraries with "intrinsic chemical biology handles" (e.g., covalent warheads for affinity capture) and employing modern 'omics' technologies (chemoproteomics, transcriptomics) have significantly streamlined this process [109].

Integrating DOS Libraries into Phenotypic Screens

The effectiveness of a phenotypic screen is profoundly influenced by the chemical library screened. DOS libraries designed with natural product-inspired complexity are ideally suited for this purpose due to several key attributes:

  • Skeletal and Stereochemical Diversity: Mimics the broad structural diversity found in nature, increasing the likelihood of interacting with diverse protein folds and surfaces [4] [47].
  • Privileged Scaffolds: Scaffolds derived from or inspired by natural products have an inherent propensity for biological activity and bioavailability.
  • Favorable Physicochemical Properties: Well-designed DOS libraries prioritize cell permeability and drug-like properties, essential for cellular phenotypic assays.

Table 1: Comparison of Screening Paradigms

Aspect Target-Centric Screening Target-Agnostic Phenotypic Screening
Starting Point A defined, purified protein target. A disease-relevant cellular or organismal model.
Primary Question Does the compound modulate the specific target's activity? Does the compound produce a therapeutically desirable phenotype?
Assay Context Simplified, often biochemical. Physiologically complex.
Strength Enables rational, structure-based optimization. Discovers novel biology and therapeutics; agnostic to target druggability.
Major Challenge Target validation; relevance of in vitro activity to disease phenotype. Mechanism of action deconvolution.
Optimal Compound Library Focused libraries for a target class; fragment libraries. Diverse, complex, cell-permeable libraries (e.g., DOS libraries).

The general framework for a successful campaign involves careful assay design to minimize false positives, screening of a maximally diverse DOS library, robust hit validation, and systematic MoA deconvolution [109].

G NP Natural Product Scaffolds DOS Diversity-Oriented Synthesis (DOS) NP->DOS Inspiration Lib Complex DOS Chemical Library DOS->Lib Generates Assay Phenotypic Screening Assay Lib->Assay Screened in Pheno Therapeutically Relevant Phenotype Assay->Pheno Measures Hit Validated Hit Compound Pheno->Hit Identifies MoA Mechanism of Action Deconvolution Hit->MoA Subject to Probe Novel Chemical Probe or Therapeutic Lead Hit->Probe Direct Path Targ Novel Target or Pathway Identified MoA->Targ Reveals Targ->Probe Enables

Diagram 1: Target-Agnostic Discovery Workflow. This diagram illustrates the integrated pipeline from natural product inspiration to novel probe discovery [108] [109] [4].

Application Notes: Key Experiments and Findings

Case Study: Antitubercular Tetrahydroquinolines from a Natural Product-Inspired DOS Library

A seminal example demonstrating the power of this integrated approach is the synthesis and screening of a tetrahydroquinoline library for antitubercular activity [108].

  • Library Synthesis & Design: Researchers developed an efficient, diastereoselective multicomponent aza-Diels-Alder reaction inspired by natural product scaffolds. The reaction used a reusable solid acid catalyst and could be tuned (by switching solvent from acetonitrile to water) to produce either cis or trans diastereomers, deliberately building stereochemical diversity. Variation of starting materials (aromatic amines, aldehydes, dienophiles) yielded a library of tetrahydroquinoline and benzopyran analogues with high skeletal and substitutional diversity [108].
  • Phenotypic Screening: The entire library was screened in a target-agnostic phenotypic assay against Mycobacterium tuberculosis H37Ra and H37Rv strains, measuring the direct phenotype of bacterial growth inhibition [108].
  • Key Finding: Several synthetic analogues exhibited a better activity profile than their natural product counterparts, validating the DOS strategy to improve upon natural product activity. This experiment successfully identified novel antitubercular leads while being completely agnostic to the specific protein target within the bacterium [108].

Table 2: Representative Phenotypic Screening Library Profile

Parameter Specification Notes / Relevance
Total Compounds 5,760 compounds [110] Optimized size for broad exploration with manageable throughput.
Core Composition ~900 approved drugs + similar compounds; ~2000 potent inhibitors + biosimilars [110]. Enriched for bioactivity; provides anchor points in chemical space.
Design Principle Balance of biological activity diversity and structural diversity [110]. Aims to maximize chance of phenotype modulation.
Key Properties Cell-permeable; pharmacology-compliant physicochemical properties [110]. Essential for cellular phenotypic assays.
Typical Screening Format 10 mM in DMSO, pre-plated in 384- or 1536-well microplates [110]. Enables high-throughput screening (HTS) automation.

Framework for Screening with Chemically Induced Proximity (CIP) in Mind

Recent advances highlight the potential of phenotypic screening to discover compounds that work via Chemically Induced Proximity (CIP), such as molecular glues or monovalent inducers of novel protein-protein interactions [109]. These mechanisms represent a gain-of-function (GoF) that is difficult to identify through target-centric inhibition. A proposed framework for such screens includes [109]:

  • Compound Selection: Prioritize libraries with features conducive to CIP (e.g., covalent fragments, stereochemical complexity) and containing "intrinsic handles" for MoA deconvolution.
  • Assay Design: Employ shorter compound incubation times to select for direct events and reduce secondary effects. Use reporters sensitive to pathway modulation (e.g., transcription, phosphorylation).
  • Hit Triage: Immediately employ counter-screens (e.g., cytotoxicity, general transcription assays) to filter non-specific hits. Validate enantiomer-specific activity to confirm a specific, binding-dependent mechanism.
  • Focused MoA: Leverage the compound's handle (e.g., covalent warhead) for chemoproteomic pull-down to rapidly identify the engaged protein target(s) [109].

Experimental Protocols

Objective: To synthesize a diastereoselective library of tetrahydroquinoline analogues via a solid-acid catalyzed multicomponent reaction. Materials:

  • Starting Materials: Aromatic amines, aromatic aldehydes (e.g., salicylaldehyde for benzopyrans), dienophiles (e.g., ethyl vinyl ether).
  • Catalyst: Natural carbohydrate-derived solid acid catalyst.
  • Solvents: Anhydrous acetonitrile, deionized water.
  • Equipment: Round-bottom flasks, magnetic stirrer, heating mantle, reflux condenser, TLC plates, silica gel for column chromatography.

Procedure:

  • Imine Formation: In a round-bottom flask, dissolve the aromatic amine (1.0 equiv) and aromatic aldehyde (1.05 equiv) in anhydrous acetonitrile (0.5 M). Stir at room temperature for 1-2 hours to generate the imine in situ.
  • Aza-Diels-Alder Cycloaddition: Add the dienophile (1.2 equiv) and the solid acid catalyst (10 mol%) to the reaction mixture. Reflux the reaction at 80°C with stirring for 12-18 hours. Monitor reaction completion by TLC.
  • Diastereoselectivity Control:
    • For trans-diastereoselectivity: Perform the reaction in anhydrous acetonitrile.
    • For cis-diastereoselectivity: Use deionized water as the solvent instead of acetonitrile.
  • Work-up: Cool the mixture to room temperature. Filter the reaction mixture to recover the reusable solid catalyst. Concentrate the filtrate under reduced pressure.
  • Purification: Purify the crude product by silica gel column chromatography using an appropriate gradient of hexanes and ethyl acetate to obtain the pure tetrahydroquinoline product.
  • Characterization: Characterize all products by 1H NMR, 13C NMR, and high-resolution mass spectrometry (HRMS). Analyze diastereomeric ratio (dr) by 1H NMR or HPLC.

Protocol 2: Phenotypic Cell-Based Screening for Inhibitors of Pathogenic Gene Expression

Objective: To perform a target-agnostic screen for compounds that reduce the mRNA expression of a disease-driving gene (e.g., Androgen Receptor (AR) in prostate cancer [109]). Materials:

  • Cell Line: Disease-relevant cell line (e.g., 22Rv1 prostate carcinoma cells for AR).
  • Compound Library: DOS library pre-plated in 384-well plates, 10 mM in DMSO [110].
  • Assay Reagents: Cell culture media, transfection reagent (if using a reporter construct), RT-qPCR kits for target gene and housekeeping genes, cell viability assay kit (e.g., CellTiter-Glo).
  • Equipment: Tissue culture hood, CO2 incubator, liquid handler, multichannel pipettes, real-time PCR instrument, plate reader.

Procedure:

  • Cell Seeding: Seed cells in growth medium into 384-well assay plates at an optimized density (e.g., 2000 cells/well in 50 µL) and incubate overnight.
  • Compound Addition: Using a liquid handler or pin tool, transfer a small volume of compound from the library plate to the assay plate to achieve a final desired concentration (e.g., 10 µM). Include DMSO-only wells as negative controls and wells with a known inhibitor (if available) as positive controls.
  • Compound Incubation: Incubate plates for a relatively short, predetermined time (e.g., 6 hours [109]) to capture primary effects.
  • Cell Lysis and RNA Harvest: At the endpoint, carefully aspirate medium and lyse cells directly in the plate using a suitable lysis buffer.
  • RT-qPCR Analysis: Perform reverse transcription and quantitative PCR (RT-qPCR) on the lysates using TaqMan or SYBR Green assays specific for the target mRNA (e.g., AR-FL, AR-V7) and a housekeeping gene (e.g., GAPDH).
  • Viability Counter-Screen: In parallel, set up an identical assay plate treated with compounds for 24-72 hours. At endpoint, measure cell viability using a luminescent ATP-based assay (e.g., CellTiter-Glo) to filter out cytotoxic false positives.
  • Data Analysis: Calculate ∆∆Ct values for target genes normalized to housekeeping gene and DMSO controls. Define hit criteria (e.g., >30% mRNA reduction [109]). Triage hits that show cytotoxicity in the viability counter-screen.

Diagram 2: Detailed Phenotypic Screening Protocol. This flowchart outlines the key experimental phases from library synthesis to validated hit identification [108] [109] [110].

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Research Reagent Solutions for DOS & Phenotypic Screening

Category Item / Solution Function / Description Example / Specification
DOS Synthesis Natural Product-Inspired Building Blocks Provide the core chemical scaffolds that ensure biological relevance and complexity. Tetrahydroquinoline precursors, spirocyclic fragments, macrocyclic seeds [108] [4].
Diversifiable Core Scaffolds Multifunctional intermediates amenable to multiple diversification pathways (appendage, stereochemistry, skeleton). Poly-functionalized cyclic compounds with orthogonal protecting groups [47].
Broad-Scope Catalysts Enable key transformations (e.g., cycloadditions, cross-couplings, C-H activation) across diverse substrates. Chiral organocatalysts, reusable solid acids [108], transition metal catalysts for late-stage diversification [47].
Phenotypic Screening Validated Phenotypic Screening Library A pre-designed, formatted collection of diverse, cell-permeable compounds optimized for phenotypic assays. Commercial libraries (e.g., 5,760-compound PSL with annotated bioactivity) [110].
Disease-Relevant Cellular Models Engineered cell lines, primary cells, or co-culture systems that accurately reflect the disease pathophysiology. Reporter cell lines, patient-derived organoids, induced pluripotent stem cell (iPSC)-derived cells.
High-Content Readout Assays Multiparametric assays that capture complex phenotypes (morphology, protein localization, cell count). Assays for apoptosis, neurite outgrowth, cell motility, or protein aggregation.
MoA Deconvolution Covalent Probe Libraries / Kits Compounds with affinity tags (biotin, alkyne/azide) for chemoproteomic pull-down and target identification. Photoaffinity probes, activity-based protein profiling (ABPP) kits [109].
CRISPR-based Genetic Tools Enable genome-wide knockout or activation screens to identify genes essential for compound activity. CRISPR-Cas9 knockout pooled libraries, sgRNA vectors.
Data Analysis Chemical Informatics Software For library design, diversity analysis, and structure-activity relationship (SAR) modeling. Software for calculating molecular descriptors, clustering, and visualizing chemical space.
Bioinformatics & Pathway Analysis Platforms To interpret 'omics data (transcriptomics, proteomics) from treated cells and map hits to biological pathways. Tools like Ingenuity Pathway Analysis (IPA), Gene Set Enrichment Analysis (GSEA).

Discussion and Future Perspectives

The synergy between natural product-inspired DOS and target-agnostic phenotypic screening creates a powerful, unbiased engine for discovering novel chemical probes and therapeutic leads. This approach is particularly vital for addressing "undruggable" targets and complex polygenic diseases where single-target strategies have faltered [109]. The case study of antitubercular tetrahydroquinolines demonstrates the tangible success of this pipeline, yielding improved analogues from inspired scaffolds [108].

Future advancements in this field will focus on several key areas:

  • Advanced MoA Deconvolution: Integrating rapid, multi-optic profiling (chemoproteomics, phosphoproteomics, transcriptomics) directly into the screening workflow to accelerate target identification [109].
  • Library Design Evolution: Developing DOS strategies that not only explore diversity but also incorporate predictive elements for bioavailability and safety, and deliberately include chemotypes prone to novel mechanisms like CIP [109] [47].
  • Complex Model Systems: Moving screening beyond simple 2D cell cultures to more physiologically relevant 3D organoids, co-cultures, and whole-organism models (e.g., zebrafish), while adapting DOS libraries for compatibility with these systems.
  • AI and Machine Learning Integration: Using screening data from DOS libraries to train models that predict both compound bioactivity and potential mechanism, creating a virtuous cycle of library design and testing.

By continuing to bridge innovative synthetic chemistry with biologically complex screening models, the DOS-phenotypic screening paradigm will remain at the forefront of uncovering new biology and launching novel therapeutic modalities.

The exploration of "undruggable" targets, particularly those governed by extensive protein-protein interaction (PPI) networks, represents a frontier in therapeutic discovery [111]. These targets, which include transcription factors like p53 and Myc, small GTPases such as KRAS, and anti-apoptotic proteins like Bcl-2 family members, are characterized by flat, featureless interaction surfaces that lack conventional binding pockets [111]. Successfully modulating these PPIs requires chemical probes that move beyond traditional drug-like properties to embrace greater structural complexity and three-dimensionality [2].

This challenge aligns directly with the core philosophy of Diversity-Oriented Synthesis (DOS). DOS aims to efficiently populate broad regions of biologically relevant chemical space with small molecules that possess high skeletal, stereochemical, and appendage diversity [2]. Natural products, which have evolved to interact with complex biological interfaces, serve as ideal inspirational scaffolds for DOS libraries [4]. They are "pre-validated" to reside in bioactive chemical space and often exhibit the precise type of three-dimensional complexity needed to disrupt challenging PPIs [4] [2]. By applying DOS strategies to natural product-inspired scaffolds, researchers can generate innovative chemical libraries purpose-built to interrogate and inhibit historically intractable PPI targets [14].

Key Case Studies: Quantitative Outcomes & Strategies

The following table summarizes recent successful case studies in modulating "undruggable" PPIs, highlighting the quantitative outcomes and the strategic role of diverse, complex chemical matter.

Table 1: Case Studies in Modulating "Undruggable" Protein-Protein Interactions

Target PPI / Protein Class Therapeutic Context Modulation Strategy Key Compound / Technology Quantitative Outcome & Significance Link to DOS/Natural Product Inspiration
KRASG12C-SOS1 Interaction (Small GTPase) [111] Non-small cell lung cancer, Colorectal cancer Covalent Allosteric Inhibition: Trapping KRAS in its inactive, GDP-bound state by targeting a mutant cysteine [111]. Sotorasib (AMG 510) FDA-approved (2021); Objective response rate: ~36% in NSCLC [111]. Milestone for direct KRAS inhibition. Illustrates the power of covalent library screening to find unique chemotypes that exploit a rare vulnerability.
Bcl-2 Family Anti-apoptotic PPIs [111] Hematological cancers Direct PPI Inhibition: Small molecule occupying the hydrophobic groove used by pro-apoptotic proteins (e.g., BIM). Venetoclax (ABT-199) FDA-approved; Achieves deep responses in CLL; derived from fragment-based screening and NMR [14]. Demonstrates how fragment libraries with 3D character (a DOS goal) can yield starting points for inhibiting tight PPIs [14].
p53-MDM2/MDM4 Interaction (Transcription Factor) [111] Cancers with wild-type p53 Stapled Peptide / PROTAC: Helical peptide mimic of p53 or heterobifunctional degrader recruiting E3 ligase to MDM2. ALRN-6924 (Stapled Peptide), MD-224 (PROTAC) Stapled peptide: Disrupts interaction at nM potency in cells [111]. PROTAC: Achieves sub-nM DC50 and robust tumor regression in vivo [111]. Stapled peptides mimic natural secondary structure. PROTACs benefit from ligands for non-traditional targets (E3 ligases), expandable via DOS [112].
Extracellular & CNS Targets (e.g., Tau, α-synuclein) [112] Neurodegenerative diseases Catalytic Extracellular Targeted Protein Degradation (eTPD): Bispecific antibody or conjugate that binds target and a shuttling receptor (e.g., TfR). CYpHER Technology, sdAb-based Degraders Catalytic eTPD molecules show potent, durable degradation in vivo with CNS penetration [112]. Represents a new modality for extracellular "undruggables". Relies on novel binding moieties (antibodies, ligands) that can be discovered or optimized from diverse synthetic or natural product-inspired libraries.
Wnt Signaling Pathway [112] Tissue regeneration, Cancer Targeted Degradation of E3 Ligases: Engineered fusion protein (SWEETS) that degrades negative regulators of Wnt signaling. SWEETS fusion protein Selective enhancement of Wnt pathway activity in a tissue-specific manner [112]. A "reverse" degradation strategy to activate a pathway. Showcases the need for highly specific binders for novel E3 ligases, a major expansion area for ligand discovery via DOS [112].

Experimental Protocols for Key Assays in PPI Modulation

Protocol: TR-FRET-Based High-Throughput Screening for PPI Inhibitors

Application: Primary screening of DOS-derived libraries to identify disruptors of a defined PPI (e.g., Bcl-2/BIM, p53/MDM2). Principle: Time-Resolved Förster Resonance Energy Transfer (TR-FRET) uses long-lifetime lanthanide donors (e.g., Europium cryptate) and acceptors (e.g., d2, Alexa Fluor 647). PPI brings donor and acceptor into proximity, generating a FRET signal. Inhibitors reduce this signal [111]. Workflow:

  • Reagent Preparation:
    • Purify recombinant target and partner proteins with appropriate tags (e.g., GST, His6).
    • Label one protein with donor (e.g., anti-GST-Eu cryptate) and the partner with acceptor (e.g., anti-His6-d2).
  • Assay Setup (384-well plate):
    • Add 2 µL of test compound (from DOS library, 10 µM final concentration in 1% DMSO).
    • Add 10 µL of donor-labeled protein (1-5 nM final).
    • Add 10 µL of acceptor-labeled partner protein (10-20 nM final) in assay buffer (e.g., PBS, 0.01% BSA, 0.005% Tween-20).
  • Incubation & Reading:
    • Incubate at room temperature for 1-2 hours.
    • Read TR-FRET signal on a compatible plate reader (e.g., PerkinElmer EnVision). Excite donor at ~337 nm, measure donor emission at ~620 nm and FRET (acceptor) emission at ~665 nm.
  • Data Analysis:
    • Calculate ratio: (Acceptor Emission @665 nm / Donor Emission @620 nm) * 10^4.
    • % Inhibition = (1 – (Ratiosample – Ratiomin) / (Ratiomax – Ratiomin)) * 100.
    • Ratio_max: DMSO control (full PPI). Ratio_min: unlabeled competitor peptide/protein (full inhibition).

Protocol: Cellular Thermal Shift Assay (CETSA) for Target Engagement

Application: Validation of direct compound-target engagement in a cellular context, crucial for targets like KRAS or transcription factors [111]. Principle: A ligand binding to its target protein stabilizes it against heat-induced denaturation. Stabilization is detected by quantifying remaining soluble protein post-heating. Workflow:

  • Cell Treatment & Heating:
    • Seed cells (e.g., cancer line expressing target) in 6-cm dishes.
    • Treat with DOS-derived compound or DMSO for 2-4 hours.
    • Harvest cells, wash, and resuspend in PBS with protease inhibitors.
    • Aliquot cell suspension into PCR tubes. Heat each aliquot at a range of temperatures (e.g., 37°C to 65°C) for 3 minutes in a thermal cycler.
  • Protein Solubilization & Analysis:
    • Freeze-heat-thaw cycles: Place tubes in liquid nitrogen for 2 minutes, then thaw at room temperature.
    • Centrifuge at high speed (20,000 x g) for 20 minutes at 4°C to pellet denatured aggregates.
    • Transfer supernatant (soluble protein) to new tubes.
  • Target Detection:
    • Analyze soluble protein fraction by Western blot for protein of interest.
    • Quantify band intensity. Plot fraction of soluble protein remaining vs. temperature.
    • A rightward shift in the melting curve (T_m) for compound-treated samples indicates target stabilization and engagement.

Protocol: Synthesis of a DOS Library Using a Build/Couple/Pair Strategy

Application: Generation of a skeletally diverse, fragment-like library inspired by natural product scaffolds for PPI screening [14]. Principle: The Build/Couple/Pair (B/C/P) algorithm is a foundational DOS strategy to maximize scaffold diversity from common precursors [14]. Detailed Workflow (Proline-Inspired 3D Fragments) [14]:

  • Build Phase:
    • Synthesize or procure enantiopure proline derivatives as core building blocks. Introduce orthogonal protecting groups (e.g., Fmoc-N, BoC-N).
    • Functionalize the proline scaffold with a variable R1 group (e.g., alkyl, aryl) via N-alkylation or at the carboxylic acid.
  • Couple Phase:
    • Intermolecularly couple the building block with a diverse set of bifunctional linkers containing a second reactive handle. For example, couple proline carboxylate with an amine-containing linker featuring a terminal alkene, alkyne, or electrophile (e.g., bromoacetamide).
    • This step introduces appendage diversity (R2 from the linker pool).
  • Pair Phase:
    • Subject the linear precursors to different cyclization reactions to generate distinct cores.
    • Example A (5-7 Bicyclic): Perform Ring-Closing Metathesis (RCM) on a di-olefin precursor using Grubbs 2nd generation catalyst.
    • Example B (Spirooxindole): Initiate a tandem Michael addition/cyclization on a precursor with an activated olefin and an oxindole moiety.
    • This phase creates skeletal diversity from common intermediates.
  • Diversification & Finalization:
    • Perform "post-pair" functional group interconversions (e.g., reduction of olefins, oxidation of alcohols, amide couplings).
    • Purify all compounds by automated flash chromatography. Characterize by LC-MS and NMR.
    • Library Design Goal: Produce 50-100 compounds spanning 10-15 distinct, rule-of-three compliant scaffolds with multiple synthetic handles for future growth [14].

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Research Reagents for PPI & DOS Research

Reagent / Material Function & Application Key Characteristics & Rationale
DNA-Encoded Library (DEL) Technology [111] Ultra-high-throughput screening platform. Each small molecule is linked to a unique DNA barcode, enabling pooled screening of billions of compounds against immobilized protein targets. Ideal for finding initial hits against "undruggable" PPIs from vast chemical space. Compatible with DOS by encoding diverse synthetic steps [111].
PROTAC Linker Toolbox [112] A collection of chemically diverse, bifunctional linkers of varying length, composition (PEG, alkyl), and biodegradability. Used to conjugate a target-binding ligand to an E3 ligase-binding ligand to create proteolysis-targeting chimeras (PROTACs). Critical for optimizing degrader efficacy and properties [112].
Stapled Peptide Synthesis Reagents Non-natural amino acids (e.g., olefinic amino acids) and ruthenium catalysts for ring-closing metathesis. Used to stabilize α-helical peptides. Enables the synthesis of peptide-based PPI inhibitors that mimic natural secondary structures, enhancing cell permeability and proteolytic stability [111].
CETSA / TPP Kits Optimized buffer systems, control ligands, and sometimes compatible antibodies for Cellular Thermal Shift Assay or Thermal Proteome Profiling. Streamlines validation of direct target engagement in cells, a critical step for novel compounds from DOS libraries targeting PPIs [111].
Chiral Building Blocks & Catalysts Enantiopure amino acids, terpene-derived fragments, and chiral organocatalysts/ metal catalysts (e.g., for asymmetric Diels-Alder). Foundation for introducing stereochemical diversity in DOS libraries, essential for creating natural product-like 3D complexity [4] [14].
E3 Ligase Ligand Collection [112] A panel of small-molecule ligands for various E3 ubiquitin ligases (e.g., beyond CRBN and VHL, such as IAP, DCAF ligands). Enables expansion of the TPD universe. DOS can be used to discover and optimize novel E3 binders, creating new degrader options [112].
Fragment Screening Library (3D-Enriched) A curated collection of rule-of-three compliant fragments with high Fsp3, chirality, and structural complexity. The ideal screening input for challenging PPIs. DOS is perfectly suited to synthesize such underrepresented, 3D fragment collections [14].

Visualization of Pathways and Workflows

Diagram 1: Core Strategies to Drug "Undruggable" PPIs

G UndruggablePPI 'Undruggable' PPI Target (e.g., p53-MDM2, Bcl-2-BIM) Direct Direct Inhibition (Orthosteric/Allosteric) UndruggablePPI->Direct Indirect Indirect Modulation (Protein Degradation) UndruggablePPI->Indirect StrategyA Small Molecule (e.g., Venetoclax) Direct->StrategyA StrategyB Stapled Peptide (e.g., ALRN-6924) Direct->StrategyB StrategyC PROTAC / Molecular Glue Recruits E3 Ligase Indirect->StrategyC StrategyD eTPD / Bispecific (e.g., CYpHER) Indirect->StrategyD DOSLibrary DOS Library (Natural Product-Inspired, 3D, Complex) DOSLibrary->Direct DOSLibrary->Indirect

Diagram 2: DOS Build/Couple/Pair Workflow for PPI Probes

G cluster_phase1 1. Build Phase cluster_phase2 2. Couple Phase cluster_phase3 3. Pair Phase NP Natural Product Scaffold Inspiration BB1 Building Block A (e.g., Proline Derivative) NP->BB1 CP1 Linear Precursor 1 BB1->CP1 CP2 Linear Precursor 2 BB1->CP2 BB2 Building Block B (Varied R Groups) BB2->CP1 BB2->CP2 SC1 Scaffold 1 (e.g., 5-7 Bicyclic) CP1->SC1 RCM SC2 Scaffold 2 (e.g., Spirocyclic) CP2->SC2 Michael Cyclization CP3 Linear Precursor N SCN Scaffold N CP3->SCN Target PPI Target Screening & Validation SC1->Target SC2->Target SCN->Target

The modulation of "undruggable" protein-protein interactions demands a departure from flat, aromatic-rich chemical libraries towards collections rich in three-dimensionality and stereochemical complexity. Diversity-Oriented Synthesis (DOS), particularly when inspired by the structural lessons of natural products, provides a powerful synthetic framework to meet this demand [4] [2]. By deliberately generating skeletally diverse compounds that occupy broader swathes of biologically relevant chemical space, DOS libraries offer a higher probability of identifying unique chemical matter capable of engaging challenging PPI interfaces [14].

The case studies and protocols outlined here demonstrate that successful PPI drug discovery is increasingly a multidisciplinary endeavor. It integrates 1) DOS for innovative library design, 2) biophysical and cellular assays (TR-FRET, CETSA) for rigorous validation, and 3) advanced modalities (PROTACs, eTPD) for indirect modulation [111] [112]. The future of this field lies in the continued synergy between synthetic chemistry—driven by DOS principles—and mechanistic biology, enabling the systematic translation of novel chemical structures into potent, selective probes and therapeutics for targets once deemed beyond reach.

The pursuit of novel therapeutics for challenging, "undruggable" targets necessitates innovative strategies that converge synthetic chemistry, chemical biology, and drug design. Within this context, Diversity-Oriented Synthesis (DOS) emerges as a powerful synthetic philosophy, deliberately constructing skeletally and stereochemically diverse small-molecule libraries that occupy broad regions of biologically relevant chemical space [4] [2]. This approach stands in contrast to target-oriented synthesis, aiming not to build a single compound but to efficiently generate collections with high scaffold diversity, thereby increasing the probability of identifying novel bioactive entities [4].

A primary application for such diverse libraries is Fragment-Based Drug Discovery (FBDD). FBDD involves screening small, low molecular weight fragments (<300 Da) to identify weak but efficient binders, which are subsequently elaborated into potent leads [113] [14]. However, a significant challenge in FBDD is the relative flatness (two-dimensionality) and lack of synthetic handles in many commercial fragment collections [14]. DOS, particularly when inspired by the complex, three-dimensional architectures of natural product scaffolds, provides an ideal solution by generating novel, stereochemically rich fragments with multiple vectors for chemical growth [4] [14].

These advanced chemical tools are critically enabling for the development of next-generation modalities, most notably Proteolysis-Targeting Chimeras (PROTACs) [114]. PROTACs are heterobifunctional molecules that recruit an E3 ubiquitin ligase to a target protein, inducing its ubiquitination and degradation by the proteasome [114] [115]. Their development requires two high-quality ligands—one for the protein of interest (POI) and one for an E3 ligase—connected by an optimized linker [116]. DOS-driven FBDD campaigns are perfectly poised to discover novel, selective ligands for challenging POIs and underutilized E3 ligases, thereby expanding the PROTAC toolbox. Furthermore, the complex ternary complex formation central to PROTAC mechanism presents a unique challenge ideally suited for interrogation by fragment-based screening methods [113] [117].

This article details the application notes and protocols that operationalize the convergence of DOS, FBDD, and PROTAC development, framing the discussion within the broader pursuit of drug discovery inspired by natural product diversity.

Core Concepts and Comparative Analysis

2.1 Foundational Principles

  • DOS and Natural Product Inspiration: Natural products are "libraries of pre-validated, functionally diverse structures" that inherently reside in biologically relevant chemical space [4]. DOS strategies often use the complex, sp³-rich cores of natural products as inspiration to design synthetic pathways that yield diverse, natural product-like scaffolds with multiple stereocenters, enhancing the probability of identifying novel bioactivity [2] [14].
  • FBDD Advantages: FBDD offers more efficient coverage of chemical space with smaller libraries (typically 1,000-5,000 compounds) compared to High-Throughput Screening (HTS) [113]. Fragment hits typically exhibit high ligand efficiency (binding energy per atom), providing superior starting points for optimization [113]. The "rule of three" (MW <300, cLogP ≤3, H-bond donors & acceptors ≤3) is a common guideline for fragment library design [14].
  • PROTAC Mechanism and Challenges: PROTACs act catalytically, enabling sub-stoichiometric degradation and targeting proteins without the need for a functional inhibitory site [114] [115]. Key challenges include the "hook effect" (loss of efficacy at high concentrations due to binary complex formation), molecular weight/physicochemical property optimization, and the empirical nature of linker design [114] [116].

Table 1: Comparative Analysis of FBDD and Traditional HTS

Aspect Fragment-Based Drug Discovery (FBDD) Traditional High-Throughput Screening (HTS)
Library Size Small (1,000 – 5,000 compounds) Large (100,000 – 1,000,000+ compounds)
Compound Properties "Rule of 3": MW <300 Da, cLogP ≤3 [14] "Drug-like": MW ~500 Da, cLogP ~5
Chemical Space Coverage Broad and efficient with small library [113] Less efficient per compound; often redundant
Typical Hit Affinity Weak (µM to mM range) Potent (nM to µM range)
Ligand Efficiency High (optimal binding per atom) Variable, often lower
Primary Screening Methods Biophysical (SPR, NMR, DSF, X-ray) [113] [117] Biochemical or cellular activity assays
Hit-to-Lead Process Fragment growing, linking, or merging Structural optimization of a single scaffold

2.2 DOS as a Source for 3D Fragment Libraries DOS enables the systematic synthesis of fragment libraries with high scaffold diversity (different core structures) and shape diversity, moving beyond flat, aromatic-rich compounds [2] [14]. This is quantified by metrics like the fraction of sp³ hybridized carbons (Fsp³) and Principal Moment of Inertia (PMI) analysis [14]. Libraries derived from chiral building blocks, such as amino acids, yield fragments with multiple stereocenters and functional handles ideal for subsequent elaboration in an FBDD campaign [14].

Table 2: Examples of DOS-Derived Fragment Libraries for FBDD

DOS Strategy / Building Block Scaffold Diversity Achieved Key Features & Fsp³ Range Screening & Outcome
Allyl Proline-Based B/C/P [14] 12 distinct fused/spiro bicyclic frameworks High 3D character; multiple growth vectors from polar handles. Fsp³ typically >0.5. Library designed for FBDD; PMI analysis confirmed broad shape space coverage.
α,α-Amino Acid Derived [14] 22 bicyclic and tricyclic heterocyclic scaffolds High skeletal diversity from varying pair-phase cyclization. Incorporates chiral centers. Methodology focused on creating lead-like compounds with FBDD-compliant properties.
1,2-Amino Alcohol-Based [14] Diverse scaffolds including morpholines & bridged bicyclic Designed for aqueous solubility; incorporates amines, alcohols for vector growth. Fragments compliant with "rule of three" and amenable to further diversification.

2.3 Application of DOS and FBDD to PROTAC Development The PROTAC molecule comprises three elements: a POI binder, an E3 ligase binder, and a linker [114]. DOS-informed FBDD can contribute decisively to the discovery and optimization of the first two components.

  • POI Ligand Discovery: For targets lacking high-quality chemical starting points (e.g., transcription factors, non-catalytic domains), screening a diverse 3D fragment library can reveal novel binding motifs that can be grown into selective ligands [2] [113].
  • E3 Ligand Expansion: While CRBN and VHL ligands dominate the field, exploiting the full human repertoire of ~600 E3 ligases is desirable for tissue-specific targeting and overcoming resistance [114] [115]. FBDD campaigns against novel E3 ligases, using DOS libraries rich in diverse shapes, can yield new recruiting elements.
  • Ternary Complex Stabilizers: Some fragments may not bind tightly to either protein alone but could stabilize the PROTAC-induced ternary complex. Specialized FBDD screens measuring cooperative binding are being developed to identify such "molecular glue" fragments [117].

Table 3: PROTAC Component Synthesis: Sources and Strategies

PROTAC Component Current Primary Sources DOS/FBDD Convergence Opportunity Key Considerations
POI Ligand Known inhibitors/substrates; HTS hits [114]. De novo discovery for "undruggable" targets via 3D fragment screening [113]. Selectivity, binding affinity, presence of suitable linker attachment vector.
E3 Ligand Mostly CRBN (thalidomide analogs) and VHL (hydroxyproline analogs) [114] [115]. Ligand discovery for novel E3 ligases (e.g., MDM2, IAPs) [115] via focused screens. Selectivity, affinity, and minimizing interference with E3's native function.
Linker Empirical exploration of PEG, alkyl, piperazine chains [116] [118]. Rational design informed by ternary complex modeling [119] [118] and fragment-based probe of protein-protein interface. Length, flexibility/rigidity, solubility, and metabolic stability.

Detailed Experimental Protocols

3.1 Protocol 1: DOS-Informed Synthesis of a 3D-Focused Fragment Library

  • Objective: To synthesize a 100-500 member fragment library with high Fsp³ (>0.4) and scaffold diversity, inspired by natural product-like cores.
  • Design (Build/Couple/Pair Algorithm):
    • Build: Select chiral, functionalized building blocks (e.g., amino acids, terpene derivatives). Incorporate orthogonal protecting groups and functional handles (amines, alcohols, carboxylic acids) [14].
    • Couple: Employ robust, high-yielding reactions (e.g., amide coupling, reductive amination, cross-coupling) to combine building blocks diversely, creating linear precursors [14].
    • Pair: Use divergent cyclization reactions (e.g., ring-closing metathesis, intramolecular aldol, Michael addition) on the common precursors to generate distinct molecular scaffolds [4] [14].
  • Synthesis & Quality Control:
    • Execute synthesis on a 10-50 mg scale suitable for screening.
    • Purify all compounds to >95% purity (LC-MS).
    • Characterize all compounds by ¹H/¹³C NMR and HRMS.
    • Determine solubility in aqueous buffer (e.g., PBS with 0.1-1% DMSO) to ensure suitability for biophysical assays. Aim for >100 µM solubility [14].

3.2 Protocol 2: FBDD Screening for a Novel E3 Ligase Ligand

  • Objective: To identify fragment hits binding to the substrate recognition domain of an underutilized E3 ligase (e.g., a RING-domain E3) using biophysical methods.
  • Target Preparation: Express and purify the recombinant substrate-binding domain of the target E3 ligase. Label it with a fluorophore for fluorescence-based assays if required [117].
  • Primary Screening (Orthogonal Methods):
    • Differential Scanning Fluorimetry (DSF): Screen the fragment library (at 0.5-1 mM fragment concentration) against the E3 protein. A significant shift in melting temperature (ΔTm > 1.0°C) indicates potential binding [113].
    • Ligand-Observed NMR: Perform saturation transfer difference (STD) or CPMG experiments. Screen fragments in pools of 4-8. Reduction in signal intensity indicates binding [117].
  • Hit Validation & Characterization:
    • Surface Plasmon Resonance (SPR) or Microscale Thermophoresis (MST): Confirm hits from primary screens and determine dissociation constants (K_D). Expect affinities in the high µM to mM range [117].
    • X-ray Crystallography or Cryo-EM: Soak or co-crystallize validated fragment hits with the E3 protein to obtain structural information on the binding mode and identify vectors for fragment growth [113].

3.3 Protocol 3: In Silico Modeling and Design of a PROTAC Ternary Complex

  • Objective: To computationally model the ternary complex of a target POI, a candidate PROTAC, and an E3 ligase (e.g., VHL) to guide linker design and predict degrader activity.
  • Software & Resources: Utilize tools like MOE, ICM-Pro, or the open-source PRosettaC [118]. Acquire PDB structures of the POI:ligand and E3:ligand binary complexes. Prepare PROTAC structures in a 2D SDF format.
  • Procedure (Based on MOE Protocol):
    • System Preparation: Prepare protein structures using the "QuickPrep" module, adding hydrogens, correcting protonation states, and removing water molecules [118].
    • Ternary Complex Generation: Use the protein-protein docking module to generate an ensemble of POI-E3 orientations. The PROTAC linker is treated as flexible, connecting the two anchored ligands [118].
    • Conformational Sampling & Clustering: Generate multiple conformers of the PROTAC linker. Dock the PROTAC into the protein-protein interface, allowing for side-chain flexibility. Cluster the resulting ternary complexes based on protein-protein and PROTAC conformations [118].
    • Ranking & Analysis: Rank clusters by population size and interaction energy. Analyze top-ranked models for productive contacts between the E3 ligase and the POI surface, proximity to lysine residues on the POI, and lack of steric clash. Models with a large, well-defined cluster population are predicted to have a higher probability of inducing degradation [118].

3.4 Protocol 4: Biochemical Evaluation of PROTAC Efficacy

  • Objective: To measure the cellular degradation activity of a newly synthesized PROTAC.
  • Cell-Based Degradation Assay:
    • Treat a cell line expressing the target POI with a concentration range of the PROTAC (e.g., 1 nM to 10 µM) for a predetermined time (e.g., 6-24 hours).
    • Lyse cells and quantify target protein levels via western blotting. Use densitometry to calculate percentage degradation relative to DMSO control [114].
    • Determine the DC₅₀ (concentration for 50% degradation) and Dmax (maximal degradation) from the dose-response curve.
  • Specificity & Hook Effect Assessment:
    • Test for the "hook effect" by including high PROTAC concentrations (e.g., 10-30 µM) in the dose-response. A decrease in degradation at high concentrations confirms the expected hook effect [114].
    • Assess selectivity by immunoblotting for related protein family members or known off-targets.
  • Ternary Complex Stabilization (Optional - Biophysical):
    • Employ techniques like Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) or Spectral Shift (SpS) assays to directly measure the formation and affinity of the PROTAC-induced POI/E3 ternary complex in vitro [117].

The Scientist's Toolkit

Table 4: Essential Research Reagent Solutions for DOS-FBDD-PROTAC Workflow

Category Item / Technology Function in the Workflow
Synthesis & Library Chiral Pool Building Blocks (Amino Acids, Hydroxy Acids) Provide stereochemical diversity and natural product-like complexity for DOS library synthesis [14].
Solid-Phase Synthesis & Encoding Technologies Enable synthesis and tracking of large, diverse DOS libraries, especially for early PROTAC linker exploration [4] [114].
Screening & Biophysics 3D-Focused Fragment Library (Fsp³ >0.4) Primary chemical tool for FBDD screens against challenging targets like novel E3 ligases [113] [14].
Dianthus Platform (Spectral Shift) / SPR / MST High-throughput, label-free biophysical methods for detecting weak fragment binding and quantifying ternary complex affinity [117].
X-ray Crystallography Platform (e.g., XChem) Provides atomic-resolution structures of fragment-protein complexes, essential for guiding fragment-to-lead optimization [113].
Computational & Design Ternary Complex Modeling Software (MOE, ICM, PRosettaC) Predicts viable structures of POI-PROTAC-E3 complexes to rationalize activity and guide linker/ligand design [119] [118].
PROTAC-Specific Databases (PROTAC-DB, PROTACpedia) Curated repositories of known PROTACs, activities, and structural data for informing design and avoiding prior art [119].
Biological Evaluation Tag-Targeted Protein Degradation (tTPD) Systems (dTAG, HaloTag) Validate target degradability and consequences before investing in full PROTAC development [114].
Cellular Thermal Shift Assay (CETSA) Confirms target engagement of the POI ligand or PROTAC in a cellular context.

Diagrams of Workflows and Mechanisms

G NP Natural Product Inspiration DOS Diversity-Oriented Synthesis (DOS) NP->DOS Scaffold Mimicry Lib 3D-Diverse Fragment Library DOS->Lib Build/Couple/Pair FBDD Fragment-Based Screening (FBDD) Lib->FBDD Primary Screen Hit Validated Fragment Hits FBDD->Hit Hit ID & Validation Opt Fragment to Lead Optimization Hit->Opt Growth/Linking Lig Optimized Ligand for POI or E3 Opt->Lig Selective Binder PROTAC_Dev PROTAC Assembly & Evaluation Lig->PROTAC_Dev Linker Conjugation E3_Node Ternary Ternary Complex & Degradation PROTAC_Dev->Ternary Cellular Testing

Workflow: From Natural Products to PROTACs

G POI Protein of Interest (POI) PROTAC PROTAC POI->PROTAC Binary Complex Ternary POI-PROTAC-E3 Ternary Complex POI->Ternary Binds PROTAC->Ternary Recruits E3 E3 Ubiquitin Ligase E3->PROTAC Binary Complex E3->Ternary Binds Ub Ubiquitin Transfer Ternary->Ub Enables PolyUb Poly-Ubiquitinated POI Ub->PolyUb Lysine Tagging Deg Degradation by 26S Proteasome PolyUb->Deg Recognized Deg->POI Destroys Hook High [PROTAC] (Hook Effect) Hook->PROTAC

PROTAC Mechanism and Hook Effect

G Start Input: PDB files of POI:Ligand & E3:Ligand + PROTAC Library (2D-SDF) Prep 1. System Preparation (Protonation, Minimization) Start->Prep Dock 2. Protein-Protein Docking (Generate POI-E3 poses) Prep->Dock Conf 3. Conformer Generation (Flexible linker sampling) Dock->Conf Assemble 4. Ternary Complex Assembly (Dock PROTAC into interface) Conf->Assemble Cluster 5. Clustering & Scoring (By geometry & energy) Assemble->Cluster Analyze 6. Analysis of Top Models (PPI interface, lysine proximity) Cluster->Analyze Output Output: Ranked list of ternary complex structures & predictions Analyze->Output

Computational Workflow for PROTAC Ternary Complex Modeling

Conclusion

Diversity-Oriented Synthesis, inspired by the intricate scaffolds of natural products, represents a paradigm shift in library design, moving beyond simple appendage variation to the deliberate creation of skeletal and stereochemical complexity. By integrating foundational inspiration from nature with advanced synthetic methodologies like C-H functionalization and ring distortion, DOS provides a powerful route to biologically relevant yet underexplored chemical space. Success in this field hinges on overcoming synthetic challenges through strategic optimization and leveraging computational tools for design and analysis. The validation of DOS libraries through the discovery of novel bioactive agents against challenging targets underscores their transformative potential in chemical biology and drug discovery. Future directions will likely see deeper integration with artificial intelligence for library design, increased application in targeted protein degradation, and a stronger emphasis on sustainable synthetic practices, solidifying DOS as an indispensable strategy for generating the next generation of therapeutic leads and biological probes[citation:2][citation:5][citation:6].

References